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Abstract 
Natural products have been an integral component of people’s health and health outcomes for 
thousands of years. In particular, several mushroom species have demonstrated beneficial 
therapeutic potential. The goals of this research are to explore the immuno-stimulatory and anti-
inflammatory potential of wild mushrooms native to the North Central region of British 
Columbia. Out of 42 mushroom extracts examined, four exhibited strong immuno-stimulatory 
activity as assessed by induction of tumor-necrosis factor alpha (TNF-α) production in 
macrophage cells.  Out of thirty-three extracts tested, nineteen demonstrated potent anti-
inflammatory activity as determined by inhibition of lipopolysaccharide-induced TNF-α 
production in macrophage cells.  Sodium hydroxide extract of Echinodontium tinctorium 
exhibited potent anti-inflammatory activity and was selected for further study. A small molecular 
weight (~5-25 kDa) carbohydrate was successfully purified using sequential size-exclusion and 
ion-exchange chromatography. GC-MS analysis showed that the polysaccharide has glucose 
(89.7%) as the major back-bone monosaccharide, and also the presence of other 
monosaccharides such as mannose (3.1%), galactose (2.8%), fucose (2.4%), and xylose (2.0%). 
The study also revealed the presence of 1,3-linked glucose, 1,6-linked glucose, 1,3-linked 
galactose and 1,3,6-linked glucose linkages. Both the semi-purified anti-inflammatory 
compound(s) from E. tinctorium and the methanol extract of Inonotus obliquus can ameliorate 
histamine-induced vasodilation in the 2A arterioles (gluteus maximus muscle) in mice. This is the 
first study to demonstrate the anti-inflammatory activity of purified compounds and extracts 
from mushroom in an animal microcirculation model using intravital microscopy.  
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Chapter 1: Background and Objectives 
 This chapter highlights the research background, specifically providing some statistics of 
cancer prevalence and a brief introduction on the historical and traditional use of mushrooms, 
their medicinal properties, their role in immuno-modulation, and the topic of human 
inflammation. Finally, the chapter outlines my research objectives and the structure of this thesis. 
1.1 The Havoc of Cancer 
Cancer is a set of diseases characterized by uncontrolled cell division and their ability to 
metastasize (invade) other tissues by causing angiogenesis (vascularization) and tumor lumps, 
thus interfering with the normal functioning of the body (Vogelstein & Kinzler, 2004). According 
to the recent World Health Organization report (2017), cancer has been one of the leading causes 
of morbidity and mortality with approximately 14 million new cases in 2012 along with 8.8 
million cancer-related deaths in 2015 (1 out of 6 of all global deaths). The coming two decades 
expect to see a rise in such cases by 70% (World Health Organization, 2017). 
Canadian Cancer Statistics (2016) rates cancer as the leading cause of deaths in Canada, 
being responsible for around 30% of all the fatalities; moreover, 202,400 new cases of cancer 
and 78,800 cancer-associated deaths had been estimated to occur in 2016 in Canada alone. 
According to an estimation in 2009, almost 40% of all Canadians (i.e. 2 out of 5) are projected to 
develop cancer at least once in their lifetimes and 25% of these (i.e. 1 out of 4), are anticipated to 
die from this deadly disease (Canadian Cancer Statistics, 2016). 
The alarming cancer death rates indicate the complexity of tumors, representing a 
combination of many diseases. Cancer cells are malignant neoplastic cells transformed by 
uncontrolled cell division, and expanding in the surrounding tissues and metastasizing to the 
important organs like the brain, lungs, and stomach. The transformation of normal cells into 
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cancerous cells can take place in 3 steps (Borchers et al., 2004; Oberstein & Olive, 2013). The 
first step is the binding of a mutagen to the cellular DNA, thus initiating the damage. This is not 
enough for triggering the entire tumor cascade and requires activation however; the second step 
is the activation of the tumor in which tumor-associated promoters are stimulated and benign 
tumors are formed. Finally, these benign tumors progress, take control of the cellular machinery, 
and cause unrestricted cellular proliferation (Borchers et al., 2004). Moreover, the transformed 
tumors are highly diverse and have many defective genes that regulate growth and division 
(Oberstein & Olive, 2013). These are not confined to the site of origin, and are marked by 
various epigenetic and genetic variations, post-transcriptional modifications, complex 
mechanisms, and various pathways alterations. Such varied alterations make it harder to target 
cancer cells.   
Currently, chemotherapy is one of the major approaches (hormonal and radiotherapy being 
others) for treating cancer in which a cytotoxic agent is delivered to the cancerous cells. This 
approach decelerates the rate of constant division and restrains the growth and development of 
cancer cells (Miles & Chang, 2004). Chemotherapy, on the other hand, also damages healthy 
cells and causes serious side effects; it can decrease the number of leucocytes in the blood, 
increase risk of internal bleeding and brain hemorrhage, and suppress the immune system thus 
making the patient vulnerable to minor diseases that can eventually cause death (Miles & Chang, 
2004, Kakde et al., 2011). Chemotherapy also causes other pharmacokinetic problems like 
altered bio-distribution, biotransformation, drug resistance, and drug clearance (Kakde et al., 
2011). Despite these numerous side effects, chemo, hormonal, and radio therapy still remain 
among the possible options for the treatment of cancer patients worldwide. Therefore, there is a 
constant need for developing synergistic anti-tumor drugs or alternative therapies that have fewer 
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side effects. Due to the severe toxicity and aforementioned reasons, scientists are extensively 
studying various natural products from plants, marine organisms, animals and fungi as a possible 
substitute (Ali et al., 2012).  
1.2 Natural Products to Treat Cancer 
Natural products have been used and studied extensively for treating almost all kind of 
diseases known to man. Despite various advances in drug discovery techniques such as 
combinational chemistry and rational drug design, natural products remain the number one 
choice as sources of potential lead molecules for drug discovery and development (Cragg & 
Newman, 2013).  
Similarly, the history of anticancer drug discovery also revolves around natural products. 
Scientists are trying to modify the cytotoxic and/or cytostatic mechanisms present in the 
defensive response of various plants, animals and other living creatures to achieve the desired 
anti-tumor response (Huryn & Wipf, 2014). Almost 80% of all marketed anticancer drugs are 
derived directly or indirectly from natural sources, indicating the efficacy and efficiency of 
natural compound (s) against cancer (Newman & Cragg, 2012). Out of 206 anti-cancer drugs, 
approved since the 1940s, 131 (64%) are either directly from natural sources or are inspired by 
them (75% without considering vaccines and biologics) (Newman & Cragg, 2012). Some well-
known examples of naturally inspired anti-cancer drugs include vincristine, vinblastine, 
methotrexate, paclitaxel, and doxorubicin, among others (Huryn & Wipf, 2014). Among natural 
resources, fungi are one of the main sources of potential lead molecules for anticancer drug 
discovery (Newman & Cragg, 2012).  The only requirement is to focus on primary screening 
from unexplored regions of the world and to combine high through-put and various other modern 
techniques in order to accelerate drug availability. 
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1.3 Mushrooms use-Historical Perspective 
Fungi encompass eukaryotic organisms including both unicellular and multicellular species 
whose cell walls are made up of chitin and have an absorptive mode of nutrition. It is a hyper-
diverse group but the estimation and collection of fungi is difficult because of their ephemeral 
and cryptic nature (Mueller et al., 2004). This kingdom is home to thousands of yeasts, rusts, 
smuts, lichens, and mushrooms which, due to the variations in their life cycles, are making 
undeniable contributions in numerous domains such as the environment (as decomposers, 
bioremediation, agriculture), industries (fermentation processes, biotechnology, fungal enzymes), 
pharmaceuticals (medically important species, holistic health benefits, biological drugs), foods 
(mushrooms, yeasts, prebiotics) and mycology research (better stains, more benefits, better 
solutions) (Lange, 2014; Lange & Grell, 2014). This makes fungi an important contributor in the 
sustainability and stability of human lives. 
The term mushroom is not a taxonomic classification; rather, it is defined as macrofungi with 
distinct fruiting bodies that can be epigeous or hypogeous, large enough for the human eye to be 
seen and collected by hand (Chang & Miles, 1992). Epigeous mushrooms have their fruiting 
bodies above ground (mostly Basidiomycetes) while hypogeous mushrooms have their fruiting 
bodies below ground (Ascomycetes and Basidiomycetes, many of them living in symbiotic 
associations with plants roots as ectomycorrhizal associates) (Tang et al., 2015).  
Of the 150,000-160,000-mushroom species that are present on Earth, hardly 10% are 
currently known to man (Hawksworth, 2012), and only 650 species have been assessed for their 
medicinal activity (Minato, 2010). Interestingly, there is an increase in the trend of discovering 
fungi, specifically mushrooms forming ectomycorrhizas with native trees, in different areas of 
Europe, North America and other tropical regions (Hawksworth, 2012). These vast and largely 
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untapped regions in the world are where novel mushrooms can be discovered and their medicinal 
value estimated. 
Mushrooms have been in use since the earliest history of mankind. Ancient Greeks believed 
that mushrooms were “strength pills” that provided power to the warriors on the battlefield 
(Blanchette et al., 1992). Similarly, for thousands of years, Chinese culture has been endorsing 
mushrooms as the "elixir of life” (Valverde et al., 2015). Mushrooms are used extensively for 
nutritional and medicinal purposes in traditional medicines in Asia (specifically China and 
Japan), Canada, Mexico, Russia, USA, and Venezuela (Comandini et al., 2012; Garibay-Orijel et 
al., 2007). 
Some mushroom species are used by human beings for both health and spiritual purposes. 
Ganoderma lucidum (Curtis) P. Karst is one of the oldest mushrooms used in traditional 
medicine as a tonic for fighting diseases, enhancing health, anti-aging, and life longevity 
(Thyagarajan-Sahu et al., 2011). Even in Europe, the traditional use of mushrooms can be 
witnessed after the discovery of the prehistoric mummy of the “Iceman” in the Tyrolean Alps in 
1991. The mummified body had Fomes fomentarius (L.: Fr.) in a bag that was tied around his 
waist and it was probably used as a tinder for fire making (Peintner et al., 1998; Pöder & 
Peintner, 1999). Mushrooms were also part of the traditional diet of native North Americans 
because of the flavor and nutritional value they added to the food. Oyster mushroom, Pleurotus 
ostreatus (Jacq.) P. Kumm., is one of the common used mushroom by all four groups of Interior 
Salish peoples of British Columbia (i.e. the Okanagan, Nlaka'pamux, Lillooet, and Shuswap) 
(Turner & Szczawinski, 1991). Pine mushroom, Tricholoma magnivelare (Peck) Redhead, is also 
historically used by Lillooet, Nlaka'pamux and Lower Lillooet groups, specifically among the 
four groups of Interior Salish peoples of British Columbia (Turner 1975). Cottonwood 
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mushroom, Tricholoma populinum J.E. Lange, is another commonly food mushroom used by all 
four groups of Interior Salish peoples of British Columbia (Turner et al., 1980). Métis Nation of 
Ontario identified Chaga, Inonotus obliquus (Ach. ex Pers.) Pilát, and Turkey tail mushroom, 
Trametes versicolor (L.) Lloyd (=Coriolus versicolor (L.) Quél.), as strong therapeutic fungi and 
a cure for various diseases (Kuhnlein & Turner, 1991; Métis Nation of Ontario, 2010). Therefore, 
the medicinal potential of these mushrooms was not hidden from the first nation people as they 
used and applied these fungi for curing human diseases. 
1.4 Mushrooms & Modern Medicines 
In a western medicine context, mushrooms have been successful in making a profound 
impact since about half a century ago, after the publication of scientific articles on their various 
medicinal properties including anti-cancer effects (Espenshade & Griffith, 1966; Gregory et al., 
1966). These studies have revolutionized the herbal perspective of mushrooms and introduced 
them into the pharmaceutical market (Wasser & Weis, 1999). Also, in recent times there has been 
a shift in the trend of consumption and research on wild mushrooms because of their 
pharmacological, nutritional, and prophylaxis characteristics (Günç et al., 2013).  
Currently, mushrooms are treated as “mini-pharmaceutical biofactories”, manufacturing 
compounds with important biological properties (Ferreira et al., 2010; Patel & Goyal, 2012). 
Hundreds of pharmacological benefits have been acquired from different mushrooms because of 
their widespread use as an antioxidant, antibacterial, antiallergic, antidiabetic, cardiovascular 
protector, anti-cholesterolemic, antiviral, antiparasitic, antifungal, detoxificant, hepatic-protector, 
anti-cancer, and immuno-modulator (Phan et al., 2015; Soccol et al., 2016). Mushrooms are also 
used as prophylactic (preventive) agents against inflammation development and tumorigenesis 
(Chang & Wasser, 2012). Thus, compounds from medicinal mushrooms can be a viable 
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alternative as they have the ability to activate the immune system against tumors while being 
cheaper and safer than conventional therapies (Miles & Chang, 2004). Therefore, the implication 
of this cumulative body of work is that mushrooms can potentially be used to treat various 
diseases, including many cancers.  
1.5 British Columbia Fungi 
Canada, and especially British Columbia, is host to various biogeoclimatic ecological zones, 
providing favorable habitats and ecosystems for growth of countless Basidiomycete and 
Ascomycete mushrooms, the majority of which have not been tested for their potential medicinal 
value. Extensive research has been conducted on mushrooms native to Asia; however, studies for 
mushrooms residing in North America, particularly British Columbia, are relatively minimal. It 
is likely that BC mushrooms contain biologically active compounds, some of which have unique 
medicinal properties. This thesis focuses on some of the wild mushrooms collected in forests of 
north central British Columbia in an effort to find and characterize novel immuno-modulatory 
compound(s). 
1.6 Immunotherapy & Cancer 
The defense mechanism in all living beings, especially humans, is a multiplex system that 
involves many immune cell types and pathways with unique yet interwoven responsibilities 
(Schepetkin & Quinn, 2006). The immune system, being the first barrier to pathogens, generates 
diverse immuno-modulators for the maintenance of the normal homeostasis of the human body 
(Fudenberg, 2012). Immunotherapy is based on the idea of using the immune system to treat the 
disease itself. This concept is a crucial factor in the prevention and eradication of many diseases 
including tumors. Major immune cells, present in the tumor vicinity, regulate the progression of 
the tumor. Cancer biologists are trying to manipulate these immune cells in the cancerous 
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microenvironment to enhance anti-tumor immunity while decreasing the power of cancer cells to 
surpass immune surveillance. This theory of treating cancer by modulating immune response is 
now becoming a clinical reality (Weiskopf & Weissman, 2015).  
Immuno-modulation can be achieved by immuno-stimulation, immuno-suppression, and 
immuno-adjuvation. Immuno-stimulation is the activation of the immune system through 
induction of certain mediators or components of the immune system in order to enhance the 
defensive mechanism against diseases; immuno-suppression is inhibition of the immune system 
by shutting down different key mediators, thus helping the body fight against hypersensitive 
immune conditions, such as inflammation and autoimmune diseases; immuno-adjuvation is the 
enhancement of the efficacy of vaccines, and it may also act through a stimulation pathway (El 
Enshasy & Hatti-Kaul, 2013; Fudenberg, 2012). Immuno-modulators enhance the host’s immune 
response to assist the efficient anti-tumor response. This occurs as a result of combined effort of 
both the innate and the adapted immune response. However, the impact of immuno-modulators 
(i.e. enhancement or suppression of immune responses) is dependent on a number of factors such 
as dosage, administrative route, and the timing and frequency of administration (Tzianabos, 
2000).  
The concept of immunotherapy is more than a century old, when William Coley (for the first 
time) tested bacterial derivatives for the treatment of solid tumors by manipulating the host’s 
immune response (Coley, 1893). A few decades later, the role of cytokines in cancer was 
discovered with the initial trials of administrating IFN-α (Atanasiu, & Chany, 1960; Lampson et 
al., 1963) and later interleukin-2 (IL-2) in the hope of initiating a therapeutic revolution (Pizza et 
al., 1984). Recently, immunologists are focusing more on harnessing the immune system 
together with training it to recognize a patient’s specific tumor. 
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Thus, immunotherapy empowers the patient’s own immune system to distinguish the 
cancerous cells from normal body cells and equip it to combat them in a better way. This is also 
supported by the unprecedented advances in immunotherapy by the scientific community. There 
are also recent breakthroughs regarding getting the desired response by augmenting the action of 
T cells, including immune check point inhibitors and chimeric antigen receptor (CAR) T cells 
(Weiskopf & Weissman, 2015). Two main groups of checkpoint blockers include Programmed 
death ligand 1 (PD-1) blocker and cytotoxic T lymphocyte associated protein 4 (CTLA-4) 
blockers (Barrett et al., 2014). Recently, three main monoclonal antibody checkpoint blockers 
(ipilimumab, nivolumab and pembrolizumab) have been approved by the FDA for melanoma and 
are being tested for other types of cancers (Weiskopf & Weissman, 2015).  
Macrophages, the major cells of innate immune response, are activated as a result of the first 
line defense brigade; these constitute the mononuclear phagocyte system with monocytes. 
Macrophage cells are involved in phagocytosis of invading pathogen; they have the ability to 
successfully eliminate mutated cells before the complete activation of humoral or cell mediated 
immune response (Borchers et al., 2008). Macrophages also behave as antigen-presenting cells 
and interact with T lymphocytes, thus acting as a mediator between innate and adaptive immune 
response. Moreover, these phagocytic cells are also involved in chemotaxis, wound healing, 
surveillance, tissue repair, and removal of cellular debris after apoptosis and hemolysis (Murray 
& Wynn, 2011; Steidl et al., 2010). 
Macrophages are regulated by various chemical messengers called cytokines. Macrophages, 
once activated, release various pro-inflammatory cytokines such as tumor necrosis factor (TNF), 
interleukins (IL), and interferons (IFN) that help eradicate the tumor cells (Weiskopf and 
Weissman, 2015). 
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Thus, targeting the non-specific innate immune response by developing novel therapeutics 
could be one of the ideal approaches for killing tumor cells. This could overcome the resistance 
and serious side effects presented by chemotherapy. Therefore, targeting macrophages as key 
players in tumor immunity is a clever strategy for immuno-modulation. 
1.7 Mushrooms with potential immuno-modulatory activity 
Among many medicinal properties that mushrooms exhibit, immuno-modulation is the most 
prominent one. It is now widely accepted that compounds derived from mushrooms re-establish 
the normal homeostasis along with enhancing the resistance to various diseases (Borchers et al., 
2008). This restoration of normal homeostasis is the central dogma of oriental medicine that 
relates the normal homeostasis within a healthy individual. Most mushrooms’ immuno-
modulators tend to stimulate both innate and adaptive immune responses (El Enshasy & Hatti-
Kaul, 2013). For innate immunity, they have the ability to activate certain components like 
neutrophils, macrophages and natural killer (NK) cells. This stimulates the secretion and 
expression of different cytokines (Chen & Seviour, 2007), which in turn activate cellular immune 
response by either assisting the differentiation of T cells in the case of helper T cells (Th1 and 
Th2) or by producing antibodies after activating B cells. Therefore, cytokines mediate both 
cellular and humoral immunity (Borchers et al., 2008).  
However, pharmacokinetically, the molecular weight of the immuno-modulatory 
polysaccharide also affects the bioavailability of the bioactive molecule. The higher the 
mushroom polysaccharide molecular weight, the more difficult it is for it to cross the plasma 
membrane and to activate immune cells directly. The activation occurs through different cellular 
receptors such as Complement receptor 3 (CR-3), Toll-like receptor 2 (TLR-2), 
Lactosylceramide (LacCer) and dectin 1 (reviewed in El Enshasy & Hatti-Kaul, 2013). Thus, the 
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higher the binding affinity of a polysaccharide to immune cell receptors, the higher the 
effectiveness of that polysaccharide in modulating the immune system (Chen & Seviour, 2007). 
This aspect will help pharmaceutical experts to develop an effective and efficacious dosage with 
maximum absorbance and distribution. Some well-known mushrooms bearing strong immuno-
modulatory activities are as follows (modified from El Enshasy & Hatti-Kaul, 2013): 
1.7.1 Lentinula edodes (Berk), Pegler 
Shiitake (Lentinula edodes), is an edible mushroom in Japan and has been widely used 
for its immuno-modulatory activity, especially its polysaccharide Lentinan, which is a 1,3-β-
glucan with 1,6-β-D-glucopyranoside. Lentinan has been used as an adjuvant therapy for cancer 
immuno-modulation or as an adjacent therapy in cancer chemo and/or radiotherapy. It enhances 
various cytokines levels and enhances cytotoxicity in macrophage cell lines (Bisen et al., 2010). 
1.7.2 Inonotus obliquus 
 Chaga (Inonotus obliquus) is found widely across North America, Korea and Siberia 
along the trunk of birch trees. It has also been used as an immuno-modulator because of its high 
β-glucan content. This β-glucan has the ability to induce nitric oxide synthase (iNOS), 
interleukins (IL-1β & IL-6), and TNF-α for a strong immuno-stimulatory action in various in 
vitro and in vivo models (Won et al., 2011). Some extracts of Chaga are also very famous for 
potent anti-inflammatory potential.   
1.7.3 Ganoderma lucidum 
  Ganoderma lucidum commonly known as Reishi, Lingzhi, and spiritual plant has been in 
use in China and Japan for a long time. It is documented to have almost 120 bio-active 
compounds (e.g. triterpenes) and more than fifty polysaccharides and peptide polysaccharide 
complexes. Some compounds in G. lucidum have immuno-stimulating effects. They can 
stimulate TNF-α, IL-1, IFN-γ, and NF- Κβ (Zhu et al., 2007). Some others also possess anti-
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inflammatory potential (Taofiq et al., 2016). Moreover, the fungal immuno-modulatory protein 
isolated from G. lucidum also can enhance transcription of a variety of immuno-stimulatory 
cytokines including interferons (IFN-γ), TNF-α, and interleukins (IL-2, IL-3, & IL-4) among 
others for an enhanced immune response (Li et al., 2010b) 
1.7.4 Schizophyllum commune Fr. 
 Schizophyllum commune (Split gill) can activate macrophages (via binding to Dectin-1 
receptor) and T cells, thereby increasing secretion of various interleukins and TNF-α (which in 
turn helps in reducing the size and growth of tumor cells) and also enhancing the survival rate of 
various tumor bearing test animals. The active β-glucan of this species, schizophyllan, is 
approved as an adjuvant in chemotherapy (Hobbs, 2005). 
1.7.5 Trametes versicolor 
Commonly known as “Turkey tail” has been proven (with over 400 clinical trials) to have 
beneficial effects on the human immune system due to the presence of the polysaccharide 
Krestin (PSK) and the fungal immuno-modulatory protein, tvc (FIP tvc). Krestin, along with 
other polysaccharides, initiates the activation of T cells and enhances the production and gene 
expression of cytokines such as interleukin (IL-1, IL-2, IL-6 and IL-8) TNF-α, and IFN-γ (Cui & 
Chisti, 2003). Likewise, Luo et al. (2014) observed the effects of this species in metastatic breast 
cancer mice model and found remarkable immuno-stimulatory, anti-metastasis and anti-tumor 
action. It was concluded that the stimulatory effects are due to increasing concentrations of IFN-
γ, TNF-α, and interleukins (IL-2, IL-6, IL-12) among others. This extract also demonstrated the 
prophylaxis ability against the breast cancer-induced bone destruction. FIP tvc has the tendency 
to increase human peripheral blood lymphocytes and enhance the production of TNF-α and nitric 
oxide (NO) (Li et al., 2011). Piotrowski and colleagues (2014) reviewed the anti-tumor activity 
of PSP (polysaccharide P) isolated from T. versicolor and concluded that PSP can restore 
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weakened immune response by: (i) activating various immune cells; and (ii) by inducing 
production of various eicosanoids (e.g. prostaglandin E2-PGE2), cytokines (e.g. IL-1β, IL-6 and 
TNF-α), reactive oxygen and nitrogen species, and histamine, among others. 
1.7.6 Miscellaneous Mushrooms 
 In addition, there are some other mushrooms that can also modulate the immune system. 
Fu et al. (2015) found that the immuno-modulatory activity of the mushroom Dictyophora 
indusiata (Vent.) Desv., veiled lady mushroom, on macrophage cell line (RAW 264.7) is due to 
its induction of production of NO and cytokines such as interleukins (IL-1, IL-6, IL-12) and 
TNF-α. Similarly, Liu et al. (2015) studied that KOMAP (polysaccharide isolated from alkaline 
extract of Pleurotus eryngii (DC.) Quél demonstrated antitumor activity in Renca tumor-bearing 
mice (renal cancer model) via directly inhibiting the growth of implanted tumor; this inhibition 
was related to the improvement of the immune system function as various immuno-stimulatory 
mechanisms were observed such as activation of immune cells in the spleen (e.g. natural killer 
cells-NK and cytotoxic T lymphocytes), increase in splenocyte proliferation, and enhanced levels 
of various cytokines (e.g. IL-2, TNF-α, and IFN-γ). 
Polysaccharide isolated from the medicinal fungus Flammulina velutipes (Curtis) Singer, 
exhibited antioxidant and immuno-modulatory activity via enhancing NO levels and augmenting 
cytokines such as IL-1β, IL-6, and TNF-α in RAW264.7 macrophage cell lines (Wu et al., 2014).  
Therefore, an efficient immune system is important to recognize and eliminate tumor cells 
prior to the major damage to the surrounding microenvironment. Mushroom-derived compounds 
have a potential to modify the cellular machinery in favor of anti-tumor immunity by enhancing 
host recognition of tumor cells, targeting mutated pathways or signals and directly killing the 
cancerous cells. Consequently, the identification and isolation of immuno-stimulatory 
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compounds from mushrooms that can stimulate innate or acquired immune response might be 
useful in treating various tumors effectively with minimum side effects to the host system. 
1.8 Mushrooms, Inflammation and Micro-circulation 
Inflammation is a localized protective mechanism of the body in response to tissue injury or 
pathogen invasion. However, in chronic state, it can lead to serious diseases such as diabetes, and 
other cardiovascular issues. Previous literature has demonstrated that mushrooms, as mini 
pharmaceutical factories, are potential sources of natural anti-inflammatory metabolites tested in 
in vitro and in vivo settings (Elsayed et al., 2014). However, to our knowledge, this thesis will be 
the first of its kind to explore the effect of mushrooms in ameliorating the negative impact of 
inflammation at the level of animal microcirculation. 
Microcirculation deals with the vasculature at the micro level. It constitutes arterioles, 
capillaries, venules, and vascular wall components (endothelium, pericytes, and vascular smooth 
muscles) that play a central role in delivering nutrients, removing wastes, transporting hormones, 
and providing defense against harmful agents.  
Microcirculation holds importance in the initiation and perpetuation of inflammation (Libby 
et al., 2009). It is highly responsive to the inflammatory cascade and all of its vasculature 
components (arterioles, capillaries, venules, endothelial cells, vascular smooth muscles, and 
pericytes etc.) undergoing significant physiological changes during the inflammatory process 
(Libby et al., 2009; Medzhitov, 2008; Tuma, 2011). Rubor (redness), calor (heat), dolor (pain), 
and tumor (swelling) are the typical hallmarks of inflammation (Medzhitov, 2008; Serhan et al., 
2010) and all these four manifestations predominantly encompass microcirculation. Heat and 
redness occur because of vasodilation (Medzhitov, 2008); pain is triggered because of 
nociceptors stimulation (Serhan et al., 2010), and microvascular leakage is clinically expressed 
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as swelling or edema (Granger & Senchenkova, 2010). Moreover, there is also a fifth symptom 
associated with inflammation, “functio laesa” (loss of function) which, at the microcirculation 
level, manifests as permeation of blood in arterioles that percolate the entire tissue (Granger & 
Senchenkova, 2010; Tuma, 2011). The microcirculation and its vasomotor control mechanisms 
play an integral role in engaging and resolving the inflammatory event through a variety of 
signaling mechanisms. One aspect of the inflammatory cascade is compromising cellular 
communication by increasing the vascular permeability of the vessels (Payne et al., 2004). 
Therefore, restoring vascular communication could be a pre-requisite for the anti-inflammatory 
response. 
Thus, the fact that inflammation is a complex mechanism manifesting its true 
physiological form at the microcirculation level, coupled with the evidence that mushrooms are a 
potential source for treating inflammation, suggests that the successful anti-inflammatory 
extracts with the ability to reverse the induced inflammatory response in microcirculation will 
elucidate new mechanism of combating inflammation at the cellular level.  
Mushrooms have an established reputation as a dietary supplement, owing to their 
nutritional benefits, supported both by traditional use and scientific literature. There is therefore, 
a strong potential for finding novel immuno-modulatory compounds (anti-cancer and anti-
inflammatory) from BC wild mushrooms which have not been explored greatly for their 
therapeutic potential. Figure 1 illustrates the pharmacological basis of this thesis interconnecting 
role of medicinal mushrooms in both suppressed and hyper-active immune response.  
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  Figure 1.1 Illustration of an imbalanced immune system in pathology. 
An under-reacted immune system is prone to various infections, including cancers whereas a 
hyper-activated immune system initiates inflammatory pathways causing allergic reactions and 
autoimmune disorders (e.g. arthritis, lupus, inflammatory bowel disease, inflammation dependent 
tumors). The immuno-modulatory compounds from mushrooms could potentially rescue both 
conditions by harnessing the depressed state (i.e. immuno-stimulation/immunotherapy) and by 
slowing down the hyper-activated one (i.e. anti-inflammation). (Graphics credit: Nosheen Javed). 
1.9 Research Objectives 
The major objective of this study is to discover novel immuno-modulatory compound(s) 
extracted from BC wild mushrooms. 
1.9.1 Specific Aims 
 
i. To determine the immuno-stimulatory potential of 10 BC wild mushrooms (44 fractions) for 
their ability to induce TNF-α production in RAW 264.7 macrophages cells (Immuno-
stimulation) 
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ii. To determine the anti-inflammatory activity of 14 BC wild mushrooms (inactive for 
Immuno-stimulation) for their ability to inhibit Lipopolysaccharide (LPS) induced TNF-α 
production in RAW 264.7 macrophages cells (Anti-Inflammation) 
iii. To perform large-scale chemical extraction of selected mushroom species and establish a 
protocol for purification and characterization of the compound(s) responsible for anti-
inflammatory activity. 
iv. To understand the effects of the selected mushroom species in mice microcirculation for 
their ability to improve the negative impact of histamine-induced inflammatory response (in 
vivo model). 
1.10 Thesis Structure 
 
Chapter 1 contains the research background, specific aims and objectives of the research with an 
outline of the thesis. Chapter 2 deals with the connection of immuno-stimulation and cancer and 
discusses the screening of mushrooms for immuno-stimulation (i.e. the production of TNF-α). 
The second part of this chapter describes the implication of inflammation and explains the 
screening of mushrooms for anti-inflammation (i.e. the inhibition of TNF-α) induced by LPS. 
Chapter 3 presents the purification and characterization of the selected mushroom extract (i.e. 
5% NaOH fraction of Echinodontium tinctorium). Chapter 4 focuses on the impact of 
inflammation at micro-circulation and discusses the in vivo model of testing the most potent 
extracts of Echinodontium tinctorium (Fraction 4) and Inonotus obliquus (Fraction 2) in 
inflammatory micro-circulation of mice. Chapter 5 provides conclusions and future 
recommendations. 
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Chapter 2: Immuno-modulatory Studies 
This chapter is divided in two main parts. The first part encompasses the immuno-stimulatory 
assay while the second part is related to the anti-inflammatory analysis. The following flowchart 
describes the flow of the experimental steps. 
 
Figure 2.1. Flowchart demonstrating wild mushroom screening for Immuno-modulation. 
The chart also indicates the potential role of immuno-stimulatory and anti-inflammatory 
compound(s) towards pharmaceutical or nutraceutical development (Graphics Credit: Nosheen 
Javed). 
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Immuno-stimulatory Potential 
 
This part of the chapter gives a brief introduction on the functioning of the immune system 
with a focus on macrophages as representative of the immune system and specifically on TNF-α 
as a potential target for immunotherapy. Some important immuno-modulatory compounds 
isolated from mushrooms will be discussed. The experimental design, methodology and the 
primary results on the screening of 10 wild mushrooms (44 extracts) for their immuno-
stimulatory activity (i.e. stimulation of TNF-α in mice macrophage cells) are presented. 
Introduction to Immuno-stimulation concepts 
2.1 An overview of the immune system 
A generalized overview of the immune system is presented for better understanding and 
appreciation of the mechanism of action of mushroom immuno-modulators and their role in anti-
tumor immunity.  
The immune system in animals, including humans, is extremely complex. We are 
constantly exposed to different microorganisms and infectious agents from our surroundings. The 
first line of defense, the external or internal epithelial surfaces, is always ready to combat these 
foreign invaders from any route of entry. The respiratory tract mucosa offers defense against 
airborne agents, the gastrointestinal mucosa combats infectious agents present in the food and 
water, and the skin provides a physical and chemical barrier against the outside world. Any 
damage to these barriers will allow micro-organisms to permeate the body (Janeway, 2001). 
2.11 Innate immune response 
In all vertebrates, invasions by nocuous agents are initially encountered by a pre-existing 
innate defense system of the body, the non-specific response, which is activated minutes after 
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exposure, providing the same non-specific response against any type of pathogen (Abbas et al., 
2014; Janeway, 2001). 
 Macrophages, major cells of the innate immune response, are the first cells to encounter 
these infectious agents, but they are soon reinforced by numerous neutrophils recruiting at the 
site of infection (Abbas et al., 2014). Macrophages recognize these invading microorganisms 
immediately and engulf these agents by phagocytosis. These macrophages are the activated form 
of circulating monocytes that, once mature, reside in the tissues throughout the body (Abbas et 
al., 2014; Janeway, 2001). Neutrophils, or polymorpho-nuclear neutrophilic leukocytes, are the 
second major family of phagocytes that are activated following invasion of infectious agents 
(Janeway, 2001). Both macrophages and neutrophils are involved in recognition, ingestion, and 
destruction of many pathogens and are important components of the innate immune response 
(Abbas et al., 2014; Janeway, 2001). Later, certain dendritic cells and other lymphocytes also 
play their role in the recognition, and ultimately elimination, of the un-wanted foreign invaders. 
 This non-specific (innate) immunity is able to combat many invading foreigners without 
initiating the adaptive immune response (Janeway, 2001). Thus, innate immunity with the help of 
its effector mechanisms provides a front line of host defense that senses the pathogens 
immediately, combats them directly, and shows similar response irrespective of the invader type. 
2.1.2 Adaptive Immune Response 
Adaptive immune response is specific and selective in its target: it deals with the foreign or 
abnormal signal in a more directed manner and eliminates the offender selectively. Unlike innate 
immunity, this response is antigen-specific, diverse, possesses immunogenic memory, and can 
distinguish self from non-self molecules, thus minimizing the chances of auto-immune response.  
This adaptive immune system is triggered because of the activating cascade of the innate 
immune system’s phagocytes and natural killer cells’ action. Interestingly, these adaptive 
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immune cells, once activated, further augment the action of innate immune cells, thus working in 
concert to provide an enhanced and stronger defense system. B and T lymphocytes (simply 
known as B and T cells), major components of adaptive immune response, are produced in bone 
marrow, circulated in blood and lymphatic system, and are concentrated in various lymphoid 
organs (Kuby, 1997).  
B lymphocytes (B cells) mature in bone marrow and carry a distinct B cell (antigen-binding) 
receptor on the surface of their membrane. When these receptors are activated, B cells secrete 
specific antibodies that bind to the foreign antigen, producing antigen-antibody complexes. Such 
complexes are “destruction markers” for cytotoxic T lymphocytes in a process called antibody 
dependent cell cytotoxicity (ADCC). Moreover, antibodies also help in the direct neutralization 
of antigens by macrophages (phagocytosis) through opsonization (Kuby, 1997). 
T lymphocytes (T cells), on the other hand, mature in the thymus gland and carry their 
unique antigen-binding receptor, T cell receptor (TCR). For identification and specificity, they 
can only recognize major histocompatibility complex (MHC) molecules (Kuby, 1997).  
Naïve T cells (undifferentiated T cells), after encountering MHC associations, differentiates 
into memory T cells and various effectors T cells (Helper T cells, Suppressor T cells, and/or 
Cytotoxic T cells). In general, T cells displaying CD4+ act as helper T cells, interacting with an 
antigen-MHC II molecule complex, and secrete various cytokines to help cytotoxic T cells. On 
the other hand, T cells displaying CD8+ act as cytotoxic T cells, interacting with an antigen-MHC 
I molecule complex, and directly kill the affected cells (Kuby, 1997). These cytotoxic T cells are 
vital for destroying various infectious agents and tumor cells; these cells are also potential targets 
for immunotherapy, especially in recent scientific breakthroughs that augment the T cell response 
to achieve the anti-tumor activity. These involve immune checkpoint inhibitors, e.g. cytotoxic T 
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cell-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) antibodies. These 
antagonists along with engineered (chimeric) antigen receptor (CAR) T cells can improve the T 
cells action for enhanced host derived anti-cancer effect (Page et al., 2014; Weiskopf & 
Weissman, 2015).  
Thus, both innate and adaptive components of the immune system are needed for the 
optimum working of the immune response. The suppression of the innate response also 
suppresses the adaptive response; this is the underlying mechanism of various diseases including 
cancer. Therefore, the main focus of immunotherapy is to re-activate this suppressed immune 
state so that it can regain the power to kill pathogens, including tumor cells.  
2.2 Immunotherapy-Role of Macrophages 
Macrophages, major cells of the innate system, are part of mononuclear phagocyte system 
derived from circulating monocytes; they act as first line defense and are involved in 
phagocytosis of the invading pathogen as well as in the pathology of many diseases such as 
infections, inflammation, wound healing, and tumor biology (Murray and Wynn, 2011).  
Macrophages have two major phenotypes: M1 and M2. Inactive M1 macrophages are 
classically activated by various microbial products, including lipopolysaccharide (LPS: a wall 
component in gram negative bacteria), and IFN-γ etc. to secrete various pro-inflammatory 
cytokines (IL-1, IL-6, TNF-α etc.). The M1 phenotype is capable of phagocytosis and therefore 
kills various foreign invaders and tumors; they promote tumor destruction via antibody fragment 
crystallizable gamma receptors (Fcγ) that promotes ADCC response (Solinas et al., 2009). M1 
phenotype is reduced in tumor micro-environment because of the increased level of the invading 
tumor and the side effects of chemotherapeutic drugs. M2 macrophages are the suppressed form 
of the macrophages that are involved in immuno-suppression and immuno-regulatory 
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mechanisms. The macrophages present in tumor stroma are similar to M2 phenotype and are 
called “Tumor associated Macrophages (TAMs)” (Mills et al., 2016). These tumor promoting 
macrophages suppress the immune system and enhance tumor angiogenesis and tumor 
infiltration capacity by compromising endothelium matrix integrity and therefore nourishing 
tumor development (Weiskopf & Weissman, 2015). TAMs also tilt the balance of the immune 
system to the suppressed state, thereby causing a decrease in M1 macrophages and pro-
inflammatory cytokines.  
Upon activation, M1 macrophages could eliminate cancer by initiating the pro-inflammatory 
response, secreting various cytokines and by enhancing the phagocytosis and direct killing of 
cancer cells (activating cytotoxic T cell response) (Solinas et al., 2009). Therefore, the aim 
behind the mechanism of action of anti-cancer immuno-modulatory drugs (targeting 
macrophages) is to increase the levels of pro-inflammatory macrophages (M1) that can exhibit a 
strong immune response while reducing the number of tumor associated macrophages (TAMs) 
that replenish the tumor microenvironment.  
In early trials (1980’s), monoclonal antibodies (mAbs) were used in vitro to stimulate 
macrophages against cancer cell lines. These mAbs enhance macrophages infiltration and 
ultimately enhance in vivo anti-tumor immunity by promoting macrophage-associated cancer cell 
destruction in mice models (Weiskopf & Weissman, 2015). Recently, studies are supporting the 
correlation of the efficiency of monoclonal antibodies and the presence of activated macrophages 
in the tumor micro-environment. For instance, the anti-CD20 antibody rituximab is dependent on 
the presence of macrophages for its effectual action both in in vitro (lymphoma and leukemia 
model) (Bologna et al., 2011) and in in vivo (CSF-1op mice – lacking normal number and 
development macrophage model) settings. Surprisingly these antibodies were not affected by B 
24 
 
cells, T cells, or natural killer cells depletion, thus highlighting the role of macrophages in the 
anti-tumor response (Uchida et al., 2004). 
Tumor associated macrophages may enhance tumor progression in the absence of anti-tumor 
therapy. On the other hand, immuno-stimulatory and pro-inflammatory macrophages increase 
specific anti-tumor antibody level and are also involved in direct phagocytosis and ADCC anti-
tumor response. Therefore, macrophages, being major immune effector cells, are one of the 
recent and main targets for cancer immunotherapy. However, it should also be kept in mind that 
only targeting macrophages may not demonstrate benefit in every tumor type, rather, the 
combinational therapy with other anti-neoplastic agents may be a more appropriate and effective 
approach for a strong and enhanced anti-cancer drug therapy response. 
2.3 Immunotherapy-Role of TNF-α 
TNF-α is a 157 amino-acid protein, first identified in 1975, and successfully cloned in 1984. 
It is one of the major immuno-modulatory cytokines released by macrophages and other immune 
cells including T cells, NK cells, and fibroblasts, among others (Rosenblum & Donato, 1988; 
Van Horssen et al., 2006). It is a multifunctional cytokine and is the main focus of the current 
study; TNF-α is involved in the inhibition of tumor proliferation and induction of tumor 
regression. It has two key TNF receptors (TNFRs): TNF-α receptor 1 (TNFR-1) and TNF-α 
receptor 2 (TNFR-2). Out of these two receptors, TNFR-2 is only confined to the immune cells. 
TNFR-1, on the other hand, is present on all cells and is the major initiator of all biological 
processes that comes under the tasks umbrella of TNF-α. This receptor has dual roles: it gives 
both cell apoptosis and cell survival signals which ultimately decide the cellular outcomes in 
terms of cell survival and proliferation or cell death (Bouwmeester et al., 2004; Wang & Lin, 
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2008). Thus, tumor death could be controlled by regulating the capability of TNF-α to generate 
apoptotic signaling. 
The apoptotic or survival cascade of TNF-α is mainly dependent on the type of signal 
generated from the TNFR-1 receptor (Balkwill, 2006; Bouwmeester et al., 2004). When TNFR-1 
signals apoptosis, FADD (Fas associated death domain) activates pro-caspase 8 that starts a 
protease cascade generating apoptotic signals and activating certain endonucleases like EndoG. 
This activation ultimately causes DNA fragmentation (Balkwill, 2006; Wang & Lin, 2008). 
However, when TNFR-1 signals survival, TRAF-2 (TNF-α associated factor 2) forms a complex 
and generates a cascade inhibiting apoptosis through cIAP (i.e. cytoplasmic inhibitor of 
apoptosis protein) (Wang & Lin, 2008). This triggers phosphorylation and activates cFOS / cJUN 
through stimulation of MAPK (mitogen activated protein kinase) and JNK (cJUN- N – terminal 
kinase) (Wang & Lin, 2008). TRAF-2 is also involved in the activation of NF-ĸB. These cFOS / 
cJUN and NF-ĸB are all the transcription factors that induce transcription for genes that are 
involved in anti-apoptosis cascades, proliferation, immunomodulation, and inflammation (Wang 
& Lin, 2008). The above pathway demonstrates that it is either the immuno-modulatory effect or 
the anti-tumor manifestation that is initiated with the activation of TNF-α. Detailed studies 
exploring the mechanism of action of TNF-α have revealed that the ability of TNF-α to cause 
apoptosis, could be applied to get a desired anti-tumor response. However, the signals that 
program TNF-α to opt for one of the aforementioned cascades still needs more exploration 
(Wang & Lin, 2008). 
Previous studies have suggested that the stimulation of TNF-α could exert positive anti-
cancer effects. In 1975, using in-vivo models, it was shown that TNF-α (produced by 
macrophages of endotoxins) could successfully induce hemorrhagic necrosis in Bacillus 
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Calmette Guerin (BCG, an attenuated strain of Mycobacterium bovis) infected mice (Carswell et 
al., 1975). Later, numerous recombinant TNF-α were applied both as a single agent 
(Braczkowski et al., 1998; Furman et al., 1993) as well as in combination with other cytokines 
and chemotherapeutic agents in various Phase I and Phase II clinical trials to explore their 
effectiveness against tumor in various in vivo and in vitro models (Roberts et al., 2011). In vitro 
studies encompassing TNF-α have shown inhibitory effects on SV-40-human mammary 
epithelial and human breast cancer cell lines. However, this is dependent on the type of cancer 
cell lines, pointing out to the specificity of the TNF-α mode of action (Dealtry et al., 1987). TNF-
α has been shown to enhance the anti-cancer effects of various anti-neoplastic drugs e.g. 
etoposide, actinomycin D, DNA topoisomerase inhibitors, and Adriamycin in murine bladder 
tumor (MBT-2) cell lines (Roberts et al., 2011). However, sadly, injecting TNF-α (whether alone 
or in combination) is also associated with some serious side effects and toxicities, e.g. 
hypotension, neurotoxicity, hepatotoxicity, cardiotoxicity etc. Hence, keeping in view the 
problems with exogenous TNF-α, the emphasis of the current research is to stimulate the 
macrophages already present inside the body so that the TNF-α could be released in an indirect 
and safer mode to combat the tumor cells in a more effective way.  
Therefore, the focus of this chapter will be on the induction of TNF-α as a major marker of 
immuno-stimulation. It will highlight the primary screening result of mushroom fractions for the 
stimulation of TNF-α (i.e. the stimulation of inactivated macrophage cells to release TNF-α) for 
the enhanced immuno-stimulatory effect. 
2.4 Immuno-modulatory compounds from wild mushrooms 
Mushrooms, as described earlier, act as dietary supplements because of their nutritional and 
medicinal values (Miles & Chang, 2004) and their medicinal potential has been confirmed by 
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extensive studies. There are four main classes of mushroom immuno-modulators depending upon 
their chemical nature: (i) immuno-modulatory polysaccharides, (ii) fungal immuno-modulatory 
proteins (FIPs), (iii) immuno-modulatory lectins and, (iv) immuno-modulatory terpenes and 
terpenoids (El Enshasy & Hatti-Kaul, 2013). 
2.4.1 Immuno-modulatory polysaccharides 
Mushrooms have various polysaccharides that have immuno-modulating properties. Krestin 
(PSK) from T. versicolor is a highly promising orally active polysaccharide that has a history of 
successful clinical trials in breast, colorectal, lung, stomach, and head and neck cancers. PSK is 
an approved adjuvant of chemotherapy in Japan since 1980 (Sun et al., 2012). In in vitro models, 
PSK increases human peripheral blood lymphocytes and enhance the production of TNF-α and 
NO (Li et al., 2011). Lentinan (a β-1, 3-D-glucan with β-1,6 branches) was the first reported 
polysaccharide with potential immuno-modulating and anticancer activity. It was extracted from 
fruiting bodies of Lentinula edodes in Japan in the 1960s (Bisen et al., 2010). Lentinan has also 
been approved for its adjuvant use with chemotherapy for treatment of stomach cancers in Japan 
since 1985 (Higashi et al., 2012) 
Thus, immuno-modulatory polysaccharides have strong impact in the enhancement and/or 
restoration of immune responses in different cell and animal models. 
2.4.2 Fungal immuno-modulatory proteins (FIPs) 
Recently, a new family of proteins from mushrooms, the fungal immuno-modulatory proteins 
(FIPs), has been documented with strong immuno-modulating properties. The first FIP was 
characterized from G. lucidum in 1989 and named Ling-Zhi-8 (Tanaka et al., 1989). Other 
examples of FIP include FIP-fve from F. velutipes (Wang et al., 2004), FIP-gsi from G. sinensis 
(Li et al., 2010a), FIP-vvo and FIP-vvl from Volvariella volvacea (Bull.) Singer (Hsu et al., 
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2008), FIP-pcp from Poria cocos F.A. Wolf (Chang & Sheu, 2007), FIP-gmi from G. 
microsporum R.S. Hseu (Li et al., 2010b), and FIP-tvc from T. versicolor (Li et al., 2011). 
2.4.3 Immuno-modulatory lectins 
Immuno-modulatory lectins constitute a diverse family of carbohydrate-binding proteins that 
have precise binding capabilities. Lectins isolated from mushrooms have well documented anti-
tumor, anti-proliferative, and immuno-modulatory properties. TML-1 and TML-2, from 
Tricholoma mongolicum S. Imai, and Concanavalin A, from V. volvacea also exhibited anti-
tumor and immuno-modulatory activities by activating the immune system rather than showing 
cytotoxicity effects (Wang et al., 1998). These lectins show their mechanism of action by 
inducing TNF-α and nitrite production and by producing macrophage-activating factors that 
inhibit the growth of mouse lymphoblast (p815) mastocytoma cells. Some of these macrophage-
activating factors are IFN-γ and other cytokines and interleukins, triggered by enhanced 
expression of IL-1β, iNOS and transforming growth factor-β (TGF-β) (Liu et al., 2005). The 
lectins of Grifola frondosa (Dicks.) Gray, have stronger cytotoxic effects even at low doses and 
are thus more potent and effective against HeLa cells (El Enshasy & Hatti-Kaul, 2013). 
2.4.4 Immuno-modulatory terpenes and terpenoids 
Mushrooms also have a large number of immuno-modulatory terpenes showing anticancer 
and anti-infective properties. Terpenes constitute basic building blocks of isoprene unit which 
consists of five-carbon atom and have a molecular formula of (C5H6)n. G. lucidum and G. 
applanatum (Pers.) Pat., have been documented to contain high terpene and tri-terpenoid 
concentrations. Lanostane (a triterpenoid) isolated from G. lucidum shows strong modulation 
activities against the immune system (Jeong et al., 2008); these terpenes from G. lucidum are 
even capable of preventing drug-induced nephrotoxicity and inflammation (Tanaka et al., 1989). 
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Some other examples of terpenes and terpenoids from Ganoderma species include 
ganodermanontriol, ganoderols, ganoderals, lucidone, ganodermanondiol, ganodermic and 
ganoderic acids that have strong roles in stimulating NF-k β and mitogen-activated protein 
kinases (MAP-K) pathways (Gao et al., 2002). 
 This literature indicates the role of the medicinal mushrooms in immunotherapy. The 
main principle of natural immuno-modulators is to employ bioactive metabolites from 
mushrooms to re-program the suppressed immune system for the eradication of tumor initiation 
and progression. 
2.5 Materials & Methods 
2.5.1 Mushroom Collection & Identification 
At the outset of my research, the UNBC team comprising of Drs. Chow Lee, Hugues 
Massicotte and Keith Egger, collected several species of fungi from the North Central region of 
BC (e.g. Prince George, Prince Rupert, Terrace, McBride). These collected fungi belonged to one 
of three categories: (i) fungi found in BC and around the world, well known for their immuno-
modulatory properties, (ii) fungi found only in BC that are sister species of others present around 
the world and are known to have immuno-modulatory properties, or (iii) fungi that are only 
found in BC and have not been previously explored for their therapeutic properties. 
After collection, the specimens were dried and identified, first based on their morphology 
and later confirmed through DNA sequence analysis. Morphological identification involved 
measurements of height, cap diameter, stem length and width, as well as descriptions of habitat, 
color, odor, textures, and shape. Spore prints were also collected. Morphological identification 
was made using the identification software, “Matchmaker” (Gibson et al., 2010) and the 
dichotomous keys in the reference guide Mushrooms Demystified (Arora, 1986). Tissue samples 
from the internal flesh of the cap were stored at freezing temperature (-20°C) until DNA analysis 
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was performed. Specimens were preserved at 4°C so that deterioration could be minimized while 
handling was required.  
To further confirm the identity of mushrooms, fungal specific primers for the internal 
transcribed spacer (ITS) region of ribosomal DNA (rDNA) were used; a successful protocol for 
the identification of a wide range of fungi (Schoch et al., 2012). Primers designed for the ITS 
region were also capable of amplifying fungal DNA from samples having other contaminating 
DNAs such as plant tissues or soil (Peay et al., 2008). Methods of identification in Dr. Lee’s lab 
were similar to those of Rajaratnam & Thiagarajan (2012). Briefly, DNA was extracted from the 
samples and subjected to the polymerase chain reaction with the ITS3 (forward) and NLB4 
(reverse) primers. The amplified DNA was checked for purity by agarose gel electrophoresis.  
The purified PCR products were then submitted to Macrogen Inc. (USA) for DNA sequencing 
and BLAST searches against the GenBank database were used to identify the fungal species. The 
analysis was based upon the sequence differences in the ITS2 spacer region in rDNA. This ITS2 
region identification was consistent with the morphological identification with high certainty for 
all of the mushrooms tested (Figure 2.2.) 
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Figure 2.2 Illustration of ITS-1 and ITS-2 regions between conserved flanking regions with 
position of both forward (above) and reverse (below) primers. ITS3 is used as forward 
primer and NLB4 is used as reverse primer. Figure modified from Martin & Rygiewicz (2012). 
2.5.2 Chemical extraction 
After successful identification, fungal specimens were dehydrated at 50°C using a drying 
oven, and ground into a fine powder with a conventional household blender; for woody 
specimens (conks), a hammer mill was used for grinding. After this step, powdered fungal 
samples were kept at room temperature until chemical extraction was done. 
The fungal extractions were performed by a colleague graduate student in Dr. Chow Lee’s 
lab (Mr. Aaron Smith). For effective extraction of organic material from natural products, 
Mizuno (1999) had developed a basic four-step extraction that is widely accepted and practiced 
in the mycology world. This can be modified according to the specific extraction target (Mizuno, 
1999, Zhang et al., 2007). Using the Mizuno method, samples were initially extracted with 80% 
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ethanol so that any low molecular weight compounds can be removed. Further samples were 
extracted with hot water (100°C, 3 hours), 2% ammonium oxalate (100°C, 6hrs), and 5% sodium 
hydroxide (80°C, 6hrs) (Mizuno, 1999). It is believed that the hot water fraction contains the 
water-soluble polysaccharides, and the alkali fractions contain the water-insoluble 
polysaccharides. The conditions of this extraction can be changed to suit the nature of any target 
molecules (Zhang et al., 2007).  
The Mizuno’s protocol was modified to fit the current fungal extraction process. The fungal 
samples were extracted using 80% ethanol (65°C, 3 hours) for the separation of soluble low 
molecular weight compounds. This solution, filtered through Whatman® paper No.3, is referred 
to as fraction 1, while the residue was subjected to the second step: 50% methanol extraction 
(65°C, 3 hours). Similarly, the filtrate (F2) was preserved and the residue was extracted with 
water, F3, (65°C, 6 hours). Finally, the residue was subjected to the last step, 5% NaOH, F4, 
(65°C, 6 hours). The flowchart of this extraction procedure is summarized in Figure 2.3. Initially, 
some samples were also extracted using 2% Ammonium hydroxide in the 4th step but it was 
omitted later because of its incompatibility with the anti-proliferative anti-tumor cell assay. 
However, for immuno-modulatory assay (both immuno-stimulatory and anti-inflammatory 
assay) of six fungal species (Fomitopsis pinicola (Sw.) P. Karst., L. edodes, F. fomentarius, 
Piptoporus betulinus (Bull.) P. Karst., G. applanatum, and Echinodontium tinctorium (Ellis & 
Everh.) Ellis & Everh. fraction 4 still represented the 2% ammonium oxalate extraction filtrate, 
while fraction 5 represented the 5% sodium hydroxide extraction filtrate. This extraction 
procedure allowed us to have low molecular weight compounds in the first two fractions, some 
water-soluble polysaccharides in the third fraction, and water insoluble polysaccharides in the 
fourth fraction. Collected fractions were subjected to rotor-evaporation for concentration. These  
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were later lyophilized and stored at 4ºC until assays were performed. 
 
 
Figure 2.3. Flowchart showing the chemical extraction scheme adopted in the current 
study. This scheme is proposed to separate compounds on the basis of their molecular 
weights and solubility (Graphic credit: Nosheen Javed). 
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2.5.3  Assessing chemical fractions for immuno-stimulatory activity 
Raw 264.7 mouse macrophage cell line for use in immuno-modulatory activities was 
purchased from the American Type Culture Collection (Rockville, Maryland). Cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM), supplemented with glutamine 
(LONZA, Walkersville, Maryland) and containing 10% v/v fetal bovine serum (FBS) in a 
humidified incubator at 37°C supplied with 5% carbon dioxide.  A day following retrieval from 
the maintenance solution, Raw 264.7 cells were plated in a 96-well plate (100,000 cells/well) and 
were incubated overnight in 200 L DMEM without FBS.  
After an overnight incubation, the medium (200 uL DMEM without FBS) was removed. 
Cells were washed with 200 µL BioWhittaker® Phosphate Buffer Saline (PBS) (Lonza, 
Walkersville, Maryland) and then treated with 100 L DMEM without FBS with: (i) various 
mushroom fractions (conc. 1 g/uL), (ii) lipopolysaccharide (LPS) (500 ng/mL) for use as the 
positive control, or (iii) DMEM and respective solvents (i.e. water or methanol used for 
resuspension of lyophilized samples) for use as negative controls.  
After a further 6 hours of incubation, supernatants (~100 L) were collected, centrifuged 
(4°C, 200xg, 5 min using Allegra® X-15R, benchtop centrifuge, Beckman Coulter, CA, USA) 
and stored at -80ºC freezer until ELISA was performed for the quantification of TNF-α 
production.  
2.5.4 Enzyme-Linked Immunosorbent Assay (ELISA) 
For ELISA, BD OptEIA™ Mouse TNF (Mono/Mono) ELISA Set & Reagent Set A (BD 
Biosciences, CA, USA) were used according to the manufacturer’s protocol to quantify the 
amount of TNF-α in the supernatant.  
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Briefly, a 96-well Microtiter™ polystyrene plate (Thermo Fisher Scientific, MA, USA) was 
coated overnight at 4°C with a capturing antibody (i.e. anti-mouse TNF-monoclonal antibody) 
diluted in coating buffer (1:500). The following day, the plate was washed with washing buffer 
(300 µL of wash buffer thrice) and blocked with assay diluent (200 L) for 1 hour. After one 
hour, the plate was washed with washing buffer (300 µL of wash buffer thrice) and supernatants 
were added (diluted 1:10 in assay diluent) and incubated for 2 hours at room temperature. At this 
time, the TNF-α standard concentrations (1000, 500, 250, 125, 62.5, 31.3 and 15.6 pg/mL) were 
prepared and added for the generation of standard curve. Subsequently, the wells were washed 
again (300 µL of wash buffer, five times), and the working detector (biotinylated mouse TNF-α 
monoclonal antibody + Streptavidin-horseradish peroxidase conjugate) was added (100 uL) for 
an hour. This was followed by an extensive washing (300 µL of wash buffer, five times), addition 
of substrate solutions (100 L) and incubation for another 30 minutes. Finally, 50 µL of stop 
solution was added. The optical density was measured at 450 and 550 nm using a Synergy-2 
(BioTek®, VT, USA) fluorescent polarizer. The concentration of TNF-α was calculated from the 
standard curve of mouse recombinant TNF-α via a log-log regression analysis using PRISM6. 
Figure 2.4 summarizes the protocol of immuno-modulation in RAW 264.7 cells from Day 1 to 5.  
2.5.5 Data Analysis 
Each experiment was repeated with at least one more biological replicate with 4 wells 
(quadruplicate) per treatment. Data was expressed as mean ± standard deviation. Error bars were 
incorporated as a representation of standard deviation. One-way ANOVA was performed for 
statistical analysis using PRISM. 
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Figure 2.4. Schematic representation of immuno-modulation assay protocol using RAW 
264.7 cells. The protocol is spread over a period of 5 days in the following sequence: cell 
reviving, cell dividing, cell plating, and cell treatment with mushroom extracts (Graphics credit: 
Sukhpreet Buttar).  
2.6 Results 
2.6.1 Mushroom Collection and Identification: 
A total of 14 fungi were used for this study (10 species for immuno-stimulatory and 4 
additional only for anti-inflammatory assays). These fungi were collected from 9 different 
locations of North Central BC between the 2012 and 2014. The fungal identification was 
performed by Ms. Sukhpreet Buttar and Mr. Jatinder Khatra (Undergraduate students in Dr. Lee 
lab) and the results presented confirmed the initial identification performed via morphological 
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analysis. Table 2.1 summarizes fungal samples collected across the BC wild forests with the 
relevant details on collection and identification of fungal species.  
Table 2.1: Summary of fungi collected from North Central forests of British Columbia 
Identity Collected 
By 
Date of 
Collection 
Place of Collection in BC Best GenBank Match 
(%similarity/%Coverage) 
Fomitopsis  
pinicola  
(Sw.: Fr.) P. Karst.  
Drs. Keith 
Egger & 
Hugues 
Massicotte 
Summer 
2012 
Terrace, BC No sequencing data (verified via 
morphological analysis) 
Lentinula edodes 
(Berk.) Pegler 
Dr. Chow Lee
  
Jan 2013 Purchased at Shoppers 
Wholesale, Prince George 
No sequencing data (verified via 
morphological analysis) 
Piptoporus betulinus  
(Bull.) P. Karst.  
Marta 
Zmudzinski 
25 Oct 2012 Forests For The World 
(FFTW), Greenway Tr., 
Prince George 
JX109856.1  
(99%/100%) 
Fomes fomentarius  
(L.) Fr. 
Marta 
Zmudzinski 
25 Oct 2012 FFTW, Greenway Trail, 
Prince George 
JX109860.1  
(98%/100%) 
Ganoderma  
applanatum  
(Pers.) Pat. 
Dr. Keith 
Egger 
20 Aug 2012  Thornhill Mountain Trail, 
Terrace 
KC581319.1  
(99%/100%)  
Echinodontium 
tinctorium  
(Ellis & Everh.) Ellis 
& Everh 
Aaron Smith Sep 2013 West Twin Prov Park No sequencing data (verified via 
morphological analysis) 
Inonotus obliquus  
(Ach. ex Pers.) Pilát 
Marta 
Zmudzinski 
April 2013  FFTW, Prince George No sequencing data (verified via 
morphological analysis) 
Leucocybe connata 
(Schumach.) Vizzini, 
P. Alvarado, G. 
Moreno, & Consiglio 
Marta 
Zmudzinski 
22 Sep 2012 Eskers Provincial Park, 
Prince George 
KC581297.1  
(99%/100%)  
Laetiporus  
sulphureus (Bull.)  
Murrill 
Drs. Keith 
Egger & 
Hugues 
Massicotte 
Summer 
2013 
UNBC Campus, Prince 
George 
No sequencing data (verified via 
morphological analysis) 
Phellinus nigricans 
(Fr.) P. Karst 
Keith Aug 2012  Thornhill Mountain Trail, 
Terrace 
AY558631.1  
(98%/70%)  
Phellinus  
igniarius* (L.) Quel 
 Jul 2014  Kitselas Rd, Terrace 
Mountain, Terrace 
AY558623.1  
(99%/100%)  
Trichaptum  
abietinum* (Pers. Ex 
J.F. Gmel.) Ryvarden 
Ankush Oct 2013  FFTW, Prince George KC581332.1  
(99%/100%)  
Hericium  
coralloides* (Scop.) 
Pers.  
Vicky Myhre Sep 2013  Cottonwood Island Park, 
Prince George 
AF506459.1  
(99%/100%)  
Letharia vulpina* 
(L.) Hue 
Vicky Myhre June 2014 Beaverdam Lake, Clinton 75% (verified via morphological 
analysis) 
*Immuno-stimulatory activity of extracts from these species was assessed by Mr. Ankush Barad and Ms. Vicky 
Myhre (Graduate students in Dr. Lee lab). Only inactive fractions of these fungi were assessed for anti-inflammatory 
activity and described in this thesis. 
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2.6.2 Mushroom Extraction 
After the collection and identification of mushrooms, chemical extraction of mushrooms was 
performed using four successive solvent systems: 80% ethanol (F1), 50% methanol (F2), water 
(F3) and 5% NaOH (F4). Initially, 2% ammonium oxalate extraction was also performed at the 
fourth step, but it was later omitted because of the incompatibility of oxalate with the medium 
used for growing Raw264.7 cell lines. So, in these extracts, F4 represent 2% ammonium oxalate 
and F5 represents 5% NaOH fraction. This scheme is not followed by F. pinicola and L. edodes 
as these species were the very initial ones to be extracted before the whole protocol was 
developed. Therefore, in these two species, 50% methanol extraction was not performed at all. In 
F. pinicola, 99% ethanol (F2) was performed as a second step but in L. edodes, this step was 
omitted completely and the extraction scheme was as follows: 80% ethanol, water, 2% 
ammonium oxalate, and 5% NaOH. Table 2.2 summarizes the extraction of each species 
followed by percent yield. The solvent that was used for re-constituting the mushroom after 
lyophilization was also mentioned. It was observed that 5% NaOH extract had notably higher 
mass as compared to the other extracts; this could possibly be due to the presence of salt in these 
extracts.  
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Table 2.2: Representation of Extraction Solvent, yield and Re-suspension solvent for Mushroom Fractions 
Mushroom  
Specimen 
Processed  
Raw Weight 
(g) 
 
Fraction 
 No. 
Extraction  
Solvent 
 Mass (g) Percent  
Yield (%) 
Resuspended 
 Solvent 
 
 
Fomitopsis pinicola 
 
33 
F1 80% Ethanol 0.16 0.50 H20 
F2 99% Ethanol 8.2 24.80 Methanol* 
F3 Water 0.65 1.96 H20** 
F4 2 % (NH₄)₂C₂O₄  N/D N/D N/D 
F5 5% NaOH 16.30 49.40 H20 
 
 
Lentinula edodes 
 
50 
F1 80% Ethanol 13.90 27.70 H20 
F2 Water 6.64 13.30 H20 
F3 2 % (NH₄)₂C₂O₄  13.94 27.88 H20 
F4 5% NaOH 30.13 60.30 H20 
 
 
Piptoporus 
betulinus 
 
128.5 
F1 80% Ethanol 3.77 2.93 Methanol* 
F2 50% Methanol 0.39 0.30 H20 
F3 Water 0.22 0.17 H20 
F4 2 % (NH₄)₂C₂O₄  4 3.1 H20 
F5 5% NaOH 22 17.1 H20 
 
 
Fomes fomentarius 
 
126.45 
F1 80% Ethanol 2.21 1.75 Methanol** 
F2 50% Methanol 0.59 0.467 H20** 
F3 Water 0.37 0.30 H20 
F4 2 % (NH₄)₂C₂O₄  13.13 10.40 H20 
F5 5% NaOH 18.94 14.97 H20 
 
 
Ganoderma 
applanatum 
 
89.31 
F1 80% Ethanol 1.56 1.75 Methanol** 
F2 50% Methanol 0.66 0.74 H20** 
F3 Water 0.51 0.57 H20 
F4 2 % (NH₄)₂C₂O₄  6.25 6.99 H20 
40 
 
F5 5% NaOH 12.3 13.77 H20 
 
 
Echinodontium 
tinctorium 
 
273.15 
F1 80% Ethanol 4.05 1.48 H20 
F2 50% Methanol 0.37 0.14 H20 
F3 Water 0.93 0.34 H20 
F4 2 % (NH₄)₂C₂O₄  6.15 2.25 H20 
F5 5% NaOH 14.7 5.38 H20 
 
 
Inonotus obliquus 
 
315 
F1 80% Ethanol 5.5 1.75 H20 
F2 50% Methanol 11.8 3.75 H20 
F3 Water 7.6 2.41 H20 
F4 5% NaOH 64.8 20.57 H20 
 
 
Leucocybe connata 
 
80 
F1 80% Ethanol 17.63 22.03 H20 
F2 50% Methanol 11.78 14.72 H20 
F3 Water 3.53 4.41 H20 
F4 5% NaOH 22.91 28.64 H20 
 
 
Laetiporus 
sulphureus 
 
77 
F1 80% Ethanol 6.28 8.16 H20 
F2 50% Methanol 3.22 4.18 H20 
F3 Water 1.17 1.52 H20 
F4 5% NaOH 23.65 30.71 H20 
 
 
Phellinus nigricans 
 
135.89 
F1 80% Ethanol 2.31 1.70 H20 
F2 50% Methanol 0.77 0.56 H20 
F3 Water 1.74 1.28 H20 
F4 5% Sodium 
Hydroxide 
46.72 34.38 H20 
       
*Previously re-suspended in ethanol, changed due to interference with anti-inflammatory assay   
**Previously re-suspended in DMSO, changed due to interference with anti-inflammatory assay. 
N/D is the fraction that was misplaced so this could not be assessed for biological activities.  
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2.6.3 Immuno-stimulatory Assay 
Immuno-stimulatory activity of fungal fractions was assessed by measuring TNF-α 
production in Raw 264.7 cells when treated with 1 µg/µL of the fungal fractions. LPS was used 
as the positive control and DMEM, water and/or solvents (methanol and/or ethanol) were used as 
negative controls.  
The following fractions stimulated the production of TNF-α at or above 500 pg/mL: All 
fractions of L. edodes; fraction 5 of F. fomentarius; fractions 3-5 of G. applanatum; fractions 3 
and 4 of E. tinctorium, L. connata, L. sulphureus and P. nigricans. Fractions from three fungi (F. 
pinicola, P. betulinus, and I. obliquus) stimulated the production of TNF-α at a level below 500 
pg/mL or had no stimulatory activity at all. Results are presented in Figure 2.5.1, 2.5.2, and 
2.5.3. 
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Figure 2.5.1. Assessing immuno-stimulatory potential of fungal extracts in RAW 264.7 macrophage 
cells. Fungal conc. 1 μg/μL; LPS (500 ng/mL) was used as positive control; solvents and media were used 
as negative controls. Error bars are standard deviation and One-way ANOVA analysis was performed as 
described in Materials and Methods (*, P < 0.0001). 
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Figure 2.5.2. Assessing immuno-stimulatory potential of fungal extracts in RAW 264.7 macrophage 
cells. Fungal conc. 1 μg/μL; LPS (500 ng/mL) was used as positive control; solvents and media were used 
as negative controls. Error bars are standard deviation and One-way ANOVA analysis was performed as 
described in Materials and Methods (*, P < 0.0001). 
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Figure 2.5.3. Assessing immuno-stimulatory potential of fungal extracts in RAW 264.7 macrophage 
cells. Fungal conc. 1 μg/μL, LPS (500 ng/mL) was used as positive control; solvents and media were used 
as negative controls. Error bars are standard deviation and One-way ANOVA analysis was performed as 
described in Materials and Methods (*, P < 0.0001). 
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2.7 Discussion 
The current study explores the immuno-modulatory activity of wild fungi collected from the 
forests of North Central BC and the overall results show that immuno-modulation potential is not 
uncommon in BC wild mushrooms as 9 out of forty-four extracts tested have shown at least 
moderate (≥40% stimulation w.r.t LPS) and 4 have shown strong (≥90% stimulation w.r.t LPS) 
immuno-stimulation potential. The following information encompasses the immuno-modulatory 
literature of the fungi that exhibited positive immuno-stimulatory activity in the present study. 
In this thesis, we determined that all 4 extracts of Lentinula edodes presented strong 
immuno-stimulatory activity with high stimulatory concentrations of TNF-α, making the results 
consistent with previous studies. Lentinula edodes is a well-known biological response modifier, 
especially its active polysaccharide “Lentinan” which is a cell wall β-glucan. Lentinan is not 
cytotoxic, rather it exerts its effect via immuno-modulation. Lentinan is being manufactured by 
various pharmaceutical companies and is approved for clinical use in Japan; it is used as an 
adjuvant in anti-cancer therapy because of its ability to augment helper T cells’ and natural killer 
cells’ activity and to enhance various cytokine and interferon levels (Sunagawa et al., 2014). 
Consumption of L. edodes improves human immune function by increasing T cell and natural 
killer cell function (Dai et al., 2015). In human cell line models, Lentinan has shown synergistic 
effects with various anticancer drugs when it is used with docetaxel, cisplatin (Zhao et al., 2013) 
and paclitaxel (Liu et al., 2015). In human case studies, Lentinan has demonstrated enhanced 
effect when used with gemcitabine (Sun et al., 2015). In mouse models, Lentinan has augmented 
the effects of anti-cancer monoclonal antibodies (Allendorf et al., 2005) and, as an adjuvant with 
chemotherapy, it has improved survival rate in patients with gastric (Oba et al., 2009) and 
hepatocellular (Yang et al., 2008) carcinomas. Also, gastric (Yoshino et al., 2010), hepatocellular 
(Isoda et al., 2009), pancreatic (Shimizu et al., 2009) and colorectal (Hazama et al., 2010) cancer 
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patients were reported to have improvement in their quality of life and outcomes with oral doses 
of lentinan.  
There is also a report of improved quality of life in esophageal carcinoma cases (Wang et al., 
2012a). As described earlier, since 1985, lentinan is an approved adjuvant of chemotherapy for 
stomach cancers in Japan (Higashi et al., 2012). In RAW 264.7 cell lines, L. edodes’s 
polysaccharides are reported to have immuno-stimulatory effects on various cytokine levels both 
at the innate and adaptive immune response level (Bisen et al., 2010; Xu et al., 2011). Lentinan is 
also known to enhance ROS, NO, TNF-α, IL1, and phagocytosis in various murine peritoneal 
macrophages, C4M macrophages, and human monocytes (reviewed in Schepetkin and Quinn, 
2006). In the current study, all 4 extracts of L. edodes presented strong immuno-stimulatory 
activity with high stimulatory concentrations of TNF-α making the results consistent with the 
previous studies. 
Fomes fomentarius, the tinder fungus, is a well-known ancient mushroom with documented 
use for more than 5000 years. The iceman called Oetzi used this mushroom for preserving fire, 
as an insect repellant, and for medical and spiritual therapy (Pöder & Peintner, 1999).  In the 
current research, the 5% NaOH soluble of F. fomentarius extract stimulates TNF-α in RAW 
264.7 cells, which is consistent with the previous research findings. In 5th century BC, F. 
fomentarius was commonly used for cauterization. Surprisingly, the same treatment of using F. 
fomentarius for cauterization was practiced by Okanagan-Colville natives of BC for curing 
rheumatic and inflammatory diseases (Hobbs, 1995). It is commonly known as “Mudi” in 
Chinese culture and is used traditionally for the treatment of gastro-enteric disorders, gastric and 
uterine carcinoma, inflammation, and various other cancers. Positive anti-proliferative, anti-
cancer effects of F. fomentarius were reported on SGC-7901 and MKN-45 human gastric cancer 
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cell lines (Chen et al. 2008, Chen et al. 2011). Immuno-stimulatory effects of F. fomentarius 
were also reported by Kim et al. (2014): they observed 80% methanol extract to stimulate 
macrophages and to augment the levels of NO, TNF-α, IL-1β, IL-6, IκBα and MAP kinases (p38, 
ERK, and JNK) levels. Moreover, the polysaccharides of F. fomentarius enhance humoral 
immunity, improve phagocytosis in macrophages, and induce TNF-α, IFN-γ, and IL-2 level in 
mouse immunocytes (Gao et al. 2009).  
Ganoderma applanatum, commonly known as “Artist’s Conk”, is a member of the 
Ganoderma genus whose members are reputed for their promising therapeutic potential in China, 
for at least 2000 years. We have observed strong immuno-stimulatory activity of 3 fractions 
(water, 2% ammonium oxalate and 5% NaOH) of G. applanatum, making it a promising species 
for future studies. Fruiting bodies of G. applanatum are documented to have anti-viral, anti-
cancer and immuno-modulatory potential (Lee et al., 2007). Its β-D-glucan has shown anti-tumor 
activity against Sarcoma-180 that was transplanted in mice (Sasaki et al., 1971). Later, it was 
found that this anti-tumor activity is related to immuno-modulation as natural killer cell activity 
was enhanced in a similar study (Jeong et al., 2008). Recently, a new exopolysaccharide isolated 
from this fungus has shown anti-tumor and immuno-stimulatory properties in vitro. The 
exopolysaccharide demonstrated cytotoxic effects against SiHa tumor cell lines and stimulated 
production of macrophages derived from TNF-𝛼 and THP-1 (human leukemia monocytic cell 
line) (Osińska-Jaroszuk, 2014).  
Strong stimulating activity was exhibited by water and 2% ammonium oxalate extract of E. 
tinctorium, which is the first report of immuno-stimulatory activity of this wild mushroom. This 
represents another potentially novel source of immuno-modulatory anti-cancer lead candidate(s) 
for drug development. Echinodontium tinctorium (toothed conk) is a wood decaying fungus 
48 
 
commonly known as “Indian paint fungus”. It is only found in western North America, and it is 
not related to the other toothed fungi so it is sequestered in a family of its own. No literature on 
the therapeutic activity of this fungi is available. It owes its common name “Indian Paint 
Fungus” to its use by Native Americans in a preparation of war paint (Arora 1986; Gibson 2014). 
Also, natives from Oregon used this mushroom as an anti-bacterial agent (Ye et al., 1996).  
In the present study, the water and 5% NaOH extracts of Leucocybe connata were found to 
stimulate macrophages for the release of TNF-α, which is a novel finding. Leucocybe connata is 
a wide spread edible basidiomycete. This species has limited scientific literature in regards to the 
therapeutic potential. There has been one study on the anti-oxidant potential of ergothioneines 
derived from L. connata that could scavenge free radicals in in vitro assay (Kimura et al., 2005) 
but there has been no literature, to date, regarding immuno-modulatory effects of this species.  
Laetiporus sulphureus, commonly known as chicken of the woods, is an edible bracket 
fungus widely found in Europe and North America. We observed that water and 5% NaOH 
soluble extracts of L. sulphureus bear immuno-stimulatory potential and therefore have 
stimulated RAW 264.7 macrophage cells to release TNF-α. Lanostanoid triterpenes isolated from 
this species shows cytotoxic effects against human promyelocytic leukemia cell lines (HL-60) by 
activating caspase-3, an apoptotic inducer (León et al., 2004; Rios et al., 2012). Moreover, 
exopolysaccharide isolated from L. sulphureus demonstrates immuno-modulation on U937 
human leukemia cell lines by activating genes and proteins (Bax and Bad) of the B cell 
lymphoma-2 (Bcl-2) family that regulates cell death (Seo et al., 2011). However, little or no 
literature is available on the immuno-stimulatory activity with regards to stimulation of TNF-α in 
RAW-264.7 macrophage cells.  
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Phellinus nigricans is a wood decay fungus. In our study, the primary screening also showed 
positive immuno-stimulatory activity of water and 5% NaOH soluble extracts of P. nigricans 
which is consistent with previously reported studies.Two proteoglycans isolated from P. 
nigricans (PNW1 and PNM1) demonstrated anti-tumor activity in vivo in mice transplanted with 
Sarcoma 180 model; however, this anti-tumor effect could not be associated with direct 
tumoricidal activity, rather detailed experiments deduce the possibility of immuno-modulation. 
These results indicated that the anti-tumor effect could be because of the stimulation of 
lymphocytes and activation of macrophages as increased concentrations of TNF-α and NO 
production were observed (Li, 2008). More recently, researchers from China have demonstrated 
immuno-modulatory activity of three polysaccharides (PNMP1, PNMP2, and PNMP3) isolated 
from P. nigricans that stimulate lymphocyte proliferation proving their immuno-stimulatory 
potential (Wang et al., 2014).  
These primary screening results show the immense potential of BC wild mushrooms to 
stimulate the immune system, as an important source for drug discovery.  
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Anti-inflammatory Studies 
This section provides first a brief overview of inflammation and discusses some important 
anti-inflammatory compounds isolated from mushrooms. It then explores the experimental 
design, methodology and primary results on the screening of 13 wild fungi (31 extracts) for their 
potential anti-inflammatory activity (i.e. inhibition of LPS-induced TNF-α production in mouse 
Raw264.7 macrophage cells). 
2.8 Introduction 
 2.8.1 Inflammation 
Inflammation is the localized protective mechanism of the body in response to tissue injury 
or pathogen invasion. During inflammation, an immune system stimulant will enhance the 
production of pro-inflammatory immune cells e.g. macrophages and monocytes to release 
inflammatory mediators like NO, ROS, IL1, IL6, TNF-α, COX-2, PGE2, and NF-κβ etc. 
(Balkwill & Mantovani, 2001). 
Innate inflammation is usually self-limiting, and resolves through apoptosis, scarring, and 
clearing of inflammatory debris (Wu & Zhou, 2010). The uncontrolled release of inflammatory 
mediators causes cellular damage and initiates the chronic inflammatory cascade. This 
unrestrained, persistent, and unresolved condition contributes to the pathophysiology of various 
inflammatory mediated diseases like diabetes, hepatitis, arthritis, and other cardiovascular 
complications. There is also a strong correlation between inflammation and the development of 
cancer (Balkwill & Mantovani, 2001). 
Macrophages are major immune cells present in the inflammatory microenvironment. These 
cells are activated by various pro-inflammatory cytokines such as LPS, TNF-α, IFN-γ to name a 
few. These phagocytic cells are one of the most important cells of the inflammatory environment 
that are involved throughout the process of inflammation from initiation to resolution and even in 
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case of its exacerbation into the chronic stage (Ostuni et al., 2015). While macrophages in major 
tumor micro-environments are in suppressive or inactivated forms, macrophages in the 
inflammatory environment are highly activated; their stimulated form release various cytokines 
(including TNF-α) and other biological mediators that control the inflammatory cascade. 
Because of their major role in inflammation, macrophages could be a lucrative target for the anti-
inflammatory response (Weiskopf & Weissman, 2015) 
TNF-α is one of the important pro-inflammatory cytokines released during inflammation. As 
described earlier, it is mainly secreted by activated macrophages but may also be secreted by 
monocytes, natural killer cells, and other inflammatory cells (Chu, 2013). Once released, TNF-α 
is involved in the secretion of other inflammatory cytokines and chemokines for an enhanced 
inflammatory response. Endothelial TNF-α enhances endothelial cell permeability, thereby 
enhancing inflammatory cells infiltration (Waters et al., 2013). It also increases vascular 
endothelial growth factor (VEGF) therefore, supporting angiogenesis. This mechanism is one of 
the major pieces of evidence relating excess TNF-α with tumor growth and progression. 
Enhanced levels of this cytokine are observed in cellular damage, chronic inflammatory 
mediated diseases, and apoptotic cell death (O’shea et al., 2002). Thus, the suppression of this 
crucial pro-inflammatory mediator could be a pre-requisite for an anti-inflammatory response.  
2.8.2 Anti-Inflammatory Activity/Compounds from Mushrooms 
Like immuno-stimulation, natural products (specifically mushrooms) are also being screened 
and used as anti-inflammatory agents because they have fewer or no side effects.  
The general trend of research studies on the therapeutic potential of mushrooms involve the 
ability of mushroom extracts and/or active constituents to reduce the levels of pro-inflammatory 
cytokines (i.e. NO, TNF-α, IL-1, IL-6) as an indicator of decreasing inflammation. The RAW 
264.7 macrophage cell model is a common in vitro cell model for exploring the anti-
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inflammatory potential of mushrooms based on their ability to inhibit the induced inflammatory 
mediators/cytokines (Elsayed et al., 2014; Taofiq et al., 2016). Some of the common mushrooms 
recognized for their anti-inflammatory potential described briefly here are Cordyceps sinensis 
(Berk.) Saac., I. obliquus and G. lucidum.  
Cordyceps sinensis has a long history of use as a folk and herbal medicine. The major anti-
inﬂammatory ability of this species is exhibited by its purified peptide “cordymin” that inhibited 
IL-1β and TNF-α serum levels in a carrageenan-induced inflammatory mice model. It also 
inhibited, in a dose dependent manner, acetic acid induced abdominal constrictions in mice, 
reflecting the anti-inflammatory potential of this peptide (Qian & Guo, 2012). Cordymin, due to 
its anti-inflammatory and anti-oxidant activity, was also found useful in treating ischemia in rat 
brain (Wang et al., 2012b). The methanol extract of C. sinensis from Taiwan has also exhibited 
anti-inflammatory effects by inhibiting TNF-α and NO in LPS/IFN-γ induced murine peritoneal 
macrophage cell lines (Rao et al., 2010). 
Inonotus obliquus (Chaga) is an important folk medicine in Russia and Western Siberia. 
Sterols isolated from this species reduced the NO concentration by 50% and inhibited the levels 
of IL-1𝛽, IL-6, and TNF𝛼 in LPS induced RAW 164.7 cells in a dose dependent manner (Van et 
al., 2009). Trametenolic acid, ergosterol peroxide, 3𝛽-hydroxy-8, 24-dien-21-al, ergosterol, 
trametenolic acid and inotodiol isolated from the petroleum ether and ethyl acetate fractions of 
Chaga inhibited NO and NF-κβ in RAW 264.7 macrophage cells (Ma et al., 2013).  
Methanolic extract of I. obliquus inhibited production of NO, prostaglandin E2, and TNF-𝛼; 
it also inhibited mRNA expression of iNOS and COX-2 in RAW264.7 macrophage cells (in 
vitro) and reduced inflammation in a carrageenan-induced paw edema mice (in vivo) model (Park 
et al., 2005). Ethanol extract of I. obliquus grown on germinated brown rice decreased levels of 
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TNF-α, COX-2, IL-4, IFN-γ, signal transducers and activators of transcription (STAT) 1, and 
STAT6. The levels of IgE and IgA in the spleen and mesenteric lymph node were also reduced 
significantly in Colitis associated inflammatory mice model (Debnath et al., 2012). 
Ganoderma lucidum, as mentioned earlier, is a well-known traditional mushroom that has 
also demonstrated potent anti-inflammatory activity. It is widely used as an anti-allergic, anti-
aging, anti-inflammatory and longevity supplement. Active immuno-modulatory protein (FIP-
LZ8), isolated from G. lucidum, has immunosuppressive action as it can inhibit autoimmune 
reactions in diabetic animal models with lesser toxic effects on kidneys as compared to 
cyclosporine A, an immunosuppressive drug with strong nephrotoxic side effects (Van der Hem 
et al., 1995). Both ethanolic and methanolic extracts have also shown anti-inflammatory 
potential in in vitro settings (Chu et al., 2015; Yoon et al., 2013). Ethanolic extracts have shown 
to inhibit IL-1β, NO, TNF-α, and PGE2 in LPS-stimulated murine BV2 (mouse brain, microglial) 
cell lines while methanolic extract has shown inhibition of LPS-induced NO production in 
RAW264.7 cell lines (Chu et al., 2015). 
The anti-inflammatory metabolites of medicinal mushrooms belong to a chemically diverse 
group. This section of my thesis will highlight some of the major anti-inflammatory classes of 
medicinal mushrooms based on their chemical structures (i.e. anti-inflammatory polysaccharides, 
glyco-proteins, steroids, terpenoids, lectins, lipids etc).  
Anti-inflammatory polysaccharides represent the major class of medicinal mushroom 
compounds and have been shown to be effective in many in vitro and in vivo settings. 
Polysaccharide isolated from the chloroform extract of Agaricus blazei Murrill, inhibited IL-6 
production in mouse bone marrow derived mast cells; these mast cells were stimulated with 
phorbol myristate acetate and calcium ionophore A23187. This purified polysaccharide also 
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suppressed the production of prostaglandin D2 and leukotriene C4 and downregulated the 
phosphorylation of the serine/threonine kinase AKT (Song et al., 2012). In 2009, a Phase 1 
clinical trial on healthy individuals demonstrated that a regular oral dose (60 mL for 12 days) of 
a blend of mushroom extracts (82% A. blazei with 15% Hericium erinaceum (Bull.) Pers. and 
3% Grifola frondosa (Dicks.) Gray) reduces the level of certain pro-inflammatory cytokines (IL-
1β, Il-2, Il-6, Il-7 and TNF-α) in the body, thus acting as prophylactic agents against 
inflammation. This aqueous extract is named AndoSan. Although not completely purified, this 
extract has been found to be rich in proteoglucan and β-glucan (Johnson et al., 2009); in 2011, 
the same AndoSan extract with the same dose (60 mL for 12 days) was administered to 21 
patients suffering from chronic inflammatory diseases e.g. ulcerative colitis, inflammatory bowel 
disease and Crohn’s disease and results showed suppressed levels of pro-inflammatory cytokines, 
indicating the extract potential against inflammatory diseases (Førland et al., 2011).  
Terpenoids are another important class of anti-inflammatory compounds from medicinal 
mushrooms. Out of five novel di-terpenes isolated from Cyathus africanus H.J. Brodie, three 
(Cyathins D-H 3 and 5, 11-O-acetylcyatha-triol, and neosarcodonin) significantly inhibited NO 
production in LPS-induced macrophage cells (Han et al., 2013).  Triterpenes isolated from G. 
lucidum also significantly inhibited IL-6, TNF-α, NO, PGE-2 and NF-κβ in an LPS-induced 
RAW 264.7 macrophage cell model (Dudhgaonkar et al., 2009). Moreover, six Lanostane type 
triterpenes isolated from P. betulinus are active anti-inflammatory candidates in in vivo mouse 
ear edema model (Kamo et al., 2003) 
Mushroom anti-inflammatory compounds include the “Sterols” family of compounds. Chaga, 
as described earlier, is an important source of anti-inflammatory sterols isolated on the basis of 
their exclusive ability to suppress inflammatory cytokines in in vitro cell model (RAW 164.7) 
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(Van et al., 2009). Six other sterols (Trametenolic acid, ergosterol peroxide, 3𝛽-hydroxy-8,24-
dien-21-al, ergosterol, trametenolic acid and inotodiol) from the same species were also isolated 
on the basis of their anti-inflammatory potential in RAW 264.7 cells.  
Peptides are a small family of anti-inflammatory metabolites from mushrooms. Cordymin, as 
described earlier, is a reputed peptide that shows documented action against inflammation in 
various in vitro and in vivo models. Phenolics (especially hispolon) isolated from Phellinus 
linteus (Berk. & M.A. Curtis) Teng, Zhong Guo De Zhen Jun are active against inflammation as 
they have significantly suppressed NO production in LPS-induced RAW 264.7 macrophage cells 
(Lin et al., 2014).  
Thus, the anti-inflammatory metabolites from medicinal mushrooms have immense diversity 
in terms of their chemical structure and characterization. There is a lot more literature on the 
chemical extracts of mushrooms showing anti-inflammatory activity but in most cases, the active 
molecules were not isolated nor identified. The active metabolites that have already being 
isolated, combined with ones that are yet to be purified, serve as a library of potential lead 
molecules for the development of mushroom-based nutraceuticals or drugs that are effective 
against inflammation.  
2.9 Material & Methods 
2.9.1 Tumor Necrosis Factor Alpha Inhibition after LPS treatment 
For the anti-inflammatory assay, RAW264.7 cells were used. The maintenance and 
plating of RAW264.7 cells was essentially as previously described in the first part of this chapter. 
The difference is on the day of treatment after overnight incubation. The medium in cells (200 
µL DMEM without FBS) was removed and the cells were washed with 200 µL BioWhittaker® 
Phosphate Buffer Saline (PBS) (Lonza, Walkersville, Maryland) followed by treatment with 100 
uL DMEM (added LPS so final conc. of LPS is 250 ng/ml) without FBS with: (i) various 
56 
 
mushroom fractions (conc. 1 µg/µL), (ii) Polymyxin B (PMB; Sigma 100 units) as the positive 
control, or (iii) DMEM and respective solvents (i.e. water or methanol, used for re-suspension of 
lyophilized samples) for use as negative controls.  
After a further 6 hours of incubation, supernatants (~100 µL) were collected, centrifuged 
(4°C, 200xg, 5 min using Allegra® X-15R, benchtop centrifuge; Beckman Coulter, CA, USA) 
and stored at -80ºC freezer until ELISA was performed for the quantification of TNF-α.  
2.9.2 Tumor Necrosis Factor Alpha Inhibition after Histamine treatment 
In the in-vivo mouse model described in Chapter 4, the effect of fungal extracts in response to 
histamine-induced inflammatory was evaluated. So, in order to mimic similar conditions, 
histamine-induced inflammation was also assessed in the RAW264.7 cell-based assay. LPS is 
replaced by histamine to assess the effect of various histamine concentrations in RAW 264.7 
macrophage cells. For this assay, the maintenance and plating of cells was as previously 
described.  
The difference is on the treatment day, cells were treated with: i) various concentrations of 
histamine (1 M-1 µM), ii) I. obliquus (F2) and E. tinctorium (F5) (1 μg/μL) plus histamine, iii) 
PMB as the positive control, and iv) DMEM and/or solvents as negative controls. The time of 
treatment and the collection protocol was also as previously described. 
2.9.3 Chemical Extracts-Treatment  
Fungal extracts that do not show any stimulatory activity were selected for the anti-
inflammatory assay. These are from 10 species used for immuno-stimulatory assay and 4 more 
species assessed for stimulation by 2 other graduate students in Dr. Lee’s lab (Mr. Ankush Barad 
and Ms. Vicky Myhre).  
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2.9.4 Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA following fungal treatment was also as previoule described, except that, the 
inhibition of TNF-α induced by LPS indicated the anti-inflammatory potential. 
2.10 Results 
2.10.1 Tumor Necrosis Factor Alpha Inhibition after LPS treatment 
To assess anti-inflammatory activity, cells were treated with 250ng/mL of LPS plus 
fungal extracts. The concentration of each extract was 1 µg/µL, except for Inonotus obliquus 
which was applied with 3 concentrations. Polymyxin B (PMB: active ingredient of reputed anti-
inflammatory ointment-Polysporin®) was used as positive control for the estimation of relative 
anti-inflammatory potential of wild fungi. PMB consistently inhibited TNF-α induced by LPS. 
Only fungal extracts that did not demonstrate any stimulatory activity in Figure 2.4 were selected 
for the anti-inflammatory assay.  
Results are presented in Figure 2.6.1, 2.6.2, 2.6.3, and 2.6.4; they shows that all four 
extracts of I. obliquus have potent anti-inflammatory potential, at concentration as low as 
0.25µg/µL. Other active extracts that were strongly effective against inflammation included 
fractions of F. pinicola (F1 & F3), P. betulinus (F1, F2 & F3), F. fomentarius (F1 & F2), G. 
applanatum (F1 & F2), E. tinctorium (F5), L. connata (F2), L. sulphureus (F1), P. nigricans (F2), 
P. igniarius (F1), and T.  abietinum (F1). Moderate activity was demonstrated by E. tinctorium 
(F1 & F2), L. sulphureus (F2), P. nigricans (F1), Phellinus igniarius (F4), H. coralloides (F2), 
and L. vulpina (F2).  
2.10.2 Tumor Necrosis Factor Alpha Inhibition after Histamine treatment 
 As the in vivo model involved the induction of inflammatory events in the 
microcirculation, therefore the in vivo anti-inflammatory conditions were simulated in RAW 
264.7 macrophage cells. This was done by stimulating RAW cells with histamine, instead of 
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LPS. Initially, cells were treated with different concentrations of histamine to explore the dose at 
which the maximum stimulation of TNF-α is observed. Figure 2.7.1 demonstrates the effect of 
histamine concentration on RAW 264.7 cells. The extent of stimulation in the presence of 
histamine is less compared to LPS; 1μM triggered the activation of macrophages to its maximum 
so this concentration was selected as the optimum dose for the anti-inflammatory assay. Later, 
potent extracts of I. obliquus (F2) and E. tinctorium (F5) (1μg/μL) were treated in the presence 
of histamine to observe the inhibitory tendency of these extracts in the presence of an 
inflammatory mediator. Both extracts inhibited histamine induced TNF-α > 90% indicating their 
strong potential in treating inflammation (Figure 2.7.2.). 
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Figure 2.6.1. Assessing anti-inflammatory potential of fungal extracts in LPS (250ng/mL) induced 
RAW 264.7 macrophage cells. Fungal conc. 1μg/1μL, PMB (100 units) is used as positive control, solvents 
and media as negative control. Error bars are standard deviations and One-way ANOVA analysis was 
performed as described in Materials and Methods (*, P < 0.0001). 
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Figure 2.6.2. Assessing anti-inflammatory potential of fungal extracts in LPS (250ng/mL) induced 
RAW 264.7 macrophage cells. Fungal conc. 1 μg/1μL; PMB (100 units) was used as positive control; 
solvents and media were used as negative controls. Error bars are standard deviations and One-way ANOVA 
analysis was performed as described in Materials and Methods (*, P < 0.0001). 
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Figure 2.6.3. Assessing anti-inflammatory potential of I. obliquus in LPS (250ng/mL) induced RAW 
264.7 macrophage cells. Fungal conc. 1 μg, 0.5μg; 0.25 μg/μL, PMB (100 units) was used as positive 
control; solvents and media were used as negative controls. Error bars are standard deviations and One-way 
ANOVA analysis was performed as described in Materials and Methods (*, P < 0.0001). 
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Figure 2.6.4. Assessing anti-inflammatory potential of fungal extracts in LPS (250ng/mL) induced 
RAW 264.7 macrophage cells. Fungal conc. 1 μg/μL; PMB (100 units) was used as positive control; 
solvents and media were used as negative controls. Error bars are standard deviations and One-way ANOVA 
analysis was performed as described in Materials and Methods (*, P < 0.0001). 
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Figure 2.7.2. Inhibition of histamine induced TNF-α in RAW 264.7 macrophage cells by 
potent mushroom extracts E. tinctorium F4 (left) and I. obliquus (right). The histamine conc. 
used is the dose for inducing maximum TNF-α- 10-6M. Error bars represent standard deviation 
and One-way ANOVA analysis was performed as described in Materials and Methods (*, P < 
0.0001). 
Figure 2.7.1. Histamine dose response curve for inducing 
TNF-α in RAW 264.7 macrophage cells. The histamine 
conc. was 1, 10-1, 10-2, 10-3, 10-4, 10-5, and 10-6 M. The 
maximum induction occurs at 10-6 M. Error bars represent 
standard deviation and One-way ANOVA analysis was 
performed as described in Materials and Methods (*, P < 
0.0001). 
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2.11 Discussion 
Natural products extracted from fungi also have impressive anti-inflammatory properties.  
The following literature brings forward the existing knowledge regarding anti-inflammatory 
fungal extracts that have exhibited positive activity in this thesis chapter.  
In the current study, strong anti-inflammatory activity (strong inhibition of TNF-α induced 
with LPS) by 99% ethanol and water fractions of F. pinicola was observed which, to our 
knowledge, is the first report in RAW 264.7 cells but also consistent with previous anti-
inflammatory activity in other in vitro and in vivo models. Fomitopsis pinicola is a brown rot 
fungus present widely in Asia and Europe. In traditional medicines, this mushroom is used for 
treating nausea, headaches and hepatic complications. Other traditional uses of F. pinicola 
include haemostatics (as astringent) and as anti-inflammatory agent (Grienke et al., 2014). 
Fomitopsis pinicola from Taiwan has demonstrated strong anti-angiogenic and anti-
inflammatory activity in vitro; a strong inhibitory effect was also observed by extracted 
polysaccharides on VEGF-induced tube formation in endothelial cells while the ethanolic extract 
of the same mushroom showed inhibition of IFN-γ induced IP-10 protein (a marker for 
inflammation) (Cheng et al., 2008). Lanostane, triterpenoids and triterpene glycosides isolated 
from F. pinicola also showed anti-inflammatory activity by inhibiting cylooxygenase-1 and 
cylooxygenase-2 in in vitro setting (Yoshikawa et al., 2005).  
In the current study, the first three extracts (80% ethanol, 50% methanol and water extracts) 
of P. betulinus exhibited strong anti-inflammatory activity by inhibiting LPS-induced TNF-α in 
mouse macrophage cells. Piptoporus betulinus is a birch polypore and its tea is well known for 
soothing and anti-fatigue effects among traditional users (Peintner & Pöder, 2000). Also, in 
Finland and Siberia P. betulinus tea from young fruit bodies is known to have anti-cancer effects 
(Lucas 1960). The fungal exacts from P. betulinus were also effective in treating vaginal cancer 
65 
 
in female dogs where tumors disappeared in 5 weeks upon treatment with this wild fungus 
(Grienke et al., 2014). Scientists from Japan have isolated 6 lanostane type triterpenes from P. 
betulinus and found all of them to be active in in vivo mouse ear edema model (Kamo et al., 
2003). This indicates the potential of finding new anti-inflammatory molecules from this wild 
mushroom.  
In the present study both ethanolic and methanolic extracts of F. fomentarius have 
demonstrated strong anti-inflammatory activity which is consistent with the literature. Similar to 
its immuno-stimulatory activity, F. fomentarius has also been explored for its anti-inflammatory 
effects. Methanolic extract of Korean F. fomentarius have shown positive anti-inflammatory 
activity both in in vivo (reduced carrageenan induced acute paw edema in rats) and in vitro 
(inhibition of LPS induced NO, PGE2 and TNF-α in RAW 264.7 macrophage cells) settings 
(Park et al., 2004).  
The ethanolic and methanolic fractions of G. applanatum have demonstrated strong anti-
inflammatory activities, which is supported by the previous literature. Ganodermycin isolated 
from G. applanatum by German scientists has demonstrated inhibition of CXCL-10 (inducible 
protein-10), an inflammatory chemoattractant marker, in LPS + IL induced CXCL-10 promoter 
in acute monocytic leukemia derived cell lines (MonoMac-6) (Jung et al., 2011). 
The current study has shown a novel anti-inflammatory potential of previously un-studied E. 
tinctorium extracts. Both ethanolic and methanolic extracts have demonstrated moderate anti-
inflammatory activity but the 5% NaOH extract showed strong anti-inflammatory potential. This 
extract has also shown inhibition of TNF-α induced by histamine in RAW264.7 cells. Because of 
this new finding and its abundance in Northern British Columbian forests, the 5% NaOH extract 
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of E. tinctorium was selected for further study on purification, identification and characterization 
of anti-inflammatory compound(s) (Chapter 3) and on mice microcirculation (Chapter 4). 
Inonotus obliquus, as explained above, is a well-known and well characterized mushroom 
since the time of Avicenna. It is one of the most abundant wild mushrooms present in forests of 
Northern BC, Canada. All four fractions of this species showed strong anti-inflammatory activity 
which supports the previously published research. The methanol extract (F2) showed the most 
potent activity. It has also inhibited histamine-induced TNF-α in RAW 264.7 cells. Owing to this 
powerful therapeutic effect, this extract was used as a positive control for the in vivo mouse 
model described in Chapter 4. Methanolic extract of L. connata showed strong inhibition on 
LPS-induced TNF-α production, which is a new finding.  
In the current study, the 80% ethanol fraction of L. sulphureus exhibited strong anti-
inflammatory activity while the 50% methanol extract showed a milder inhibition of LPS-
induced TNF-α in RAW 264.7 cells, thus supporting the previous findings. Korean researchers 
have isolated an exopolysaccharide from L. sulphureus that suppressed LPS induced pro-
inflammatory mediators like NO, PEG2, and TNF-α. The down regulation of protein and mRNA 
levels of iNOS, COX-2 and TNF-α in LPS induced BV2 microglia cells (brain and spinal cord 
resident macrophage) were observed. Moreover, this anti-inflammatory activity is via inhibiting 
the NF-κβ pathway (Jayasooriya et al., 2011). Recently, Korean scientists have documented the 
anti-inflammatory activity of a triterpene isolated from L. sulphureus that inhibits LPS-induced 
NO production in RAW 264.7 cells. They further observed the suppression of various pro-
inflammatory cytokines like iNOS, COX-2, IL-1β, IL-6 and TNF-α levels, suggesting a possible 
explanation for the mechanism of action (Saba et al., 2015) 
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Contrary to the immuno-stimulatory study, there is no literature available for anti-
inflammatory activity of P. nigricans. The methanol extract of this BC wild mushroom showed a 
strong effect while the 80% ethanol fraction showed mild anti-inflammatory activity in in vitro 
model.  
In the current primary screening, ethanolic extract of P. igniarius showed very strong 
anti-inflammatory activity while the 5% NaOH exhibited mild inhibition of TNF-α production. 
Phellinus igniarius is a well-characterized Chinese traditional mushroom that has been studied 
for its anti-tumor and anti-inflammatory properties. Recently, Suabjakyong et al. (2015) have 
shown that a β-D-Polysaccharide isolated from P. igniarius has the potential to inhibit expression 
of TNF-α and IL-6 and stimulate the expression of IL-10 (anti-inflammatory cytokine) in LPS 
induced RAW 264.7 macrophage model (Suabjakyong et al., 2015). 
Trichaptum abietinum is a wood decaying polypore fungus present widely in boreal 
coniferous forests across the northern hemisphere (Kauserud & Schumacher, 2003). It has not 
been studied previously for its medicinal values. The 80% ethanolic extract of T. abietinum has 
demonstrated potent anti-inflammatory activity.  
In this study, the 50% methanol extract of H. coralloides has also shown moderate anti-
inflammatory activity which is a novel finding. The genus Hericium is a traditional mushroom 
genus well-known for its therapeutic potential, especially in Asia. Hericium erinaceus (Bull.) 
Pers. has been a major constituent of health supplements in China for a long time. However, H. 
coralloides has not been explored for its immuno-modulatory or anti-inflammatory potential.  
The 50% methanol (F2) extract of L. vulpina has shown moderate anti-inflammatory 
potential, which is a novel finding. Letharia vulpina is a relatively abundant lichen present in 
North America but is nearly extinct species in Europe (Hogberg et al., 2002). This lichen is a rich 
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source of vulpinic acid. It has been studied for its anti-bacterial effect but the current study is the 
first to explore its anti-inflammatory potential.  
2.12 Conclusion 
The primary screening results highlight the therapeutic importance of BC wild mushroom 
extracts as potential sources of anti-inflammatory compounds. The challenge is to purify the 
bioactive metabolites so that they can be applied in pharmaceutical and biotechnological 
industries to determine the optimum dosage and to design compounds for maximum efficacy and 
effectiveness. The next chapter of this thesis will highlight the purification and characterization 
of the 5% NaOH fraction of E. tinctorium.  
The summarized results from the primary screening of the wild mushrooms used in the 
current study (immuno-stimulatory and anti-inflammatory potential) are presented in Tables 2.3 
and 2.4. Table 2.3 also summarizes the current literature available regarding the specific species 
used in the present research. 
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Table 2.3 Immuno-stimulatory and anti-inflammatory activities of BC wild mushrooms and 
lichen 
Species Fractions 
Immuno-
stimulation1 
Anti-
inflammatory2 
Known Immuno-
stimulatory and Anti-
inflammatory activity 
 
References 
Fomitopsis 
pinicola 
F1 19% -  
No immuno-stimulatory 
study 
 
Anti-inflammatory 
 
Cheng et al, 
2008 
Yoshikawa et 
al, 2004 
F2 1.7% 99% 
F3 1.2% 94% 
F4 ND ND 
F5 10.5% - 
 
Lentinula 
edodes 
F1 62% - Immuno-stimulatory  
(RAW 264.7 cells) 
Bisen et al., 
2014 
Xu et al., 
2011 
F2 94% - 
F3 29% - 
F4 76% - 
 
Piptoporus 
betulinus 
F1 1.17% 99%  
Anti-Inflammatory (6 
Lanostanes) 
 
Kamo et al., 
2003 
F2 0.5% 96.5% 
F3 2% 89% 
F4 6.5% 0% 
F5 7% 0% 
Fomes 
fomentarius 
F1 1.2% 99% Immuno-stimulation 
(Isolated Polysaccharide) 
Anti-Inflammation 
(methanolic extract) 
Kim et al., 
2014, Gao 
2009 
Park et al., 
2004 
F2 2.0% 95% 
F3 12% - 
F4 5.5% 0% 
F5 22% - 
 
Ganoderma 
applanatum 
F1 1.8% 98% Immuno-stimulation 
(GpEPS) 
Anti-inflammation 
(Ganodermycin) 
Osińska-
Jaroszuk, 
2014 
Jung et al., 
2011 
F2 1.9% 98% 
F3 126% - 
F4 44% - 
F5 36% - 
 
Echinodontium 
tinctorium 
F1 8% 65%  
 
Not studied 
- 
F2 1% 67% 
F3 129% - 
F4 46% - 
F5 3% 97% 
Inonotus 
obliquus 
F1 0.6% 92% Anti-inflammatory 
(Sterols) 
Anti-inflammatory 
Van et al., 
2009 F2 0.5% 99% 
F3 1.2% 98% 
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Summary of data taken from Figures 2.4, 2.5 & 2.6. F1, F2, F3, F4 correspond to the 80% 
ethanol (F1), 50% methanol (F2), H2O (F3) and 5% sodium hydroxide (F4). In cases where there 
is F5 (F. pinicola, P. betulinus, F. fomentarius, G. applanatum and E. tinctorium) F4 represents 
2% Ammonium oxalate extract and F5 represents 5% sodium hydroxide extract.  
 
The 2% Ammonium oxalate extract was omitted later as this was incompatible with the medium 
used. F. pinicola and L. edodes follow a different extraction pattern as stated in Table 2.2.  
 
1Percent stimulation of TNF-α relative to LPS.  
 
2Percent inhibition of LPS induced TNF-α. 
 
 
 
 
F4 46% 98% 
(Ergosterols derivatives) Ma et al., 
2013 
Leucocybe 
connata 
F1 3.5% 97%  
 
Not studied 
 
F2 8% 7.5%  
F3 49% - - 
F4 31.5% -   
 
Laetiporus 
sulphureus 
F1 0.9%s 86% Immuno-stimulation 
Anti-inflammatory 
(exopolysaccharide) 
Anti-inflammatory 
(triterpenoid) 
Seo et al., 
2011 
Jayasooriya 
et al., 2011 
Saba et al., 
2015 
F2 4% 18% 
F3 86.5% - 
F4 15% - 
 
Phellinus 
nigricans 
F1 2.5% 32% Immuno-stimulatory 
(Isolated PNMP1, 
PNMP2, PNMP3 
immuno-stimulatory) 
No anti-inflammatory 
Study 
Li, 2008 
F2 4% 91.5% 
Wang et al., 
2014 
F3 22.5% -  
F4 65% -  
 
Phellinus 
igniarius 
F1 AB* 98% Anti-inflammatory  
  (Β-D-Polysaccharide) 
 
Suabjakyong 
et al, 2015 
F2 AB* 3% 
F4 AB* 12% 
Trichaptum 
abietinum 
F1 AB* 96% 
Not studied - 
Hericium 
coralloides 
F1 VM* 20% 
 
Not studied 
- 
Letharia 
vulpina 
F2 VM* 76% 
 
Not studied 
- 
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Table 2.4. Summary of the biological activity (immuno-stimulation and anti-inflammation) of 
the mushroom species of BC 
 
Summary of data taken from Figures. 2.4, 2.5 & 2.6. F1, F2, F3, F4 correspond to the 80% ethanol (F1), 
50% methanol (F2), H2O (F3) and 5% sodium hydroxide (F4). In cases where there is F5 (F. pinicola, P. 
betulinus, F. fomentarius, G. applanatum and E. tinctorium) F4 represents 2% Ammonium oxalate 
extract and F5 represents 5% sodium hydroxide extract. F. pinicola and L. edodes follow a different 
extraction pattern as stated in Table 2.2.  
 
1Percent stimulation of TNF-α relative to LPS. 2Percent inhibition of LPS induced TNF-α. 
 
+++; greater than 80% stimulation1; greater than 80% inhibition or complete inhibition2
 
  
++; 40-80% stimulation1  ; 40-80% inhibition2  
+; 10%- 40% stimulation1  ; 10%- 40% inhibition2, - less than 10%1,2 or no stimulation1; no inhibition2 
 
-AB* immune-stimulatory assay performed by Ankush Barad (a former graduate student in Dr. Lee lab). 
Fractions less than 10% stimulatory or no stimulatory were selected for anti-inflammation assay. 
 
-VM* immune-stimulatory assay performed by Vicky Myhre (a graduate student in Dr. Lee lab). 
Fractions less than 10% stimulatory or no stimulatory were selected for anti-inflammation assay. -ND 
denotes not determine
Names of Species Biological Activity 
 
Immuno-stimulation1 Anti-inflammatory2 
Fomitopsis pinicola + (F1, F5) +++ (F2, F3) 
Lentinula edodes +++(F2), ++ (F1, F4), + (F3), ND 
Piptoporus betulinus - +++ (F1, F2, F3), - (F4, F5) 
Fomes fomentarius + (F3, F5) +++ (F1, F2), - (F4) 
Ganoderma applanatum +++ (F3) ++ (F4) + (F5) +++ (F1, F2) 
Echinodontium tinctorium +++ (F3) ++ (F4) +++ (F5), ++(F1, F2) 
Inonotus obliquus - +++ (F1, F2, F3, F4) 
Leucocybe connata ++ (F3) + (F4) +++ (F1), + (F2) 
Laetiporus sulphureus +++(F3), +(F4) +++ (F1), +(F2) 
Phellinus nigricans ++ (F4), +(F3) +++ (F2), +(F1) 
Phellinus igniarius AB* +++ (F1), +(F4), - (F2) 
Trichaptum abietinum AB* +++ (F1) 
Hericium coralloides VM* + (F1) 
Letharia vulpina VM* ++ (F2) 
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Chapter 3: Purification and Characterization of Anti-Inflammatory 
Compound(s) from Echinodontium tinctorium 
This chapter focuses on the purification and characterization of anti-inflammatory 
compound(s) from the 5% NaOH extract of E. tinctorium. 
3.1 Introduction 
3.1.1 Approaches in isolating active therapeutic compounds from medicinal 
mushrooms 
Extracts of natural products have an established history for their applications in many 
industries around the globe (e.g. food, pharmaceuticals, cosmetics, additives etc.). Since their use 
is mainly associated with the mechanism of action of their active constituent(s), the desire to 
purify the active compound responsible for the main activity is a central goal. Moreover, the 
isolation and purification of the active constituent is also associated with the following 
advantages: understanding the chemical structure of the active component, obtaining potent 
biological activity, quantifying the active constituent for quality assurance purposes, exploring 
the structure activity relationship (SAR) for synthetic and semi-synthetic drug development, and 
industrial scale production. Extensive studies on the isolation of the active ingredients along with 
the development of newer approaches have made analytical chemistry much easier in recent 
years. Over the past few decades, techniques like high performance liquid chromatography 
(HPLC), liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass 
spectrometry (GC-MS), nuclear magnetic resonance (NMR), fast protein liquid chromatography 
(FPLC), and membrane filtration have revolutionized the field of natural products chemistry.  
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Medicinal mushrooms have a variety of active chemical constituents possessing a 
plethora of biological activities. As the fungal extract contains both therapeutic and non-
therapeutic constituents, it is essential to purify the active agent responsible for the respective 
biological activity. As described earlier, Mizuno (1996) successfully developed a reliable method 
for the extraction of various chemical constituents from mushrooms. He further suggested the 
possibility of water insoluble polysaccharide in 5% NaOH extract, which is the major focus of 
the current study.  
The fungal cell wall, a complex structure, is rich in two types of polysaccharides: chitin 
and glucans. Both these polysaccharides cross-link firmly to provide strength and integrity to the 
cell wall. Chitin is an abundant polysaccharide present around the outer core of the cell wall 
whereas glucans are present in the central core. A typical structure is a β-1,3 1,6 glucans 
connected with the outer core, chitin, via β-1,4 linkages. Mushroom bioactive polysaccharides 
belong to the glucan family of the fungal cell wall. β-1,3 and -1,6 are mainly alkali insoluble 
polysaccharides while α-1,3 glucans are alkali soluble polysaccharides (Latgé, 2007). Once the 
polysaccharides (alkali soluble or insoluble) are extracted, these can be purified by techniques 
such as ethanol precipitation, ion-exchange chromatography, and gel permeation 
chromatography, etc, however, it is worth mentioning that a single technique is often not 
sufficient and a combination of techniques may be applied simultaneously for an effective 
purification. Therefore, an individualized protocol is needed for each extract’s purification 
depending on the type of polysaccharide, its solubility characteristics, branching patterns, 
molecular weights, linkages, and various other physical and chemical factors.   
For the purification of initial crude extract, chromatography is the major technique that 
fractionates compounds based on various physical and chemical properties e.g. size (size 
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exclusion), ionic charge (ion exchange), and respective affinity (affinity chromatography)  
(Ganetsos & Barker, 1992).  Chromatography, derived from the Greek language, means “color 
writing”. It is a technique in which the components are separated based on their relative affinities 
to the stationary and mobile phase. The adsorbent or stationary phase may be paper, glass, gels 
(aluminium or silica) and combination of various solid resins packed in columns. The mobile 
phase may be either liquid or gas (Weston & Brown, 1998). In principle, the mobile phase is 
allowed to run over the stationary phase (with sample) and the mixture is separated, owing to its 
relative affinity with the respective phase. The resolving fraction is then separated and analysed 
using various sophisticated techniques such as mass spectroscopy (MS), Fourier transform 
infrared spectroscopy (FTIR), and nuclear magnetic resonance (NMR). In 1906, the importance 
of chromatography was first demonstrated by Tswett when he separated various green and 
yellow pigments from plants using a calcium carbonate column (Ganetsos & Barker, 1992).  
Based on the mobile phase, chromatography can be divided in two groups: Gas 
Chromatography (GC) and Liquid Chromatography (LC). GC is the form of chromatography in 
which the mobile phase is a gas while LC is the form of chromatography in which the mobile 
phase is liquid. The separation in LC is due to the interaction and relative affinity of various 
molecules between the solid (stationary) and the liquid (mobile) phase (Weston & Brown, 1998).  
Moreover, based on the nature of stationary and mobile phase, LC can be both normal 
and reverse phased. In normal phase, the solvent applied is less polar and organic than the 
stationary phase. The stationary phase is usually silica or alumina. In this mode, neutral 
compounds are eluted according to the degree of their polarity; the higher the polarity, the greater 
will be the retention of the active molecule in the column and vice versa. In contrast, reverse 
phase separates the compounds based on their respective hydrophobicity; the stationary phase 
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used is the adsorption of hydrophobic groups (e.g. methyl, butyl, phenyl, and amino etc.) on 
silica plate whereas the solvent system applied is more polar and aqueous e.g. water, acetonitrile, 
methanol etc. In this case, the more polar compounds are separated faster as compared to the less 
polar ones. Reverse phase chromatography is economical as compared to the normal phase, due 
to its regeneration ability. For natural products purification, specifically for the preparative scale, 
reverse phase is one of the methods of choice for the majority of natural products chemists 
(McChesney & Rodenburg, 2014). This technique was applied to the analysis of polysaccharides 
from the medicinal mushroom, Pleurotus abalonus Y.H. Han, K.M. Chen & S. Cheng, which 
was completed using HPLC, NMR, and FTIR (Wang et al., 2011).   
Size exclusion chromatography is usually one of the initial purification techniques 
applied in the isolation of the molecule of interest from the crude extract. As indicated by the 
name, the compounds are separated based on the difference in their relative molecular sizes. The 
column has the ability to sieve the sample through the pores, thus allowing molecules of higher 
molecular weight compounds to be eluted in earlier fractions as compared to the lower molecular 
weights.  In Gel Filtration (GF) size exclusion columns, the aqueous mobile phase is passed over 
a hydrophilic resin (e.g. silica gel) packed in a glass column. In Gel Permeation (GP) columns, 
the organic mobile phase is eluted through a hydrophobic column bed (e.g. polystyrene 
divinylbenzene) (Weston & Brown, 1998). Figure 3.1 represents the basic principle of a size 
exclusion chromatography. 
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Figure. 3.1. Illustration of Size Exclusion Chromatography’s principle. In this technique, the 
sample is separated based on molecular sizes; after loading the sample, the interaction with the 
resin occurs in such a way that higher molecular weight compounds (HMW) are eluted first as 
compared to the lower molecular weight compounds (LMW). 
 
Ion exchange chromatography separates the molecules based on the net charge present on 
the molecule. Like size exclusion column, ion exchange is also performed in a glass column 
packed with solid ion-exchange resin. A typical anion exchange column is used for the 
purification of biomolecules; it has a positively charged resin (cations) packed in the glass 
container. The principle is to allow the resin to bind and retain the anions from the sample which 
is later eluted with the help of a salt or a pH gradient. Figure 3.2 demonstrates the basic principle 
of an anion exchange chromatography. 
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Figure. 3.2. Illustration of Ion Exchange Chromatography’s principle. In this technique, the 
sample is separated based on molecular charges. DEAE Sephadex® A-50 resin is an anion 
exchange resin (i.e. the resin has positively charged cations that binds the negatively-charged 
active moiety from sample and allow the impurities to pass through). The sample is later eluted 
with the help of a salt or a pH gradient (modified from Blaber & Harvey, 2016).  
This chapter describes the steps used to attempt the purification of anti-inflammatory 
compound(s) from the 5% NaOH extracts of E. tinctorium; both size exclusion and ion exchange 
chromatography were used in the purification step.  
3.1.2 Echinodontium tinctorium 
Echinodontium tinctorium (toothed conk), the Indian paint fungus, is a wood decaying 
fungus found only in western North America. It owes its common name to its distinctive red 
color that was used by Native Americans in preparation of war and body paints (Arora 1986; 
Gibson 2014). It also has a history of use as anti-bacterial agent by native Americans (Ye et al., 
1996). Information is limited regarding its potential bioactivity, as most studies pertaining to the 
fungus relate to the taxonomy and host-fungus relationships (Aho et al., 1987; Gross, 1964). 
Because of its native origin from North America and lack of study for therapeutic purposes, the 
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5% NaOH extract of E. tinctorium which contains strong anti-inflammatory activity, was 
selected for purification studies.  
3.2 Materials & Methods 
3.2.1 Bulk Extraction & Confirmation of Activity 
The fresh sample of E. tinctorium was collected in August 20, 2015 by Drs. Chow Lee, 
Hugues Massicotte, and Maggie Li from hemlock trees in Twin Falls Trail, Smithers. The sample 
was identified using the same protocol as described earlier (refer 2.2.1-chapter 2). Then parts of 
the conk were powdered using a hammer mill, and bulk extraction of E. tinctorium was 
performed manually according to the protocol described earlier (refer 2.2.2 and figure 2.3 in 
chapter 2). The first two extractions (i.e. 80% ethanol and 50% methanol) were performed by Mr. 
Faran Rashid, an undergraduate student in Dr. Lee’s lab. For the current study, the extraction 
began from the residue of Fraction 2 (i.e. 50% methanol) and was processed for water and 5% 
NaOH extractions. In short, the dried mushroom powder was added in the respective solvent, 
using 1.5 L Erlenmeyer flask, in a ratio of 10 mL/g with constant stirring. After each extraction, 
the filtrate was vacuum filtered, pH neutralized, concentrated and lyophilized. The residue was 
then used for the next extraction step, the 5% NaOH extraction. The NaOH extracts were then 
used for further biological cell assays and purification studies.  
5% NaOH extracts from new batches of E. tinctorium were also tested on RAW 264.7 
macrophage cells for the reproducibility of the activity. The protocol used was previously 
described (refer section 2.6.1.1-chapter 2), and the anti-inflammatory activity was then 
quantified using the ELISA protocol also as described earlier (refer section 2.2.4-chapter 2). 
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3.2.2 Size Exclusion Chromatography- Sephadex™ LH-20 Column 
3.2.2.1 Size Exclusion Column Sizes 
Sephadex™ LH-20 (GE Healthcare, Quebec) resin was used as the stationary phase for 
all size exclusion chromatography experiments. Initially, the small-scale column was set up at 22 
mL, and later it was scaled up to 56 mL and finally to 450 mL. The 22 mL column was a gravity 
drip column made from a 25 mL serological pipette (Sarstedt, Nümbrecht, Germany). In order to 
get higher yield of the semi-purified sample, the 22 mL column was increased to 56 mL using a 
C16/70 column (GE Healthcare, Quebec), which was finally scaled up to 450 mL using a larger 
C26/100 column (GE Healthcare, Quebec). Both the 56 mL and 450 mL columns were operated 
with the help of a solvent pump maintained at a flow rate of 1 mL/min. A three-way stopper 
allowed the smooth switch between the solvent system and the loading sample. The fractions 
were collected via an automated fraction collector.  
3.2.2.2 Column Set-up 
For the size exclusion column, Sephadex™ LH-20 (GE Healthcare, Quebec) resin was 
soaked in degassed water for 3-5 hours at room temperature. For each gram of dry resin, 4 mL 
water was required for the resin to swell. After the resin was swollen, the excess water was 
discarded so that the final slurry to water ratio was 75%-80%. To make a 22 mL sized column, 
wet glass wool was introduced at the bottom of the serological pipette before pouring the resin. 
The resin was then packed swiftly in the column to avoid air bubbles. For the 56 mL and 450 mL 
columns, after pouring the resin, the adapter was loaded and the column was packed at flow rate 
of 2 mL/min. All columns were equilibrated with water in start for around 2-4 bed volumes of 
the column size.  
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3.2.2.3 Sample Preparation, Loading and Fractions collection 
 For a 22 mL column, the loading sample was prepared by dissolving 20 mg/mL of 5% 
NaOH extract of E. tinctorium filtered via a 0.2 μm filter (Sarstedt, Nümbrecht, Germany). For 
larger scale columns, 70 mg/mL sample was prepared. The sample was centrifuged at 100 x g for 
5 minutes prior to loading onto the column. In each scenario, 2% (i.e. 400 µL for 22 mL, 1120 
uL for 56 mL & 9 mL for 450 mL column) of this sample was carefully loaded onto the column 
using a Pasteur pipette (22 mL) and a sample injector (larger columns). After loading, the 
samples were collected in 20 fractions (1 mL each) were collected for 22 mL size column, 35 
fractions (2 mL each) for 56 ml size column and 45 fractions (10 mL each) for 450 mL size 
column using manual (22 mL) and automated fractions collector (larger columns). The fractions 
were stored at 4ºC until I was ready to assess them on Raw 264.7 macrophage cell lines for 
biological activity. 
3.2.2.4 Potency Estimation (Crude F4 versus Post Sephadex™ LH-20) 
After testing and eventually pooling fractions from the larger Sephadex™ LH-20 column, 
a dose-dependent assay was performed to determine the potency of the Crude sample (c) vs. Post 
Sephadex™ LH-20 sample (LH). Various doses (1 ug/uL, 0.5 ug/uL, 0.25 ug/uL and 0.1 ug/µL) 
were assessed for their ability to inhibit LPS -induced TNF-α production. 
3.2.2.5 Sephadex™ LH-20 Column Clean-up & Regeneration  
After each use, the column was washed with 2-bed volumes of water, followed by 1-bed 
volume of 0.1 M NaOH, and again by 2-bed volumes of water, at a flow rate of 1 mL/min. This 
protocol ensured that the column was reusable and cross contamination avoided. 
3.2.3 Carbohydrate & Protein Assay 
Post Sephadex™ LH-20 fractions (i.e. fractions collected from Sephadex™ LH-20) from 
the 56 mL column were tested for their carbohydrate and protein content using commercially 
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available Total Carbohydrate Assay Kit (Sigma-Aldrich®, St. Louis, MO, USA) and Pierce™ 
BCA Protein Assay Kit (Thermo Scientific®, Waltham, MA, USA) respectively. 
For carbohydrate estimation, the protocol followed the instructions of the manufacturer. 
Briefly, both Post Sephadex™ LH-20 test fractions and standards (30 uL each) were analyzed in 
a 96-well plate. These fractions were tested against the already provided standard concentrations 
of glucose at 0, 4, 8, 12, 16, 18 and 20 mg/mL. After adding the required volume of sample and 
standards, 150 uL of concentrated sulphuric acid (12 M) was added in each well and incubated 
for 15 minutes at 90°C in Haratherm™ General Oven (Thermo Fischer, Waltham, MA, USA). 
After 15 minutes, 30 μL of the developer solution was added to each well to complete the 
reaction. The plate was mixed for 5 minutes using a horizontal shaker and read at 490 nm using 
SYNERGY 2 (BioTek®, VT, USA). 
For protein estimation, the protocol followed the instructions of the manufacturer. In-
short, both the Post Sephadex™ LH-20 test fractions and standards (25 uL each) were added in a 
96-well plate. Post LH-20 fractions were tested against the already provided standard 
concentrations of albumin at 0, 25, 125, 250, 500, 750, 1000, 1500, and 2000 µg/mL. Later, 200 
uL of the working reagent was added in each well and the plate was shaken for 5 minutes. After 
shaking, the plate was incubated at 37ºC for 30 minutes and read at 562 nm using SYNERGY 2 
(BioTek®, VT, USA). 
3.2.4 Ion-Exchange Chromatography 
The post Sephadex™ LH-20 fractions which exhibited anti-inflammatory activity were 
pooled and subjected to a second step purification using ion exchange chromatography. DEAE 
Sephadex™ A-50 (GE Healthcare, Quebec), a weak anion exchange resin, was used. For initial 
trials, a variety of DEAE buffers and pH conditions were used in order to determine the optimum 
82 
 
conditions for the specific purification. The detailed protocol was followed as indicated by the 
manufacturer. Briefly, the DEAE Sephadex™ was allowed to swell in respective buffer 
(tabulated in Table 3.1) for at least 48 hours. Initially, Poly-Prep® chromatography columns 
(max. 12 mL) were used. The columns were loaded with 9 ml slurry (75% resin:25% buffer) for 
an initial bed volume and then equilibrated with 3-5 bed volumes of respective buffers. After 
equilibration, 500 uL of sample (i.e. Post Sephadex LH-20 of 5% NaOH E. tinctorium) was 
loaded-10 mg/mL).  
The column was then subjected to three bed volumes of the initial buffer to collect “flow-
through” followed by three bed volumes of the same buffer containing 1 M NaCl to collect 
“eluents”.  Both the flow through and eluent were collected manually and lyophilized using a 
FREEZONE freeze dryer (Labconco, MO, USA) at -52°C and 0.02 Torr, for 24 hours. The 
freeze-dried samples were re-constituted in water and then dialyzed using Slide-A-Lyzer™ 
dialysis cassettes (Thermo Fischer Scientific, MA, USA) with molecular size cut-off (MWCO) 
of 2000 Da to remove the salt.  The post-dialyzed fractions were again subjected to 
lyophilization followed by filter sterilization using 0.2 μm filters (Sarstedt, Nümbrecht, 
Germany) and stored at 4°C until bioassays were performed. 
Table 3.1: Buffers with respective pH and concentration used in Ion-Exchange Chromatography 
S.no Buffer pH Range pH Used in Initial Screening Concentration 
1. Methyl-piperazine 4.3-5.3 4.5 20 mM 
2. Piperazine 4.8-5.8 5.5 20 mM 
3. L-Histidine 5.5-6.5 6.1 20 mM 
4. TRIS 7.6-8.6 7.7 20 mM 
5. Diethanolamine 8.4-9.4 8.7 20 mM 
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After the initial trials, the optimum buffer (i.e. Piperazine) and pH conditions (i.e. pH= 
5.5) were selected for scaling up the ion-exchange column. A large scale XK-50 Column (GE 
Healthcare) was used to increase the column setup to 1000 mL. Eighteen grams of DEAE 
Sephadex® A-50 was swollen in about 1 L of 20 mM Piperazine buffer (pH= 5.5). The same 
buffer was used as flow through and with added 1 M NaCl used for eluting the column.  
The eluent was collected to two bed volumes (i.e. around 2000 mL), lyophilized, re-
constituted in water, dialyzed, re-lyophilized and re-constituted in water for the cell assay. The 
anti-inflammatory assay was performed in a similar way to evaluate the reproducibility of the 
activity (refer section 2.6.1.1 and 2.2.4, chapter 2). After the biological assay, this purified 
sample was then assessed for carbohydrate and protein content (along with crude and semi-
purified sample) and was then compared to the respective carbohydrate and protein content in 
Polysaccharide-K (PSK) as a reference sample (3.2.3-Chapter 3). The two-step purified sample 
was sent to Dr. Peter Cheung’s lab at the Chinese University of Hong Kong for further chemical 
characterization using GC-MS. The GC-MS analysis was performed by Dr. Maggie Li. The 
percent content of carbohydrate was calculated by the following formula: (amount of 
carbohydrate in mg/mL / stock concentration in mg/mL x 100). The same formula was used for 
percent protein estimation.  
3.2.5 Characterization of Carbohydrate Content Using GC-MS 
 For the characterization of carbohydrate content, GC-MS technique was applied in Dr. 
Peter Cheung’s lab (Hong-Kong) by Dr. Maggie Li. After the evaluation of monosaccharide 
content in the purified E. tinctorium sample, further experiments were performed for the 
estimation of the respective linkages present in the purer sample.   
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3.2.6 Heat Denaturation Experiment 
To assess whether proteins are important in the anti-inflammatory activity, both semi 
purified (Sephadex™ Post LH-20) and purified (Sephadex™ Post LH-20+Post DEAE) samples 
were subjected to heat denaturation. Both samples were heated to 100ºC for 5 minutes and then 
were evaluated on Raw 264.7 cells for anti-inflammatory activity as previously described (refer 
to section 2.6.1.1 and 2.2.4, Chapter 2).  
3.2.7 Anti-inflammatory activity of purified samples from E. tinctorium in comparison 
with Acetaminophen 
For comparing the potency of the crude, semi purified (Post Sephadex™ LH-20), and 
purified (Post Sephadex™ LH-20+Post DEAE) moieties, all samples were evaluated in a dose 
dependent manner (0.1, 0.25, 0.5, 1 µg/mL) in RAW 264.7 cell lines and compared with the 
respective dose of acetaminophen as a reference (refer section 2.6.1.1 and 2.2.4, Chapter 2). 
3.2.8 Fast protein liquid chromatography (FPLC) Superdex™ 200- ÄKTA Pure 
After getting the separation based on sizes (Sephadex™ LH-20) and charges 
(Sephadex™ DEAE), the semi-purified (Post Sephadex™ LH-20) and purified (Post 
Sephadex™ LH-20 + Post Sephadex™ DEAE) samples were subjected to FPLC analysis via 
Superdex™ 200 (GE Healthcare, Quebec) for a higher resolution separation and an estimation of 
the size of the bio-active compound(s). This column was connected with an ÄKTA pure 
chromatographic purification system (GE Healthcare, Quebec). ÄKTA pure purification is a 
systemic combination of UV multiple wavelength detection, UV fixed wavelength detection, 
conductivity monitoring and automated sample collector. For running the samples, 20 mg/mL of 
the stock solution was prepared and 2% of a 20 mL column (i.e. 500 uL) was loaded onto the 
column with a flowrate of 1 mL/min. Twenty fractions were collected with a volume of 1 mL 
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each. These fractions were then subjected to anti-inflammatory assay, protein and carbohydrate 
analysis (Refer section 2.6.1.1 and 2.2.4, Chapter 2 and Section 3.2.3-Chapter 3). 
3.2.9 Nitrite Determination Assay 
As nitric oxide (NO) is a short lived chemical in in vitro settings, for the estimation of 
inhibition of NO, the levels of nitrite were measured as representative of NO. It is important to 
point out that this assay absolutely requires the use of Raw macrophage cells that have not been 
passaged (divided) extensively. The same numbers of RAW 264.7 cells (i.e., 100,000 cells/well) 
as described previously were plated. After an overnight incubation, cells were treated with: 
DMEM without FBS (control), 1 µg of LPS (negative Control), 1 µg of LPS + PMB (100 units, 
positive control), 1 µg of LPS + Sephadex Post LH-20 + Post DEAE (1 mg, test sample). After 
treatment, cells were incubated for 24 hours. After 24 hours, supernatants were collected and 
tested using PromegaTM Griess Reagent System. The protocol was followed as mentioned by the 
supplier with a little modification. Briefly, NO standards were prepared via serial dilution from 
stock (0.1 M Sodium Nitrite). One hundred µL of samples were added in each well followed by 
50 µL of Sulphanilamide solution and 50 µL of N-1-napthylethylenediamine dihydrochloride 
(NED) solution. The plates were read at 540 nm and the amount of NO was quantified using by 
interpolating the serial dilution of nitrite (NaNO2) levels using PRISM. The experiment was 
repeated twice with triplicate wells each time.  
3.3 Results 
3.3.1 Bulk Extraction & Confirmation of Anti-inflammatory Activity 
A new batch of E. tinctorium was collected from Twin Falls Trail, Smithers in August 
2015. The conk was subjected to grinding and the first 2 steps of the extraction (80% ethanol and 
50% methanol) were performed by Mr. Faran Rashid, a former undergraduate student in Dr. 
Lee’s lab.  Three hundred grams of initial sample was extracted as mentioned previously (refer to 
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section 2.2.2- Chapter 2). The 80% ethanol extract was discarded while the 50% Methanol 
fraction was used by the undergraduate student for his research project. The residue of Fraction 2 
was subjected to sequential extraction with water (F3) and 5% NaOH (F4). Note that at this 
stage, the ammonium oxalate extraction that was performed in preliminary screening in the 
initial phase of the project was omitted, and F4 from this point forward represents the 5% NaOH 
extract. The filtrate of 5% NaOH was concentrated, pH neutralized, lyophilized and stored in 4ºC 
until cell assays were performed. The activity of this new batch was confirmed (as shown in 
Figure 3.3).  
Figure 3.3 shows that the new batch 5% NaOH (F4) demonstrated an activity similar to 
the old batch of 5% NaOH (F5), indicating the potency and reproducibility of the anti-
inflammatory activity of this extract. 
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Figure 3.3. Anti-inflammatory activity of NaOH extracts from E. tinctorium. Assessing anti-
inflammatory activity of two different batches of NaOH extracts of E. tinctorium. The newly 
extracted batch fraction (F4) and the older batch (F5) of NaOH extracts of E. tinctorium was 
assessed for their ability to inhibit LPS (250 ng/mL)-induced TNF-α production in RAW 264.7 
macrophage cells. The concentration of NaOH extracts from E. tinctorium used was 1 μg/1μL. 
PMB (100 units) was used as the positive control and solvents and media were used as negative 
controls. The assay was performed in triplicates.  Error bars are standard deviation and One-way 
ANOVA analysis was performed as described in Materials and Methods (*, P < 0.0001). 
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3.3.2 Size Exclusion Chromatography- Sephadex™ LH-20 Column 
After confirming the reproducibility of the activity, the F4 NaOH extract was subjected to 
a 22 ml Sephadex™ LH-20 column: 400 uL of 20 mg/mL sample was loaded and 20 fractions (1 
mL each) were collected for further analysis. Figure 3.4 illustrates the results from the 22 ml 
manual column: it demonstrates that fractions 7-10 and fraction 15 had strong anti-inflammatory 
activity as these inhibited the LPS induced TNF-α ≥90%.  
 
Figure 3.4. Assessing anti-inflammatory activity of fractions collected from 22-ml size 
Sephadex™ LH-20 column. The loading sample was 400 uL of NaOH extract from E. 
tinctorium (20 mg/mL) and 1 mL fractions were collected. One hundred uL from each fraction 
was tested for activity. LPS treatment alone was used as a negative control. ≥90% inhibition of 
LPS was a positive activity. The assay was performed in triplicates.  Error bars are standard 
deviation and One-way ANOVA analysis was performed as described in Materials and Methods 
(*, P < 0.0001). 
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After the anti-inflammatory activity was detected in fractions collected from the 22 mL 
size Sephadex™ LH-20 column, the column was scaled up to a 56 ml using a C 16/70 (GE 
Healthcare, Quebec) column. Crude F4 NaOH extracts (70 mg/mL) at 1120 uL was loaded and 
35 fractions of 2 mL each were collected and then assessed for anti-inflammatory activity. Figure 
3.5 shows the results from a 56 ml Sephadex™ LH-20 column: it demonstrates that fractions 10-
20 inhibited the LPS-induced TNF-α production by ≥90%. These fractions were considered 
active and thus indicated the reproducibility of Sephadex™ LH-20 column at the higher scale. 
 
Figure 3.5. Assessing anti-inflammatory activity of fractions collected from 56 mL size 
Sephadex™ LH-20 column. The loading sample was 1120 uL at 70 mg/mL. Thirty five fractions 
of 2 mL each were collected and alternate fractions were tested. LPS was used as a negative 
control. ≥90% inhibition of LPS was a positive activity. The assay was performed in triplicates.  
Error bars are standard deviation and One-way ANOVA analysis was performed as described in 
Materials and Methods (*, P < 0.0001). 
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After reproducible results were obtained from 56 mL Sephadex™ LH-20 column, the 
protocol was finally scaled up to a 450 ml using C 26/100 (GE Healthcare, Quebec) column. 
Nine mL of 70 mg/mL crude F4 NaOH extracts were loaded and 45 fractions of 10 mL each 
were collected and assessed for anti-inflammatory activity. Figure. 3.6 shows that fractions 16-24 
inhibited the LPS-induced TNF-α production at ≥90% which correlates with the activity obtained 
from the 56 mL Sephadex™ LH-20 column. These fractions are considered active and further 
testify to the reproducibility of the Sephadex™ LH-20 column at the higher scale.  
 
Figure 3.6. Assessing anti-inflammatory activity of fractions collected from a 450 mL Sephadex™ 
LH-20 column. The loading sample was 9 mL at 70 mg/mL and 45 fractions of 10 mL each were 
collected. Alternate fractions were tested for activity. LPS was used as negative control. ≥90% inhibition 
of LPS was a positive activity. The assay was performed in triplicates.  Error bars were standard deviation 
and One-way ANOVA analysis was performed as described in Materials and Methods (*, P < 0.0001). 
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Following establishement of the reproducibility of the 450 mL size Sephadex™ LH-20 
column, another 9 runs were performed at this scale in to generate sufficient quantity for the 
second purification step. After each run, the active initial elution volume fractions were pooled 
and lyophilized. Subsequently, the potency of this semi-purified, Post Sephadex™ LH-20 
samples, was determined. This was achieved by performing and comparing the dose-dependent 
effect of the crude sample vs. the semi-purified sample from the size exclusion chromatography. 
Figure 3.7 shows that the post LH-20 sample has higher potency as compared to the crude 
sample. The sample was not only more potent at 0.2-1 µg/µL but it appeared to be still active at 
and below 0.1 µg/µL. These results demonstrated the efficiency of Sephadex™ LH-20 in 
purifying the anti-inflammatory compound(s) from E. tinctorium.  
 
 
 
 
 
 
 
 
 
 
 
Figure. 3.7. Comparing the anti-inflammatory activity of the crude F4 NaOH extract with 
the semi-purified post-Sephadex LH20 sample. The following concentrations of crude NaOH 
extracts and post-Sephadex LH20 sample were used: 0.1, 0.25, 0.5, and 1 ug/uL. Results were 
plotted as percent of TNF-α inhibition relative to LPS treatment alone. Assay was performed in 
triplicates.  Error bars are standard deviation from mean and One-way ANOVA analysis was 
performed as described in Materials and Methods (*, P < 0.0001). 
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3.3.3 Carbohydrate & Protein Assay 
In addition to assessing the anti-inflammatory activity, the fractions collected from 56 mL 
Sephadex™ LH-20, using the C 16/70 column, were assessed for the possible presence of 
carbohydrate. This was performed using the Total Carbohydrate Assay Kit (Sigma-Aldrich®, St. 
Louis, MO, USA). The results in Figure 3.8 show that there are two major anti-inflammatory 
activities: one at an elution volume 20-35 mL and one at around 55 mL. Both activities appear to 
correlate with the carbohydrate content, suggesting the bio-active compound(s) contains 
carbohydrate. 
 
Figure 3.8. Carbohydrate Content-Post Sephadex™ LH-20 (56mL). Anti-inflammatory 
activity and carbohydrate content of fractions, collected from a 56 mL size Sephadex™ LH-20 C 
16/70 column. Results show a positive correlation between the carbohydrate content and the bio-
activity. Assay was performed in triplicates and error bars represented standard deviation from 
the mean. 
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The post LH-20 fractions were also assessed for the possible presence of protein. This 
was performed using a Pierce™ BCA Protein Assay Kit (Thermo Scientific®, Waltham, MA, 
USA). The results in Figure 3.9 show that the anti-inflammatory activity at elution volume 20-35 
mL correlates with protein content, suggesting the presence of protein in the bio-active 
compound. In contrast, the anti-inflammatory activity at elution volume 55 mL did not appear to 
correlate with the protein content, suggesting that this anti-inflammatory compound may not 
contain protein. 
 
Figure 3.9. Protein Content-Post Sephadex™ LH-20 (56mL). Anti-inflammatory activity and 
total protein content of fractions collected from a 56 mL size Sephadex™ LH-20 C 16/70 
column. Results show a positive correlation between the protein content and the earlier eluted 
bio-activity. Assay was performed in triplicates and error bars represents standard deviation from 
the mean.  
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3.3.4 Ion-Exchange Chromatography 
 DEAE Sephadex™ A-50 (GE Healthcare, Quebec) was used as a weak anion exchanger 
resin. The initial trials involved 5 buffers (Methyl-piperazine, piperazine, L-Histidine, TRIS & 
Diethanolamine) and 5 different pH conditions (4.5, 5.5, 6.1, 7.7 & 8.7) for the selection of the 
optimum condition(s) for use as the second purification step of the bioactive molecule). Figures 
3.10 and 3.11 illustrate the results from the mini Poly-Prep® ion-exchange column. “Flow-
through” represents the sample when subjected to the same buffer, and “eluent” represents the 
sample eluted using the same buffer containing 1 M NaCl. All the collected flow-through and 
eluent were lyophilized, re-constituted, dialyzed, and re-lyophilized. The post-lyophilized sample 
was re-constituted in water so that the final concentration for the cell treatment was 1 µg/µL. For 
buffers (methyl-piperazine, pH=4.5 and piperazine, pH=5.5), there was not enough sample for 
the flow-through test, so only the eluents were tested. As shown by Figures 3.10 and 3.11, all the 
buffer conditions applied showed bioactivity in eluents, indicating that ion-exchange column was 
successful in retaining the bio-active compound and consequently eluting in out, in the presence 
of salt. The results, however, indicate that piperazine at pH=5.5 yielded the most potent activity 
(i.e. >98%).  Based on this observation, the piperazine buffer at pH 5.5 was chosen as the buffer 
for use in the ion-exchange column. 
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Figure.3.10 Assessing different pH buffers for possible use in purifying the anti-inflammatory 
compound(s) from E. tinctorium. Raw 264.7 cells were induced with LPS (250 ng/mL) in absence or 
presence of various buffers and pH conditions (Methyl-piperazine pH=4.5, Piperazine pH=5.5, and L. 
Histidine pH= 6.1). LPS was used as negative control. Pre-load (Post LH-20: 1 µg/µL) was used as the positive 
control. Assay is performed in triplicates.  Error bars are standard deviation and One-way ANOVA analysis 
was performed as described in Materials and Methods (*, P < 0.0001). 
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Figure.3.11. Assessing different pH buffers for possible use in purifying the anti-
inflammatory compound(s) from E. tinctorium. Raw 264.7 cells were induced with LPS (250 
ng/mL) in the presence or absence of various buffers and pH conditions (Tris pH=7.7, 
Diethanolamine pH=8.7). LPS was used as negative control. Pre-load (Post LH-20: 1 µg/µL) was 
used as positive control. Assay was performed in triplicates.  Error bars were standard deviation 
and One-way ANOVA analysis was performed as described in Materials and Methods (*, P < 
0.0001). 
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Based on the above results, I proceeded to use a large-scale ion exchange column (XK-
50/100; DEAE Sephadex® A-50) to purify the anti-inflammatory compound (s). Figure 3.12 
shows that indeed the salt eluted fractions from the large scale DEAE column still possess anti-
inflammatory activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Confirmation of anti-inflammatory activity from DEAE-purified sample. An 
XK-50 1000 mL DEAE-Sephadex was used for purifying the bioactive compound collected from 
Sephadex LH20. Eluent collected after the column was washed with 1 M NaCl in Piperazine, 
pH5.5 was dialyzed and lyophilized. DEAE-Sephadex-purified sample (1 µg/µL) was assessed 
for anti-inflammatory activity in Raw 264.7 cells. LPS was used as a negative control. Assay was 
performed in triplicates.  Error bars are standard deviation and One-way ANOVA analysis was 
performed as described in Materials and Methods (*, P < 0.0001). 
 
 After obtaining the relatively pure compound, the percentage of carbohydrate and protein 
content was estimated. Table 3.2 shows the respective carbohydrate and protein content in crude, 
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semi-purified and purified molecules. The content of carbohydrate and protein in 
Polysaccharide-K (PSK) was also determined for comparison. It can be seen that, as the degree 
of purification increased, the percentages of carbohydrate content increased while the protein 
content was more in semi-purified compound(s) as compared to the purer ones. The results also 
revealed that the purified anti-inflammatory compound(s) from E. tinctorium has less 
carbohydrate but more proteins as compared to PSK. 
Table 3.2: Percentages of Carbohydrate and Protein Content in Crude and Purified Anti-
Inflammatory Sample from E. tinctorium 
Extract Characterization* Carbohydrate Content (%) Protein Content  
(%) 
Crude (F4) 31 9.9 
Semi-purified (Sephadex Post LH-20) 53 26.5 
Purified (Sephadex Post LH-20 + Post DEAE) 76.5 21.3 
Polysaccharide K (PSK) 87 12.4 
*1 mg/ml of each sample was analyzed 
This assay confirmed the presence of carbohydrate in the purified material. Next, the 
two-step (LH20 followed by DEAE) purified sample was shipped to Dr. Peter Cheung’s lab at 
the Chinese University of Hong-Kong for detailed chemical characterization of the carbohydrate 
content using GC-MS that was performed by Dr. Maggie Li. 
3.3.5 Chemical Characterization Using GC-MS 
According to the preliminary GC-MS analysis on the carbohydrate content of the 
Sephadex Post LH-20 + Post DEAE purified sample, glucose is the major component. Other 
monosaccharide contents along with their percentages as determined by Dr. Maggie Li are 
summarized in Table 3.3.  
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Table 3.3 Monosaccharide type & percent content in purified sample-determined using GC-MS 
S. No. Monosaccharide  Percent Content  
1. Xylose 2.0% 
2. Fucose 2.4% 
3. Galactose 2.8% 
4. Mannose 3.1% 
5. Glucose 89.7% 
 
Furthermore, the linkage analysis shows that the active moiety has 1,3-linked glucose, 
1,6-linked glucose, 1,3-linked galactose and 1,3,6-linked glucose present within the complex. 
3.3.6 Heat Denaturation 
To assess if the protein present in the active sample was associated with bioactivity, both 
pure and relatively semi-pure samples (1 µg/uL) were subjected to heat treatment at 100ºC for 5 
minutes. The approach is to denature the protein secondary structure at high temperature and 
correlate the change in anti-inflammatory activity with respect to the presence or absence of 
protein content in the compound. Figure 3.13 shows that the activity in the heat treatment 
experiment was retained (i.e. there was no change in the activity before and after heating). This 
indicates one of two possibilities: the proteins are denatured by heating and are not important for 
the biological activity, or the proteins are significant for the activity but destroying its secondary 
structure did not affect the activity as secondary structure of the protein may not be important in 
producing the bio-activity. With these two possibilities, the role of protein component with 
respect to the biological activity remained inconclusive and future experiments are needed to 
better answer this important question. 
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Figure 3.13. Heat denaturation had no effect on the anti-inflammatory activity of bio-
active compound(s) isolated from E. tinctorium. Assessing anti-inflammatory potential of 
semi-purified (Post LH-20, left) and purified (Post LH-20 + DEAE, right) samples on LPS-
induced RAW 264.7 macrophage cells. Assay was performed in triplicates.  Error bars were 
standard deviation and One-way ANOVA analysis was performed as described in Materials and 
Methods (*, P < 0.0001). 
3.3.7 Anti-inflammatory activity of purified samples from E. tinctorium in 
comparison with Acetaminophen 
With respect to the potency of purified and semi-purified sample, it was important to 
compare the activity to a known anti-inflammatory agent (e.g. acetaminophen). The dose-
dependent assay was performed to compare the relative potency (i.e. response per milligrams) of 
crude F4, post-Sephadex LH-20, post SephadexLH-20 + Post DEAE and acetaminophen. Figure 
3.14 shows the dose-dependent response (i.e. 1-, 0.5 -, 0.25 -, and 0.1 µg/µL). It was observed 
that the acetaminophen inhibited 99% of LPS-induced TNF-α at 1 µg/µL. This response 
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decreased with the decrease in dose (i.e. 97% at 0.5, 77% at 0.25 and 0% at 0.1 µg/µL). Crude 
mushroom sample demonstrated a slightly lesser response at the initial dose as compared with 
acetaminophen (i.e. 95% at 1 µg/µL), the response also decreased with the decrease in dose but 
there was still some anti-inflammatory response at lowest dose in contrast to acetaminophen (i.e. 
86% at 0.5, 72% at 0.25 and 37% at 0.1 µg/µL). The purified sample from E.tinctorium showed a 
similar response to the crude extract, also being active at the lowest dose (i.e. 89% at 1, 77% at 
0.5, 62% at 0.25 and 35% at 0.1 µg/µL). The semi-purified sample (i.e. SephadexTM Post LH-20) 
exhibited the same response as acetaminophen at 1 µg/µL (i.e. 99.5% inhibition), and 
surprisingly, it showed a more potent response at lower dose as compared to other samples 
including the pure sample and acetaminophen (i.e. 99.5% at 0.5, 99.3% at 0.25 and 97% at 0.1 
µg/µL). The run using Superdex200 column (see Section 3.3.8) helped clarify why the semi-
purified sample is more potent than the more pure sample. 
 
102 
 
 
Figure 3.14. Assessing the anti-inflammatory potency of purified compound(s) from 
E. tinctorium. Dose-dependent anti-inflammatory activity on LPS (250 ng/mL)-induced RAW 
264.7 macrophage cells. Acetaminophen, crude F4, Post Sephadex™ LH-20, and Post 
Sephadex™ LH-20 + DEAE were used at the following concentrations: 0.1, 0.25, 0.5, and 1 
ug/uL. Results were plotted as percent of TNF-α inhibition relative to LPS treatment alone. 
Assay was performed in triplicate.  Error bars are standard deviation from mean and One-way 
ANOVA analysis was performed as described in Materials and Methods (*, P < 0.0001). 
3.3.7 Fast protein liquid chromatography (FPLC) Superdex™ 200- ÄKTA Pure 
 FPLC analysis was performed on both semi-purified and purified samples for improved 
resolution and for estimating the size of the bio-active compound(s). The Superdex200 column 
was run by Mr. Sebastian Mackedenski, a Research Associate in Dr. Lee’s lab. Figures 3.15 and 
3.16 show the approximate size ranges for the semi-purified (Sephadex™ Post LH-20) and the 
purified (Post Sephadex™ LH-20 + Post Sephadex™ DEAE) samples respectively when plotted 
against the elution volume and the percent LPS inhibition. Figure 3.15 shows two peaks of 
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activity; the earlier peak was relatively more potent than the later peak (i.e. it exhibited greater 
percent inhibition as compared to the other one). The larger molecule peak is around 50-200 kDa 
in size, while the smaller molecule peak is around 5-25 kDa in size.   
 
 
 
 
 
 
 
 
 
 
 
FPLC analysis of the purer sample (i.e. Sephadex Post LH-20 + Post DEAE) 
demonstrated only one activity at the approximate size of 5-25 kDa. This activity corresponded 
with the second activity exhibited by the semi-purified sample shown in Figure 3.15. Based on 
this observation, I propose that the ion-exchange DEAE column was effective in purifying only 
the smaller molecular weight activity. This may partly explain why there is lower potency of the 
Figure 3.15. Estimating the size of the semi-purified bio-active compound using Superdex-
200. Assessing approximate sizes of the bio-active compound(s) purified from SephadexLH-20. The 
results show two bio-activities: a higher molecular weight compound at around 50-200 kDa in size and 
a smaller molecular weight compound at around 5-25 kDa in size. The anti-inflammatory activity 
assay (% LPS inhibition) was performed in triplicate and error bars represented standard deviation. 
from the mean. 
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relatively purer sample as the higher molecular weight compound (i.e. relatively more potent) 
had been removed in the second purification step using DEAE-Sephadex (Figure 3.14). Figure 
3.16 shows the results of the purified sample with respect to the percent inhibition and elution 
volume.  
 
Figure 3.16. Estimating the size of the purified bio-active compound using 
Superdex-200. Assessing the approximate size of the bio-active compound(s) purified 
sequentially from Sephadex LH20 and Sephadex DEAE columns. The results show a single 
activity at around 5-25 kDa size. The anti-inflammatory activity assay (% LPS inhibition) was 
performed in triplicates and error bars represented standard deviation from the mean. 
 
After the size estimation, the possible presence of carbohydrate and protein content was 
determined on the fractions collected from the Superdex-200 column.  Figures 3.17 and 3.18 
show the carbohydrate and protein content in the semi-purified and purified samples after 
passing through the Superdex-200 column. Figure 3.17 shows a correlation between the 
carbohydrate and protein content with the bioactivity while Figure 3.18 show a positive 
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correlation between the carbohydrate content, but not the protein content, with the bioactivity. 
This indicates that the larger molecular weight compound could be a combination of both 
carbohydrate and protein, while the smaller molecular weight compound could only be a 
carbohydrate. This was also observed earlier in Figure 3.9, when the anti-inflammatory activity 
at elution volume 55 mL did not appear to correlate with the protein content, suggesting that the 
5-25 kDa anti-inflammatory compound may not contain protein. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17. Assessing the presence of carbohydrate and protein in fractions 
collected from the Superdex-200 column. Semi-purified post-LH20 sample (500 L at 20 
mg/mL) was loaded onto the Superdex-200 column. Fractions collected were assessed for total 
carbohydrate (μg/mL, left) and protein content (μg/mL, right). Results show a positive 
correlation between the carbohydrate/protein content with the bioactivity. Assay was performed 
in triplicates and error bars represented standard deviation from the mean. 
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Figure 3.18. Assessing the presence of carbohydrate and protein in fractions 
collected from the Superdex-200 column. Sample purified from sequential Sephadex LH20 
and DEAE-Sephadex columns (500 L at 20 mg/mL) was loaded onto the Superdex-200 
column. Fractions collected were assessed for total carbohydrate (μg/mL, left) and protein 
content (μg/mL, right). Results show a positive correlation between the carbohydrate content, but 
not the protein content, with the bioactivity. Assay was performed in triplicates and error bars 
represented standard deviation from the mean. 
3.3.8 Nitrite Determination Assay 
After obtaining the relatively purified compound, the sample was tested for NO inhibition 
potential by measuring nitrite levels. NO assay was also performed in RAW 264.7 cells. Figure 
3.19 shows that, at 1 g/L, the purified sample was able to inhibit LPS-induced NO production 
by greater than 98%.  
107 
 
 
Figure 3.19. Inhibition of LPS-induced niric oxide production by anti-inflammatory 
compound from E. tinctorium. Purified sample (Post Sephadex™ LH-20 and Post DEAE 
Sephadex) (1µg/µL) was added to LPS (1 µg/mL) induced RAW 264.7 macrophage cells. LPS 
was used as a negative control and PMB was used as a positive control. Purified sample inhibited 
≥ 98% of stimulated NO. Assay was performed in triplicates.  Error bars were standard deviation 
and One-way ANOVA analysis was performed as described in Materials and Methods (*, P < 
0.0001). 
3.3.9 Yield of Purified Sample 
As the extraction and purification was carried out, it was essential to keep a record of the 
respective yield at each step so that a relative concentration of the product could be estimated. 
Table 3.4 summarizes the yield of the mushroom sample applied and purified at each step (i.e. 
from raw to two-step purification stage). 
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Table 3.4: Summary of the Yield of 5% NaOH Extract after Each Extraction/Purification 
Step. 
Technique Yield 
Powdered Crude Conk weight 300 g 
F4 (5% NaOH) Fraction weight 16 g 
Loaded on Sephadex™ LH-20 (450 mL) = 630 mg/run  
(9 ml of 70 mg/mL each). 
Purified on Sephadex™ LH-20 (450 mL) ~100 mg/run. 
Loaded on Sephadex™ DEAE A-50 (1000 mL) ~800 mg from 8 runs  
(Post LH-20 Sephadex®) 
Purified on Sephadex™ DEAE A-50 (1000 mL) ~60 mg 
Post Sephadex™ LH-20 and Sephadex™ DEAE shipped to Dr. 
Maggie Li for further characterization. 
~32 mg 
3.4 Discussion 
As this thesis was aimed at highlighting the special position of North American wild 
mushrooms for their novel therapeutic potential, this chapter focused on the successful 
purification and characterization of an anti-inflammatory compound(s) from the Indian paint 
fungus, E. tinctorium from northern BC forests. In Dr. Lee’s research group, the 50% methanol 
extract (F2) of this fungus has shown potent anti-proliferative activity, which was purified and 
studied by an undergraduate student Mr. Faran Rashid. The water extract of the same species (as 
shown in Figure 2.5.2) has exhibited strong immuno-stimulatory potential and is in the process 
of purification by Ms. Mehreen Zeb, a PhD Candidate in Dr. Lee’s lab. Similarly, the 5% NaOH 
extract which is the main focus of this chapter, has shown strong anti-inflammatory activity in 
RAW 264.7 cells against both LPS- and Histamine-induced TNF-α production and thus was 
purified using size exclusion (1st step) and ion-exchange chromatography (2nd-step), and further 
characterized using FLPC and GC-MS.  
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The 5% NaOH extract was first subjected to a size exclusion chromatographic 
purification. Sephadex™ LH-20 is derived from a dextran bead resin, Sephadex G-25, after the 
introduction of a hydroxy-propyl group and has been developed mainly for the separation and 
purification of the natural products. The resin has the tendency to separate molecules of less than 
5000 Da in molecular weight. Using this size exclusion resin, it was observed that the bio-active 
fractions of E. tinctorium elutes at around 32-45% of the eluting volume. This volume was close 
to the void volume of the Sephadex LH-20, which is 30% of the column bed volume. Void 
volume is the elution volume for the larger molecular weights compounds in the sample that are 
excluded from a particular column as their larger size would not allow them to interact with the 
resin so they will pass straight through the column.  
Exclusion at this volume indicates that the targeted molecule (s) was likely to have higher 
molecular weight as it was eluting out in the earlier fractions. The experiment in determining the 
potency of samples demonstrated the successful purification using Sephadex™ LH-20 because 
the post Sephadex LH-20 sample was not only more effective at the same dosage but was also 
effective at a much lower dose of 0.1 µg/µL. The active fractions collected from this size 
exclusion column correlated well with the respective carbohydrate/protein content in the higher 
molecular weight compound, suggesting the higher molecular weight bio-active compound(s) is 
made up of carbohydrate and protein, while the smaller molecular weight anti-inflammatory 
compound(s) consists mainly of carbohydrate. It was observed that, for a typical 450 mL column 
on which ~630 mg of the crude F4 extract was loaded, active fractions were pooled, lyophilized 
and ~100 mg of the sample was obtained at each run. This column was run at least 9 times and 
~800 mg of this product was saved for a large-scale ion-exchange column. The remaining 
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product was utilized in initial screening and other different protocol development trials in an 
effort to develop a reliable second purification step.  
After the first step of purification, the post SephadexTM LH-20 sample was subjected to a 
second step purification through ion exchange column chromatography. SephadexTM DEAE A-
50 is an anion exchange column in which the column was likely to bind the active compound 
with the resin in the start of the run and was expected to elute when subjected to a lower pH or a 
salt gradient. Initially, small columns were used to optimize the conditions. It was observed that 
Piperazine buffer at pH 5.5 produces potent activity in the “eluent”, so this condition was scaled 
up to get the higher yield of relatively purified bioactive compound(s). This ion-exchange 
column allowed further separation of non-bioactive molecules from the bioactive ones. Later, 
1000 mL column was adopted as the final purification step.  
The sample purified through sequential SephadexTM LH-20 and Post SephadexTM DEAE 
(~32 mg) was shipped to Dr. Peter Cheung’s Lab at the Chinese University of Hong Kong for 
further chemical characterization by Dr. Maggie Li. GC-MS analysis was conducted to determine 
the percentages of monosaccharides and the types of carbohydrate linkages present in the bio-
active sample. The preliminary results show the presence of glucose, mannose, galactose, fucose 
and xylose. It also revealed the presence of 1,3-linked glucose, 1,6-linked glucose, 1,3-linked 
galactose and 1,3,6-linked glucose linkages in the carbohydrate moiety.  
The heat denaturation experiment did not provide any conclusive findings and therefore 
future experiments are needed to explore the role of the protein component for the anti-
inflammatory activity. This could be done by treating the sample with proteases, separate the 
components through Superdex200 column and then re-assessing the collected fractions for 
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bioactivity. If the proteins have an important role in the bioactivity, the protein could be isolated 
from the complex and its amino-acid sequence determined.  
Experiments aimed at determining the potency of purified samples showed that the semi-
purified sample (bio-active sample from Sephadex LH20) is more potent than the purer sample 
(bio-active sample from sequential purification through Sephadex LH20 and DEAE-Sephadex). 
This was also confirmed by the FPLC experiments. The FPLC experiments also allowed 
determination of the size of the anti-inflammatory compound(s). The semi-purified sample 
revealed presence of two anti-inflammatory compounds with different molecular weight (higher 
molecular weight and lower molecular weight), while the purified sample only revealed the 
retention of lower molecular weight compound. Future studies could attempt to purify the larger 
molecular weight compound using a larger scale Superdex-200 column. 
Like TNF-α, Nitric oxide (NO) is also an important inflammatory biomarker, which is 
released from LPS-induced macrophage cells. A moderate level of NO is associated with anti-
inflammatory and anti-tumor response (Bogdan, 2015). However, it is known that NO over-
production causes cellular damage. Hyper-secreted NO reacts with super-oxides in the 
inflammatory micro-environment and plays a major role in chronic inflammation and 
carcinogenesis (Bogdan, 2015; Taofiq et al., 2016). Therefore, inhibition of NO could further 
support the anti-inflammatory potential of the compound. In the current study, the pure sample 
(i.e. Post LH-20 + Post DEAE) successfully inhibited LPS-induced NO release. Moreover, TNF-
α in the downstream pathway activates NF-кβ, which is the transcription factor for stimulating 
inducible nitric oxide synthase (iNOS). This iNOS then initiates the production of nitric oxide. 
This inhibition of LPS-induced NO assay confirmed that the inhibition of TNF-α production can 
lead to the inhibition of down-stream mechanisms for producing anti-inflammatory response. 
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Future studies could study the expression of various inflammatory genes and proteins in response 
to treatment of the anti-inflammatory compound purified from E. tinctorium.  
In summary, the lower molecular weight anti-inflammatory polysaccharide was 
successfully purified and partially characterized from 5% NaOH extract of E. tinctorium. 
Preliminary results show the presence of glucose as the major skeleton of the bio-molecule. 
However, the higher molecular weight anti-inflammatory compound, which is likely made up of 
polysaccharide and protein still needs to be separated and characterized. The roles of the protein 
and carbohydrate components are yet to be confirmed and need further studies. The semi-
purified sample (Sephadex Post-LH 20) was more potent than acetaminophen and was further 
tested on inflammatory animal model. The purified anti-inflammatory sample successfully 
inhibited LPS-induced NO production. To my knowledge, this is the first study reporting the 
anti-inflammatory compound(s) from E. tinctorium. However, the particular mechanism of 
action of this purified sample is yet to be investigated.  
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Chapter 4: Mushrooms in Microcirculation 
This chapter focuses on an in-vivo model for assessing the anti-inflammatory potential of 
selected mushroom extracts. A brief description of micro-circulation in skeletal muscles and the 
impact of inflammation on compromising the cellular communication are provided. The effect of 
histamine in inducing inflammatory events in mice gluteus maximus muscle was first established 
followed by investigation into the role of I. obliquus (Chaga-F2) extract and semi-purified E. 
tinctorium (F4-Post LH-20: E. tinc. PL20) in ameliorating histamine-induced inflammation. 
Introduction 
4.1 Role of Micro-circulation in Skeletal Muscles 
Skeletal muscles are voluntary controlled and present at the effector ends of the 
locomotory signaling pathway; they account for 40% of the whole muscle mass and are 
controlled via nerve stimulation (Hopkins, 2006). The muscle demands for oxygen depend 
greatly on the metabolic activity, which varies considerably during rest (blood flow: 5 
mL/min/100g) and active state (blood flow: 250-400 mL/min/100g) of the body (Segal, 2015). 
The blood supply in skeletal muscles is regulated by a coordinated interaction of the skeletal 
muscle fibers, endothelial, and smooth muscle cells, along with the local microcirculation (Segal 
et al, 2005). This vasculature is crucial for the optimum skeletal muscle output, transporting 
oxygen and essential nutrients while removing wastes. Interestingly, during intense physical 
activity, the increased oxygen demand does not increase the cardiac output significantly, 
highlighting the role of resistance vasculature that regulates and satisfies this intensified variation 
of metabolic and energy need (Segal, 2015). Miniature resistance arteries (arterioles) are 
responsible for supplying oxygen directly to the muscles at the micro-circulation level. At this 
stage, a coordinated vasodilation is crucial to meet the enhanced demand of the muscle by 
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releasing vasodilatory mediators or by spreading hyperpolarized signals between the 
endothelium and smooth muscles (Payne, 2006). These vasodilatory stimuli are generated locally 
and then are propagated upstream in the form of hyper-polarized electrical signals through gap 
junctions (present between the endothelium of the arteriolar walls) and eventually meet the 
enhanced demand by increasing the blood flow locally (Payne, 2006; Segal, 2015).  
This conducted vasodilation is manifested as a result of cell to cell coupling via gap 
junctions (Segal & Duling, 1986). Moreover, the intact endothelium is crucial for the un-
interrupted transmission of the hyperactive signal upstream, as it is now also established that 
endothelium, and not the surrounding smooth muscle layer, acts as a cellular medium for this cell 
to cell transmission of acetylcholine for the muscle contraction signals (Looft-Wilson et al., 
2004). Therefore, the endothelium integrity plays an important role in the maintenance of normal 
physiology and thus, any damage to endothelium will affect the coordinated communication 
between the endothelium (lining the interior of the arterioles) and adjacent smooth muscle cells 
in response to a neuronal impulse for the maintenance of the desired vascular tone. Given the 
importance of this coordinated cross-talk during conducted vasodilation, scientists have 
evaluated the impact of inflammation on this cellular communication.  
4.2 Impact of Inflammation on Micro-circulation  
Broadly stated, microcirculation has a major role to play in the development and 
transduction of the inflammatory response. Microvasculature undergoes several structural and 
functional changes during the inflammatory process (Granger & Senchenkova, 2010; Libby et 
al., 2009). Some of these manifestations are: the inability of the arterioles to dilate, a decline in 
the perfusion of capillaries, the activation of the endothelial cells lining the blood vessel to 
accommodate adhesion molecules stimulating the extravasation (escape) of leukocytes, and 
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finally enhanced vascular permeability (Granger & Senchenkova, 2010; Tuma, 2011). The 
primary goals of these stimulated mechanisms are: to promote the spontaneous delivery of 
inflammatory cells at the site of original insult, to counter-act the effect of hyper-stimulated 
inflammatory agents, to separate the infected region from the healthy one, and to finally start the 
process of tissue regeneration and re-modelling as soon as possible.  
Different cells that either circulate in the blood in normal conditions (i.e. platelets, 
leucocytes) or remain in the perivascular space (i.e. mast cells, macrophages); combined with 
those present in vessel wall (i.e. endothelial cells or pericytes) get activated because of the 
inflammatory response (Ley, 2001). These inflammatory cells, along with different chemical 
mediators and signaling molecules, induce phenotypic changes in the normal microvasculature of 
the body (Granger & Senchenkova, 2010; Ley, 2001). Although the roles of different chemical 
mediators and signaling mechanisms differ widely between the acute and chronic stage of 
inflammation, the role of microcirculation in sustaining and mounting the inflammatory response 
remains the same under both conditions (Granger & Senchenkova, 2010; Harlan, 1992).  
Inflammation activates almost every cell present in the vicinity of the affected area, and 
therefore, allows meaningful contribution from each cell in the outcome of the provoked 
response. Even the highly-specialized cells respond in a similar way, by releasing for instance 
certain cytokines and chemokines and by stimulating certain reactive oxygen species (ROS) and 
reactive nitrogen intermediates (RNI). These similarities in a combined response produce an 
altogether intense and effective defense for the rapid eradication of the intruding pathogen. 
Inflammation negatively impacts the vascular tree and all segments of microvasculature (i.e. 
arterioles, venules, capillaries, endothelial cells, pericytes, and vascular smooth muscles) respond 
to the inflammatory signal (Granger & Senchenkova, 2010; Kvietys & Granger, 2012; Payne, 
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2006). In arterioles, inflammatory mediators enhance superoxide (O2-) formation, halt nitric 
oxide (NO) formation, and diminish vascular smooth muscle relaxation; these changes cause 
oxidative stress (due to O2-), impair vasomotor function (due to inhibition of NO), and enhance 
thrombosis in arterioles (due to hemostasis) (Granger & Senchenkova, 2010; Sumagin & 
Sarelius, 2013). In the venules, inflammatory mediators enhance oxidative stress and leucocyte 
adhesion, and also favor platelets adhesion and enhance vascular permeability, finally promoting 
thrombosis. In the capillaries, inflammatory cascade reduces perfusion, supports the coagulation 
of leucocyte, and finally promotes angiogenesis (Granger & Senchenkova, 2010; Kvietys & 
Granger, 2012; Ley, 2001; Tuma, 2011). Consequently, the overall physiological changes in the 
micro-vasculature is summarized as: diminished capillary perfusion, vasomotor dysfunction, 
leukocyte adhesion and trans-endothelial migration, endothelial barrier deterioration (enhanced 
vascular permeability), increased proliferation rate of blood (i.e. angiogenesis) and lymphatic 
vessels, activation of coagulation cascade, and finally enhanced thrombosis (Granger & 
Senchenkova, 2010; Kvietys & Granger, 2012; Sumagin & Sarelius, 2013; Tuma, 2011). Thus, 
micro-circulation acts as a first aid responder in any inflammatory-associated event and is critical 
for any therapeutic target to maximize the targeted efficacy of any anti-inflammatory drug. 
4.3 Impact of Inflammation on Endothelium Integrity-Cellular Communication 
The endothelium, lining the inner wall of arterioles, acts as a semi-permeable membrane 
and is involved in creating a selective barrier to the transport of fluids, solutes and oxygen 
through the blood. This layer also mediates vasomotor tone and plays a role in the adhesion of 
cells (normal as well as inflammatory) and proteins within the vasculature (Granger & 
Senchenkova, 2010). Under normal conditions, the endothelium provides a non-adhesive surface 
and ensures consistent and uninterrupted hemostasis. In contrast, endothelial impairment is 
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associated with providing the ideal surfaces for the adhesion of platelets, leucocytes and other 
inflammatory cells and is ultimately associated with various pathological states, including 
inflammation (Payne, 2006). The loss of endothelial integrity during inflammation also causes 
the loss in vascular permeability and impairs cell to cell communication; thus, in a disease 
situation the upstream signal conduction, including conducted vasodilation, is compromised. 
This makes it difficult to meet the enhanced oxygen demand of the muscle in an hyper-active 
state. Further research is needed for the elucidation of the proper pathophysiology of blood flow 
in inflammatory endothelium.  
Histamine, a common inflammatory mediator, enhances the vascular permeability and is 
implied in various in-vitro and in-vivo models to simulate the inflammatory event (Majno & 
Palade, 1961). In one of the pioneering studies exploring the effect of histamine in compromising 
cellular communication in inflammatory micro-circulation, Payne et al. (2004) have 
demonstrated that the transduction of upstream signal in second order arterioles (2A) in mice 
cremaster muscle is reduced by half when the arterioles are subjected to histamine. However, the 
exact mechanism of histamine in compromising the communication remains unknown. It was 
proposed that the inhibition of the response could be attributed to a NO-dependent interaction via 
gap junctions and intracellular adhesion molecules. Moreover, histamine could alter gap junction 
configuration by either phosphorylating the connexin proteins present in the junctions or by dis-
assembling the junctional proteins isoforms (i.e. connexin Cx37, Cx40, and Cx43) (Payne, 
2004). Thus, this thesis chapter focuses on the 2A arterioles of mice gluteus maximus muscle as 
a representative of the skeletal muscle: histamine was applied to simulate the in-vivo 
inflammatory events, observe the effect of histamine in reducing vasodilation and explore the 
role of potent mushroom extracts in this diminished communication state.  
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4.4 Studies of Mushrooms on In vivo Anti-inflammatory Model 
There have been a number of studies exploring the impact of mushroom extracts and 
purified compounds in various anti-inflammatory animal models. The common model includes 
the induction of inflammation, using a chemical agent (e.g. carrageenan, acetic acid, and 
formalin etc.) and then applying mushroom extracts and/or isolated purified compounds to test 
the anti-inflammatory potential (Park et al., 2005, Qian et al., 2012, Ruthes et al., 2013). Park et 
al. (2004) showed that methanolic extract of F. fomentarius had a positive anti-inflammatory 
activity in rats as it successfully reduced carrageenan-induced acute paw edema. Qian et al. 
(2012) isolated lower molecular weight peptide (10,906 Da), Cordymin, from C. sinensis and 
successfully inhibited acetic-acid-induced inflammation in mice by decreasing TNF-α and IL-1β 
levels. The fucogalactan extract from A. bisporus also inhibited formalin-induced licking by 
decreasing iNOS and COX-2 expression (Ruthes et al., 2013). Our study using intra-vital 
microscopy technique to monitor the effects of mushroom extracts and/or purified compound(s) 
from mushrooms on the microcirculation is novel and has not been previously described. This 
model involves the live imaging of the inflammatory event and observation on the improvement 
of the inflammatory event in real time. We have applied methanolic extract of I. obliquus (F2) as 
a reference and then tested semi-purified (Sephadex Post LH-20) sample of E. tinctorium in 
replenishing the inflammatory event.  
4.5 Use of Methanolic Extract of I. obliquus as a reference for in vivo model 
Inonotus obliquus is a well-known traditional mushroom and the literature supports its 
anti-inflammatory therapeutic activity (please refer to chapter 2, section 2.8.2).  Various 
ethanolic and methanolic extracts of I. obliquus, along with isolated sterols and terpenoids have 
demonstrated positive anti-inflammatory effects in both cell cultures and animal studies. In in 
vitro model, I. obliquus inhibited LPS-induced macrophages by decreasing hyperactive release of 
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inflammatory cytokines such as: TNF-α, NO, COX-2 etc. whereas, in in vivo model, I. obliquus 
was successful in treating carrageenan-induced edema in rats and in decreasing colitis-associated 
inflammation in mice models (Debnath et al., 2012, Ma et al., 2013, Park et al., 2005, Van et al., 
2009). The following table summarizes the reported anti-inflammatory activity of I. obliquus in 
various in vivo and in vitro settings, making it a suitable candidate for our model development 
studies. Moreover, we have selected methanolic extract based on its maximum inhibitory effects 
on LPS-induced RAW 264.7 cells in our in vitro screening assay where it demonstrated potent 
anti-inflammatory activity (please refer to chapter 2, figure 2.6.3). This extract, along with the 
crude extract of E. tinctorium, also inhibited histamine-induced TNF-α in RAW 264.7 cells 
(please refer to Chapter 2, Figure 2.6.2).  
Table 4.1 A Summary of In Vivo & In vitro Anti-Inflammatory Activities of Inonotus obliquus. 
Model Activity Findings Active Structure References 
LPS stimulated 
RAW164.7 
cells   
Anti-inflammatory 
(in-vitro) 
50% reduction in nitrate conc.  
Dose-dependent inhibition of 
IL-1𝛽, IL-6, and TNF𝛼 in 
LPS Induced RAW 164.7 
cells 
Sterols Van et al., 2009 
i. LPS 
Stimulated 
RAW 264.7 
cells. 
ii. Paw edema 
in rats. 
Anti-inflammatory 
and anti-
nociceptive effects 
i. Methanolic extract 
inhibited production of NO, 
prostaglandin E2, and TNF-𝛼, 
mRNA expression of iNOS 
and COX-2 was also 
inhibited. 
ii. Inhibitory effects on 
carrageenan induced edema 
Structure analysis was not 
done in this study 
Park et al., 2005 
RAW 264.7 
macrophage 
cells 
Anti-inflammatory 
and anti-cancer 
activity 
NO production, and NF-𝜅B 
luciferase activity inhibition 
Trametenolic acid, 
ergosterol peroxide, 3𝛽-
hydroxy-8,24-dien-21-al, 
ergosterol, trametenolic 
acid and inotodiol 
Ma et al., 2013 
Colitis-induced 
Mice model  
Colitis associated 
Inflammation 
Decrease levels of TNF-α, 
COX-2, IL-4, IFN-γ, signal 
transducers and activators of 
transcription (STAT) 1, and 
STAT6. Lower levels of IgE 
and IgA in the spleen and 
mesenteric lymph node 
Structure analysis was not 
done in this study 
Debnath et al., 
2012 
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Based on our available expertise and the novelty of the technique in the field of medicinal 
mushrooms, we proceeded to investigate the feasibility of using intravital microscopy to study 
the potential anti-inflammatory effect of mushroom extracts/compounds on mice 
microcirculation. 
4.6 Material & Methods 
4.6.1 Animal and Chemicals 
Male black mice C57BL6 were purchased from Jackson Laboratories, BarHarbor, ME, 
USA. All chemicals and reagents were purchased from Sigma-Aldrich Co. (St Louis, MO, USA) 
or J. T. Baker (Phillipsburg, NJ, USA). 
4.6.2 Animal Care 
All procedures were approved by the Institutional Animal Care and Use Committee of the 
University of Northern British Columbia. The procedures used were an extension of Dr. Payne 
established protocols (Bearden et al., 2004; Looft-Wilson et al., 2004; Payne et al., 2004). Mice 
used for this study were male C57BL6 (22-30g, n=20) and were between 8–44 weeks old. Mice 
were housed at ~24°C and maintained on a 12:12-h light-dark cycle with free access to food and 
water ad libitum. Body mass was measured before each experiment. At the end of each 
experiment, mice were euthanized using intraperitoneal injection of the anesthetic (Euthanyl-
120-150mg/kg). 
4.6.3 Surgery and Glute Muscle preparation 
Each mouse was anesthetized with isoflurane with an induction rate of 3-4% and 
supplemented with a maintenance rate of 1-1.5% to maintain a surgical plane. During both 
surgical and experimental protocols, toe pinch was monitored to ensure a constant aesthetic state.  
Temperature of the animal was maintained using a heat lamp. The surgical protocol for 
the left gluteus maximus muscle was followed as described by Bearden et al. (2004). In short, the 
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left area covering glute was shaved in order to expose the muscle and was disinfected with 
alcohol.  The mouse was placed in prone position on a clear surgical (acrylic) plate. While 
observing through a stereomicroscope, the skin and connective tissue layer over the muscle was 
removed. The vasculature was exposed by carefully dissecting the proximal edge of the muscle 
away from its origin along the spine and pinning it on transparent sylgard platform. To maintain 
the internal physiological state of the muscle, the exposed tissue was constantly super fused with 
a bicarbonate-buffered physiological saline solution (PSS). The PSS used was equilibrated at 
34°C, has pH= 7.4, and has the following composition: NaCl (137 mM), KCl (4.7 mM), 
MgSO4 (1.2 mM), CaCl2 (2 mM) and NaHCO3 (18 mM). Careful skills were practiced to 
preserve the muscle architecture and to mimic the in-situ condition of the muscle so that a perfect 
in vivo model could be established.  
4.6.4 Intravital Microscopy 
After surgery, the muscle preparation was transferred to the stage of an intra-vital 
microscope (modified model 20T, Zeiss). The preparation was left to equilibrate for around 45-
60 mins while being super-fused with PSS to recover from the impact of surgery. Meanwhile, 
any signs of inflammatory event in the muscles were also observed (e.g. excessive rolling 
leukocytes) to ensure that there was no induction of inflammation by the surgery. If there is any, 
enough time was allowed to ensure the health of the preparation and vessel before recording any 
data. At that stage, PSS was equilibrated with 5% CO2 and its temperature was maintained inside 
a Radnoti perfusion reservoir. The flow rate of PSS was maintained at approximately 3mL/min 
with the help of a drip and suction line.  The preparation was then observed with bright field 
illumination (Zeiss ACH/APL condenser, numerical aperture 0.32). Then, a second order 
arteriole (2A) was selected from the central region of the tissue preparation by viewing it via a 
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Zeiss UD 40 objective (numerical aperture 0.41) coupled to a video camera (model no. C2400, 
Hamamatsu), whereby the total magnification on the video monitor (Sony model PVM-132) was 
950x. The vessel diameter was determined from the outer coat edges of the lumen with the help 
of a video caliper (modified model 321, Colorado Video, Boulder, CO) with spatial resolution of 
≤ 2μm.  The data was obtained using a PowerLab system (model 8S, ADI Instruments, Castle 
Hill, Australia) at 40Hz connected to a personal computer. Only one arteriole was studied in each 
mouse. 
4.6.5 Vasoactive Substances & Dose Response Curves: 
 The vessel tone is crucial for the optimum experimental results. Therefore, various 
concentrations of phenylephrine (PE, a selective α1-adrenergic receptor agonist-vasoconstrictor) 
and acetylcholine (ACh, a muscarinic receptor agonist-endothelium dependent vasodilator) were 
used. The stocks were prepared such that, after a 10-fold dilution with the fresh PSS, the 
concentration range was from 10-9 to 10-4 M of each reagent. Sodium nitroprusside (SNP., a 
source of NO, 10-2 M) was used in the end of each experiment to make sure that the endothelium 
was intact and healthy in all muscle preparations.   
After equilibration with PSS for 45-60 mins (as described in section 4.3.3), the resting 
diameter of vessels was first measured and then followed by ACh and PE responses to measure 
vessel tone. The dose of each vasoactive reagent was evaluated by the cumulative addition (10-9 
to 10-4M) to the super-fused solution in the Radnoti perfusion reservoir. The choice of adding PE 
or ACh first was dependent on the vessel diameter at rest. If the resting diameter was larger than 
~30μm, PE was used first as to allow the maximum diameter change from the baseline. As the 
addition of a dilator at this increased diameter will not make significant dilation, there will be 
little or no change at all from the reading at rest. If the initial diameter is smaller than ~30 μm, 
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ACh was added first. At each agonist concentration, the preparation was allowed to stabilize at 
the respective concentration for at least 2 mins before the next increment is being made. The 
preparation was subsequently washed with PSS for 30 mins in between ACh and PE applications 
to allow the return of the vessel diameter to the resting state. The addition of these vasoactive 
chemicals was in accordance to the protocol mentioned by Bearden et al. (2004). At the end of 
each experiment, maximum dilation was induced and measured by running SNP (10-2 M) over 
the preparation for 10 minutes.  
Histamine dose response was also estimated (10-9 to 10-4 M) to evaluate the response of 
histamine in 2A arterioles of mouse gluteus maximus muscle (n=5). This effect of changing 
histamine concentration was determined in the similar manner (i.e. by the cumulative addition to 
the super-fused solution). Arteriolar diameter was allowed to stabilize for 2 mins at each 
concentration and then the reading was taken, before the next increase. After the highest 
concentration, maximal dilation was induced and recorded through super-fusion of SNP. 
4.6.6 Conducted Vasodilation (CVD) 
To measure conducted responses, pre-pulled micropipettes (TIP2TW1, World Precision 
Instrument) with an inner tip diameter of 2μm were backfilled with 1 M ACh. This pipette was 
then adjusted in a micro-manipulator connected to a pressure pulse injector. The tip of the 
micropipette was then positioned adjacent to the downstream part of a 2A arteriole in the muscle 
preparation with the help of a remote-controlled micro-manipulator. This micro-manipulator 
allowed the smooth adjustment of the tip of the micro-pipette with respect to the 2A arteriole 
location. The tip was pre-equilibrated in PSS to ensure that the ACh inside is balanced and there 
was no leak on the muscle preparation. After equilibrating the muscles for 45 mins with PSS, a 
brief pulse of ACh (1 psi, 500 ms) was delivered to the selected 2A arteriole (n=10). The change 
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in diameter at the site where the micropipette was placed was recorded as “local response”, while 
the conducted vasodilation was measured 500μm upstream of the micropipette injection site and 
was recorded as “conducted response”.  
After measuring the local and conducted response under controlled conditions (i.e. PSS), 
the preparation was equilibrated with histamine (10 -5 M) for 30 mins. This concentration was 
selected as it has negligible effects on the diameter of 2A arteriole under rest condition (Figure 
4.2). Then, the effect of histamine on local and conducted vasodilation was evaluated in the same 
manner as described previously at 10 mins intervals while the histamine was still super-fused on 
the glute preparation.  
After recording the effect of histamine, the preparation was super-fused separately with 
either Chaga-F2 (n=5) or E. tinctorium (refer to as E. tinc.)-PL20 (n=5) and the added histamine 
so that the final concentration of the mushroom extract is 12.5 µg/mL.  The concentration of the 
mushroom extracts was selected on the same criteria (i.e. the dose at which there is negligible 
effects on the diameter of 2A arteriole under rest conditions) (Figure 4.3). This mixture 
(histamine + mushroom extract) was allowed to run on the preparation for 30 mins and the local 
and conducted response was measured in the same way as described previously while the 
solution was still running on the muscle preparation.  
4.6.7 Data Analysis 
The vasomotor response to ACh, PE, SNP and histamine were calculated using the 
following formula at the respective site of observation: 
% Difference =  × 100% 
For the conducted vasodilation experiment, at each site of arteriole, the response to ACh 
was calculated as the diameter change (i.e. peak response diameters minus the resting diameters). 
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For all experiments, data were analyzed using One-way repeated-measures ANOVA (PRISM). 
Summary data is represented as means ± S.E. Value of n refers to the number of arterioles 
studied in as many mice. Difference among group is statistically significant for P < 0.05. 
4.7 Results 
4.7.1 Vascular Integrity  
For determining the baseline and maximum diameters, second-order arterioles (2A) were 
studied in male C57B76 mice. Minimal variation was observed in the resting diameter of 2A 
arterioles of the mice. The average resting diameter was calculated as 19 ± 2 µm (n=10). The 
maximum dilation of the test vessel in response to ACh (10-4 M) equals 38 ± 2 µm (n=5) and that 
of SNP (10-2 M) equals 37 ± 3 µm (n=10). There is approximately a 151% change between the 
resting and the maximum diameter. Table 4.1 displays the graphical representation of minimum 
(resting) and maximum (ACh and SNP) diameters changes.  
Table 4.2: Baseline (Resting) and Maximum diameters (ACh and SNP) in 2A Arteriole 
Parameters Vessel Diameter (µm) n 
Baseline (Resting) 19 ± 2 10 
Acetylcholine (ACh) 10-4 M 38 ± 2 5 
Sodium Nitroprusside (SNP) 10-2 M 37 ± 3 10 
For evaluation of the vascular tone, gluteus maximus muscle was subjected to different 
doses of ACh and PE (10-9 to 10-4 M). Figure 4.1 demonstrates the successful induction of 
vasodilation and vasoconstriction in the arterioles with the help of ACh and PE respectively in a 
dose-dependent manner. The arteriole increased steadily by raising the dose of ACh. On the other 
hand, the percent change of diameter from resting diameter decreased gradually by increasing the 
dose of PE in the super-fused solution. These results indicate that the endothelium and smooth 
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muscles in the arterioles are intact and reactive to the added molecules and the doses of 
vasoactive chemicals were sufficient to elicit a response. 
 
Figure 4.1. Vaso-activity of ACh and PE. The percent change in diameter of the 2A 
arteriole of male C57BL/6 mouse gluteus maximus preparation (n = 5) with the addition of 
vasoactive compounds. The vasoactive compounds, phenylephrine (PE) and acetylcholine (ACh) 
were diluted in super-fused solution so that the final concentrations were 10-9 to 10-4 M using 
PSS. The percent change was measured as the (baseline diameter-recorded diameter)/baseline 
diameter multiplied by 100%. Error bars were determined using standard error of the mean. 
4.7.2 Histamine dose response 
Histamine was used to induce inflammation in the 2A arteriole in a dose-dependent 
manner. Figure 4.2 illustrates the effect of various doses (10-9 to 10-4 M) of histamine on the 
arteriolar reactivity. The dose response curve demonstrates a bi-phasic reaction in which the 
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vessels demonstrate vasodilation when subjected to 10-9 to 10-6 M histamine concentration, 
whereas it demonstrates vasoconstriction when subjected to 10-5 to 10-4 M concentration of 
histamine. Maximum dilation was observed at 10-6 M that shifts to vasoconstriction at lower dose 
of 10-5 to 10-4 M (Figure 4.2).  
 
Figure 4.2. Bi-phasic response of Histamine. The percent change in diameter of the 2A 
arteriole of male C57BL/6 mouse gluteus maximus preparation (n = 5) with the addition of 
histamine. The histamine is diluted in super-fused solution so that the final concentration is 10-9 
to 10-4 M using PSS. The percent change was measured as the (baseline diameter-recorded 
diameter)/baseline diameter multiplied by 100%. Error bars were determined using standard 
error of the mean. 
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4.7.3 Conducted Vasodilation 
For employing mushroom extract in CVD, a dose response curve for the extract was 
generated using Chaga-F2 as a reference extract. Figure 4.3 represents the dose response curve 
for Chaga-F2, indicating the decreasing tendency of the extract to change vascular diameter with 
the decrease in dose. The dose selected for the CVD experiment was 12.5 µg/mL because, at this 
dose, the vessels were minimally active. The same dose was used for the other mushroom extract 
(E. tinc. -PL20) as the mushroom has almost the same potency and dose-dependent response in 
in vitro settings (Refer to Chapter 2, Figure 2.6.2, 2.6.3, 2.7.2). 
       
Figure 4.3. Dose response curve of Chaga (Inonotus obliquus, F2). The percent change in 
diameter of the 2A arteriole of male C57BL/6 mouse gluteus maximus preparation (n = 7) with 
the addition of Chaga. The histamine is diluted in super-fused solution so that the final 
concentration is 50, 25, 12.5 and 6.25 μg/mL using PSS. The percent change was measured as 
the (baseline diameter-recorded diameter)/baseline diameter multiplied by 100%. 
For the CVD experiments, the same local response was observed among diverse treatments 
(Figure 4.4) as the baseline diameter change was almost the same among different control groups 
(15±0.2), Chaga-F2 (13.5±0.5), histamine (13±0.3), histamine + Chaga-F2 (13±0.3), E. tinc. -
PL20 (13.5±0.3) and histamine + E. tinc. -PL20 (14.8±0.16).  
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Figure 4.4. Local response to conducted vasodilation in arterioles of C57BL6 mice 
(n=10). Responses to ACh (1psi, 500 ms) were recorded at the site of stimulation (local: 
distance=0). At each site, “diameter change” was calculated as peak response diameter – resting 
diameter. There was no significant difference in the local response in arterioles of C57BL6 mice 
between control, Chaga (left), histamine, histamine + Chaga (left), E. tinc. (right) and histamine 
+ E. tinc. -PL20 (right). One-way ANOVA is applied as described in methodology section. 
 
For the conducted response, histamine decreased the conducted vasodilation at 500 µm 
upstream as predicted. The change in diameter dropped from 10±0.3 µm in controlled state to 
6±0.06 µm in inflammatory state induced by histamine indicating the decrease in the cellular 
communication. There is no significant change in response in the case of Chaga (9.5 ± 0.5 µm) 
and E. tinctorium (10 ± 0.5 µm) alone. Figure 4.5 (left) shows the CVD of Chaga in response to 
histamine-induced response. Chaga restored the decreased conducted vasodilation induced by 
histamine to 8.8 ±0.2 µm from 6±0.06 µm. Figure 4.5 (right) shows the CVD of E. tinc. -PL20 in 
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response to histamine-induced response. In this case, the semi-purified mushroom extract 
restored the conducted back to 10 ± 0.2 µm. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Conducted vasodilation in arterioles of C57BL6 mice (n=10). Responses to 
ACh (1psi, 500 ms) were recorded at the remote site upstream (with respect to blood flow) along 
the arteriole through a distance of 500 µm (conducted response). At each site, “diameter change” 
was calculated as peak response diameter – resting diameter. There is significant difference 
between conducted response of histamine vs. Chaga-F2 and E. tinc. -PL20, indicating the anti-
inflammatory potential of mushroom extracts. One-way ANOVA was applied as described in 
methodology section *P <0.001. 
4.8 Discussion 
This study determined the reactivity of 2A arterioles in mice gluteus maximus muscle 
under both normal and pathological state. The dose response curve with the ACh and PE (Figure 
4.2) demonstrated that the vessels possess a healthy vascular tone as they showed desired 
response upon treatment with a vasoconstrictor and/or a vasodilator. It further supports the skills 
of the experimenter to perform a reliable and healthy muscle preparation each time in which both 
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smooth muscles and endothelium are intact and the capacity of this preparation to produce 
powerful and consistent response without eliciting inflammatory events or compromising 
vascular tone.  
The histamine dose response curve showed a bi-phasic response and helped in choosing 
10-5 M dose for the conducted vasodilation (CVD) experiments. The biphasic histamine response 
is in accordance with the previous work done by Payne et al. (2003) in which 2A arteriole of 
cremaster muscle showed the similar trend. Furthermore, normal and pathological responses to 
the conduction of signal was observed using CVD technique. There was no significant difference 
between local response under different stages, but the conducted response (500 µm upstream 
n=5) was significantly less in the presence of histamine (inflammatory state). As suggested by 
our results, this reduced signal transmittance can be re-established by running mushroom 
extracts: F2 Chaga along with the histamine (n=5) and F4 Post LH-20 E. tinctorium with 
histamine (n=5). To our knowledge, the current study is the first of its kind to explore the role of 
wild mushrooms in micro-circulation. 
Intravital microscopy, an imaging technique, enables viewing of live vessels in the tissue 
at the micro-circulation level. Tissues are mainly prepared from live anesthetized animals, and 
are viewed using a set of high resolution lenses that enables a clear visual of the physiological 
events happening in the vessels. A physiological saline solution (PSS) replicates the internal 
physiological environment and as the muscle is still intact with the animal, an in vivo condition is 
simulated. The live event can also be seen with the help of a video camera and computer attached 
with the preparation. There is also an attached video caliper that measures the vessel diameter, 
red blood cells velocity etc. from which major qualitative and quantitative conclusions can be 
drawn in real time (Gavins & Chatterjee, 2004). 
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The mice surgical preparation using gluteus maximus and its response to vasoactive 
reagents were previously developed and applied in Dr. Payne’s lab. The same response can be 
observed in mice cremaster muscles but the gluteus maximus muscle preparation provides 
several strengths over the cremaster muscle. Some of these advantages are: intact vasculature, 
being present in all mammals, common to both sexes, and a strong organ of locomotion. The 
benefit of using glute muscle is the opportunity to study the intact microvasculature in its native 
environment (Payne, 2006; Payne & Bearden, 2006)  
Previous studies have demonstrated that the gluteus maximus arteriolar network 
architecture is highly conserved across different age groups (young, adult, old) in C57BL/6 mice 
during their lifetime (Payne & Bearden, 2006). It further explains that the tortuosity and 
branching angle of the smallest arterioles is affected with aging but there is no age-associated 
differences in arteriolar segment numbers, lengths or surface areas in these mice (Payne & 
Bearden, 2006). The baseline and maximum diameter and the responsiveness of the vessel to the 
vasoactive reagents are also similar among different age groups, indicating the intactness of 
endothelium and smooth muscle in the vessel. However, the study does show a decrease in 
vascular communication (i.e. conducted vasodilation) with the process of aging. Therefore, the 
arteriolar network architecture, endothelium-dependent and independent vasodilation, and 
smooth muscle contraction to adrenoreceptor activation are highly conserved in various age 
groups but the cellular communication is compromised in older age (Payne & Bearden, 2006). 
These reasons make the gluteus maximus muscle an ideal model system to use for intravital 
microscopy and explore the relationship of various physiological and pathological states. It is 
also worth mentioning that 2A arterioles were selected as the vessels of the choice of study as 
these are the key distributing vessels in the mouse gluteus maximus muscle and these are also 
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positioned ideally to control the flow of the blood (Payne 2006). Inducing histamine in the 
microcirculation and observing it directly via intravital microscopy (IVM) also allows the 
observer to examine the inflammatory changes at the same time as they happen.  
The current in vivo study highlights the importance and complexity of the inflammatory 
response in the microvasculature of a human body. The diverse and constantly expanding 
research on microcirculation and its role in inflammation highlights the contribution of all its 
segments (i.e. arterioles, capillaries, venules, endothelial cells, pericytes and vascular smooth 
muscles etc.) in the progression of the inflammatory micro-environment. Typical phenotypic 
changes demonstrated by the microvasculature during the inflammatory cascade include 
vasomotor dysfunction, diminished capillary perfusion, leukocytes and platelets adhesion, 
coagulation cascade and thrombosis initiation, vascular impermeability, and blood and lymphatic 
vessels hyper-proliferation. All these changes work towards fast delivery of leukocytes at 
infected sites, transportation of inflammatory cells to affected areas, isolation of damaged site 
from systemic circulation and healthy tissues, dilution of harmful agents in affected areas, and 
regulation of the regeneration and repair processes. Since inflammation is a predominant cause 
of many pathological conditions, exploring the impact of inflammation directly on the 
microcirculation clarifies the pathophysiology and the effect of inflammation as it takes place. To 
our knowledge, wild mushroom extracts being tested in mice micro-circulation is also a novel 
study.  
Conducted vasodilation experiments were also consistent with the previous studies in 
which the local response was consistently less than the conducted response (500 µm). The 
histamine super-perfusion consistently impaired the coordinated vasodilation, indicating the 
impact of inflammation in decreasing the coordinated response. These findings are also 
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consistent with the previous work on the cremaster muscles of mice, indicating the 
reproducibility of the data in gluteus maximus muscle (Payne et al., 2004; Payne, 2006). One of 
the reasons for the diminished response could be attributed to the fact that the presence of the 
inflammatory mediators may disrupt the cellular signaling transmission by causing structural 
alterations in the endothelial layer (e.g. causing hyper-permeability or changes in gap junction 
assembly) or by enhancing the production of harmful cytokines (such as, ROS or NO), therefore 
promoting the hyper-activated state and causing imbalance.  
Moreover, the current study builds upon the findings from the previous studies and 
explores the role of novel wild mushrooms extracts that have demonstrated potent anti-
inflammatory potential in in-vitro models. The methanolic extract (Chaga-F2) was applied in 
crude form while the 5% NaOH extract (E.tinc. -PL20) was applied after the first purification 
step (i.e. after size exclusion chromatography-Post LH-20; Chapter 3). This post LH-20 extract 
has already demonstrated a higher potency in the in-vitro settings as compared to the crude 
extract (Chapter 3). In the in vivo settings, this semi-purified extract has demonstrated a slightly 
higher response at the same dose as compared to the crude (Chaga-F2) extract but as the 
mushrooms species are different, these two responses are not comparable with one another. 
The fact that the respective fungal extracts consistently and dose-dependently inhibited 
LPS- and histamine-induced TNF-α production in RAW 264.7 cells (please refer to Chapter 2) 
and that these anti-inflammatory activities were also confirmed in mice microcirculation model, 
shows that indeed the mouse macrophage cell line is a useful model as a first step for screening 
for anti-inflammatory compounds.  Our study confirms the anti-inflammatory activity of I. 
obliquus which is consistent with previous studies (Debnath et al., 2012, Ma et al., 2013, Park et 
al., 2005; Van et al., 2009). This study shows for the first time the novel and previously unknown 
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anti-inflammatory potential of 5% NaOH extract of E. tinctorium (E.tinc. -PL20) in ameliorating 
the negative impact of inflammation in both in vitro and in vivo settings.  
This study provides a framework for exploring mushroom extracts in mice gluteus 
maximus micro-circulation model. Future studies could explore the specific mechanism of action 
of these extracts in perfecting the diminished conducted response. Following the model study by 
Looft-Wilson et al. (2004), future studies could also look into the role of special gap junctions’ 
protein, Connexin, and its three isoforms (i.e. Cx37, Cx40, an Cx43) in diminished (i.e. 
inflammation) and re-established (i.e. anti-inflammation) conducted response.  As the semi-
purified mushroom extract (E.tinc. -PL20) has two anti-inflammatory compounds (the larger 
molecular weight (̴ 50-200 kDa) and the smaller molecular weight (̴ 5-25 kDa) compound), 
future studies can establish their respective roles in micro-circulation and anti-inflammatory 
potential. More extensive studies could also involve the use of inflammation-induced mouse 
models (e.g. colorectal cancer mouse model) to study the effect of potent extracts in treating 
inflammation-associated tumors which will be helpful in the prevention and treatment of chronic 
inflammatory states and the tumors associated with these hyper-active immune conditions. 
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Chapter 5: General Discussion & Future Directions 
5.1 General Discussion 
5.1.1 Screening BC wild mushrooms for Immuno-stimulatory and Anti-
inflammatory activities 
One of the major aims of this MSc thesis was to study some of the wild mushrooms 
collected from Northern BC forests for their immuno-modulatory potential. Forty-four 
mushroom extracts were tested for immuno-stimulatory activity and thirty-one mushroom 
extracts were evaluated for their anti-inflammatory ability. Crude mushrooms extracts were 
screened on macrophage (RAW 264.7) cells for both immuno-stimulatory and anti-inflammatory 
potential where the activation of cells and production of TNF-α was observed in the former 
(immuno-stimulatory) and the inhibition of previously activated cells and suppression of 
excessively stimulated TNF-α was quantified in latter (anti-inflammatory) assays. After 
successful screening, the potent anti-inflammatory NaOH extract from E. tinctorium was 
selected for further purification and characterization. In addition, the semi-purified extract of E. 
tinctorium was further studied for anti-inflammatory activity in vivo using a mouse 
microcirculation model.  
Recent studies have applied various in vitro techniques to explore novel bioactive 
compounds from medicinal mushrooms. Thus, the objective of the present study was to reveal 
the immuno-stimulatory potential of ten wild mushroom species collected from across the forests 
of Northern British Columbia: F. pinicola, L. edodes, P. betulinus, F. fomentarius, G. 
applanatum, E. tinctorium, I. obliquus, L. connata, L. sulphureus, and P. nigricans. The extracts 
that failed to exhibit immuno-stimulatory potential, which include extracts from 4 other species 
extracted by fellow graduate students, P. igniarius, T. abietinum, H. coralloides, L. vulpina, were 
further studied for anti-inflammatory potential. This study was carried out to demonstrate the 
137 
 
potential of wild mushrooms from a unique and largely untapped region of the world, British 
Columbia (BC), for discovering novel mushroom extracts that could contain immuno-
modulatory compound(s) for natural product drug discovery. 
The results from the screening study on mushroom extracts demonstrated that indeed 
Northern BC’s wild mushrooms have enormous potential for the discovery of immuno-
modulatory compounds. Out of forty-four extracts tested, nine have shown at least moderate 
(≥40% stimulation) immuno-stimulation potential. Among them, four extracts, L. edodes (F2), G. 
applanatum (F3), E. tinctorium (F3) and L. sulphureus (F3), have shown very strong (≥90%) 
immuno-stimulatory activity. Out of thirty-one extracts tested, twenty-two extracts have shown 
at least moderate (≥40% inhibition) anti-inflammatory activity.  Among them, nineteen extracts 
from 11 species, F. pinicola (F2, F3), P. betulinus (F1, F2, F3), F. fomentarius (F1, F2), G. 
applanatum (F1, F2), E. tinctorium (F5), I. obliquus (F1-F4), L. connata (F1), L. sulphureus 
(F1), P. nigricans (F2), P. igniarius (F1), and T. abietinum (F1), have demonstrated very strong 
(≥90%) anti-inflammatory activity. The anti-inflammatory activity was mostly confined to the 
ethanolic and methanolic extracts of the mushrooms. The fact that there were more extracts 
active for the anti-inflammatory assay than immuno-stimulatory activity could indicate that 
Northern BC wild mushrooms might have greater potential for the anti-inflammatory 
compound(s) than immuno-stimulatory ones. However, the reasons for this remain unknown. 
The screening results have implications for future study of mushroom extracts and their potential 
bioactive compounds that can be used to aid both suppressive and hyper-active states of the 
immune system. 
Bernard Shaw, in “The Doctor’s Dilemma”, said: “Nature has provided, in the white 
corpuscles as you call them, in the phagocytes as we call them, a natural means of devouring 
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and destroying all disease germs. There is at bottom, only one genuinely scientific treatment for 
all diseases, and that is to stimulate the phagocytes”. In conformity with this quote and previous 
studies, the current study established the application of phagocytes (macrophages-RAW 264.7 
cells) in testing in vitro immuno-modulatory potential.  
The present study also reinforced the theory of stimulating macrophages in response to 
fungal extracts to stimulate TNF-α production as the quantification marker of the extract’s 
immuno-stimulatory potential.  Furthermore, lipopolysaccharide (LPS) successfully established 
the positive reference scale for comparing the immuno-stimulatory potential of the extracts. LPS 
is present in the gram-negative bacterial cell wall. It binds to the Toll Like Receptor (TLR-4) on 
the CD-14 receptor of macrophages. This binding is aided by 2 proteins CD14 and MD-2. This 
complex triggers the downstream transcription factor, nuclear factor kappa-β (NF-κβ) that 
regulates the expression of target genes that encodes and activates the release of various pro-
inflammatory cytokines including TNF-α (Solov'eva et al., 2013).  
The current project also showed that, when macrophage RAW 264.7 cells were 
stimulated with LPS, the enhanced release of pro-inflammatory cytokines (such as TNF-α) could 
be inhibited by the mushroom extracts as a measure of their anti-inflammatory potential.  
Polymyxin B (PMB) resulted in a reduction of TNF-α production in LPS-stimulated 
macrophages, therefore providing a scale for equating anti-inflammatory potential of the 
extracts. Conceptually, PMB inhibits LPS-induced TLR-4 activation by forming a LPS-PMB 
complex, which disrupts the bacterial cell wall. This ultimately inhibits the LPS-induced 
cytokines release in downstream pathway (Yu et al., 2015). The current study adopted the use of 
PMB as a negative control from these prior studies (Lei et al., 2015).  
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For the in vitro anti-inflammatory experiments exploring the potential of I. obliquus (F2) 
and E. tinctorium (F4) in inhibiting histamine-induced TNF-α, both extracts successfully 
inhibited the induced TNF-α production and therefore have shown similar results as were shown 
in experiments with LPS-induced TNF-α production. This experiment was used to simulate in 
vivo model conditions (i.e. histamine-induced inflammatory event as opposed to LPS-induced 
inflammatory response). The results with the histamine dose response in RAW 264.7 cells were 
surprising, as histamine did not stimulate the release of TNF-α at higher doses (1-10-4 M) and 
only stimulated the release at lower doses (10-5 and 10-6 M). This experiment was repeated four 
times and similar results were obtained. There was no cytotoxicity in higher doses so the 
inability of the histamine to stimulate macrophages cannot be attributed to the cell death. 
However, to our knowledge, this study is the first of its kind to explore the role of histamine in 
mouse macrophages RAW 264.7 cells. There is one similar study in human liver macrophages in 
which histamine was used to induce exocytosis and stimulate the release of pro-inflammatory 
cytokines (IL-6). Interestingly, in that study, 10-6 M histamine stimulated the maximum release 
of the cytokine, which is in agreement with the present study (Triggiani et al., 2001).  
Moreover, this research provides pioneering protocols in assessing anti-inflammatory 
potential of wild mushrooms in an in vitro setting and both anti-inflammatory models (i.e. LPS 
induced TNF-α production and histamine induced TNF-α production) are the first ones used in 
Dr. Lee’s lab. This provides a framework for the screening of other wild fungi for their anti-
inflammatory ability. Another important finding that arose during the development of the 
protocol was the observation that ethanol, DMEM and Sodium Chloride (NaCl) could inhibit the 
LPS-induced TNF-α. Thus, these solvents (ethanol and DMEM) should be avoided for re-
suspending the mushroom extracts, and the 5% NaOH extract and the NaCl eluents from the ion-
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exchange column should be thoroughly dialysed as to avoid any salt in the sample, thereby, 
circumventing any negative hits. 
5.1.2 Purification and characterization of anti-inflammatory compounds from 
Echinodontium tinctorium 
The results of the purification study presented a successful method for isolating 
polysaccharide(s) from a potent extract of E. tinctorium (F4). The purification study after the size 
exclusion and Superdex-200 (Post LH-20 + Post Superdex-200) revealed that there were 2 
bioactive anti-inflammatory compounds present in the semi-purified extract as 2 peaks were 
observed. The higher molecular weight compound (̴ 50-200kDa) was more potent than the lower 
molecular weight compound (̴ 5-25kDa). The results from carbohydrate assays on these fractions 
suggested that both compounds have carbohydrate content. The results from protein assays on 
these fractions suggested that only the larger molecular weight compound has protein, hence, the 
higher molecular weight compound is a potential protein-bound polysaccharide, while the 
smaller molecular weight compound is only a carbohydrate.  
The results from size exclusion, ion exchange and Superdex-200 (Post LH-20 + Post 
DEAE + Post Superdex-200) demonstrated a single peak suggesting that the ion exchange 
column (DEAE) was able to purify the smaller molecular weight anti-inflammatory molecule (̴5-
25 kDa). The characterization of this smaller molecular weight compound was performed by Dr. 
Maggie Li in Dr. Peter Cheung’s lab (Hong-Kong). Preliminary results showed the presence of 
glucose and other mono-saccharides with 1-3, 1-6, and 1-3-6 linkages. However, there is still a 
need to devise a method to verify the purity of this purified anti-inflammatry sample using High 
Performance Gel Permeation Chromatography (HPGPC). Moreover, the configuration of this 
purified glucan (i.e. alpha or beta) also needs to be determined using FTIR analysis. There is also 
a need to develop the method to isolate the more potent and larger molecular weight 
141 
 
polysaccharide from the semi-purified sample. To the best of our knowledge, this is the first 
study to reveal anti-inflammatory compound(s) from E. tinctorium. 
The ion exchange and size-exclusion columns used to purify the potential anti-
inflammatory compound(s) had limited capacity. Only a few milligrams (e.g. 630 mg in case of 
450 mL size exclusion column) of crude or semi-purified material could be loaded on the column 
each time as overloading would halt the column ability to cause effective separation. This would 
cause a low yield of the active compound(s) and therefore multiple runs of the same column 
were needed. These cycles were repeated several times to attain the adequate amount of the 
product, which is indeed laborious and time consuming. 
Echinodontium tinctorium is commonly known as Indian paint fungus and, living up to 
its name, produces a color pigment that created one of the biggest challenges in this project: 
chromatographic column cleaning. The mushroom stained the column and it did not become 
clean even with multiple washes of ethanol, methanol, acetone and water. The pre-loaded 
mushroom fraction was also de-colorized with charcoal treatment, but only a very small change 
in the color was observed and the original dark reddish color of the extract remained. When the 
column was cleaned with 1% bleach solution, the color on the column washed away quickly. The 
activity from the column remained reproducible (i.e. the activity peak remained same) but when 
the active fractions were pooled and lyophilized, there was a significant decrease in the percent 
yield of the final product. Finally, washing the column with 0.1 M NaOH was attempted which 
left a pink stain on the column that was easily washed away with water.  
5.1.3 An Intravital Microscopy method to study anti-inflammatory activity of Chaga 
extracts and purified compound from E. tinctorium 
Results of the experiments in the in vivo model reiterated the strong in vitro anti-
inflammatory potential of both I. obliquus and E. tinctorium as both of these extracts 
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successfully and reproducibly reversed the histamine-induced inflammatory event in mice micro-
circulation.  One of the major challenges in the intravital microscopy was the generation of intact 
muscle preparation without inducing inflammatory events from the outside environment (i.e. 
surgicals). The results indicate that, as the cellular communication was blocked up-stream by 
histamine-induced inflammatory events, both mushroom extracts were able to normalize the 
abated communication separately when tested with histamine. Chaga (I. obliquus) was used as a 
reference in this study because of existing literature in support of its anti-inflammatory potential. 
Also, this F2 extract of I. obliquus was most potent in inhibiting LPS -induced TNF-α production 
in our in vitro LPS model. This was also active in our in vitro histamine experiments. This study 
is the first of its kind in studying mushroom extracts for their anti-inflammatory activity in mice 
micro-circulation.  
5.1.4 Conclusions 
One of the limitations associated with this study could be the route of administration of 
the active polysaccharide. Normally, polysaccharides are hypothesized to be mal-absorbed by the 
gut, therefore leading to a potential problem in the pharmacokinetics studies during 
pharmaceutical dosage form development. There is, however, some literature on the efficacy of 
the active polysaccharide after oral administration. Liu et al. (1993) observed that when PSP was 
given in drinking water to C57BL/6 mice, their peritoneal macrophages showed an enhanced 
level of RNI, RON, TNFα, and other transcription factors, suggesting the enhanced immuno-
stimulatory response of the absorbed PSP. Similarly, Harada et al. (1997) observed the effect of 
oral administration of PSK on the anti-tumor T cell response in gut-associated lymphoid tissue 
(GALT). They observed the impaired anti-tumor CD4 + T cell response in GALT to produce Th1-
type cytokines. The results reinforced the efficacy of PSK upon oral administration. Likewise, 
Deng et al. (2009) observed the immunological effects of a polysaccharide extract from G. 
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frondosa in breast cancer patients in phase 1 and 2 pre-clinical trials. The post-menopausal 
women were given various doses of 0.1, 0.5, 1.5, 3, or 5 mg/kg of extract twice a day for 3 
weeks and their peripheral blood samples were collected. The results suggested the association 
of the extract with various immunological effects on the patients, highlighting the effect of oral 
polysaccharide in the cancer patients. 
This research project on the screening of BC wild mushrooms, their purification and 
chemical characterization, and their elucidation in an in vivo model is an extensive project that 
demands multi-disciplinary expertise from mycologists, biochemists, chemists, physiologists and 
pharmaceutical science experts. The present study has successfully screened BC mushrooms for 
their immuno-modulatory abilities, re-extracted the potent extract, purified and separated the 
potent anti-inflammatory compound(s) and has tested the potent extracts in vivo.  
5.2 Future Directions 
Future directions for this extensive research project require further investigations into the 
mechanism of action of the purified anti-inflammatory compound. The role of the active 
compound in inhibiting TNF-α should be explored for a profound understanding of the anti-
inflammatory response (summarized in Figure 5.1). TNF-α exerts its effect by acting on TNF 
receptor 1 or 2 (TNFR-1 or TNFR-2). This complex activates either receptor interacting protein 
(RIP) or mitogen-activated protein kinase- extracellular signal-regulated kinase kinase (MEKK). 
RIP in-turn activates IkB kinase (IKK) that ultimately activates transcription factor NF-κβ. RIP 
also activates other MEKK and activates mitogen activated protein kinase (MAPK). Similarly, 
MEKK initiates the c-Jun N-terminal protein kinase cascade that activates AP-1 and plays a role 
in inflammation (Wu & Zhou, 2010).  
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Extensive research has proven that the major inflammatory cascade after activation of 
TNF-α is the activation of transcription factor NF-κβ that enhances the expression of pro-
inflammatory cytokines genes expression such as; inducible nitric oxide synthase (iNOS), 
Vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) (Chen & Goeddel, 
2002; D'Acquisto et al., 2002; Tak & Firestein, 2001; Wu & Zhou, 2010). Thus, inhibiting TNF-α 
could demonstrate anti-inflammatory responses by inhibiting NF- κβ that could halt the 
expression of pro-inflammatory cytokines release and ameliorate the induced inflammation. 
Figure 5.1 demonstrates the summary of some of the convincing TNF-α pathway studies in 
initiating inflammation. 
 
Figure 5.1. Summary of the TNF-α activation pathways and its role in inflammation. 
The above flow-chart is a representation adopted from the research work of Chen & Goeddel 
(2002); Tak & Firestein (2001); Wu & Zhou, (2010). 
Mushroom researchers have explored the NF-κβ pathway in LPS-induced RAW 264.7 
cells for the demonstration of anti-inflammatory pathways (Kim et al., 2007; Shao et al., 2015). 
Western blotting could be used in determining the expression of MAPK, IKK, AP-1 or NF-κβ to 
have a deeper understanding (Jedinak et al., 2011; Kim et al., 2007; Shao et al., 2015). The 
expression of iNOS can also be observed as an indicator of the anti-inflammatory action of TNF-
α in reducing NO levels (an important inflammatory agent). In the current study, the NO 
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inhibition assay showed that the purified lower molecular weight compound from E. tinctorium 
successfully inhibited LPS-induced NO, which supports the involvement of the NF-κβ pathway 
in the inhibition of TNF-α. However, further studies are needed to understand the exact 
mechanism of action of both higher and lower molecular weight anti-inflammatory compounds 
identified in the current research project. There is also a dire need to determine the exact 
chemical structure of the responsible polysaccharide so that the mechanism of action could be 
justified. This will also be useful for the structure activity relationships and developing the anti-
inflammatory drugs with maximum efficacy and minimum toxicity. Therefore, a thorough and 
extensive chemical characterization is required for both bioactive compound(s). The exact 
chemical structure will be useful in exploring both in vitro as well as in vivo drug response.  
As the E. tinctorium extract used in in vivo studies has both larger (̴50-200kDa) and 
smaller molecular weight compound(s) (̴5-25kDa) (demonstrated by Post LH-20 + Post 
Superdex-200), it would be interesting to apply the large and small molecular weight compounds 
in their pure state to see whether the responsible compound can generate the in-vivo response in 
mice micro-circulation and other inflammatory animal model. 
Ultimately, after completing these preliminary studies, chemically characterizing the 
polysaccharide and determining its respective mechanism of action, as well as incorporating 
other animal studies will allow for further investigations into possible clinical applications of the 
mushroom bioactive compounds in treating inflammation. It is only possible when every aspect 
of the inflammatory pathophysiology is kept in focus to target various down-stream mechanisms. 
These reflections will also be important in designing the preventive and prophylaxis approaches 
(using mushroom extracts) against inflammation and applying this concept to a larger 
population. Indeed, the take-home message from this effort of bridging the practices against 
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treating chronic inflammatory conditions would be the simple fact that “Inflammatory conditions 
are preventable”. Preventing inflammation will help with the prophylaxis of certain chronic 
disease states like arthritis, chronic heart diseases, diabetes etc. (Esser et al., 2014). Therefore, 
treating inflammation at the right time with the right pharmacological interventions may 
potentially inhibit pathways that can lead to development of these serious pathologies.  
Future research efforts should continue to focus on identifying new bioactive molecules 
from natural products research and in discovering molecules from wild mushrooms to target 
specific inflammatory events for the therapeutic purposes. The focus of the studies should also be 
on the possibility of studying single chemical target/mediator intervention vs. multiple 
targets/mediators for better synergistic outcomes in clinical settings. This is just the beginning of 
research on the immuno-modulatory compound(s) from Northern British Columbian wild 
mushrooms and the future shows a lot of promise. The current need is to carefully process the 
promising extracts for purification and other molecular studies so that the distance from bench to 
bedside could be reduced significantly, as Isaac Newton said: 
 “I seem to have been only like a boy playing on the seashore, and diverting myself in 
now and then finding a smoother pebble or a prettier shell than ordinary, whilst the great ocean 
of truth lay all undiscovered before me”. 
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